КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ ОССН - РКО - РНМОТ. СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ: ХРОНИЧЕСКАЯ (ХСН) И ОСТРАЯ ДЕКОМПЕНСИРОВАННАЯ (ОДСН). ДИАГНОСТИКА, ПРОФИЛАКТИКА И ЛЕЧЕНИЕ

РЕКОМЕНДАЦИИ, СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ, ХРОНИЧЕСКАЯ СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ, ОСТРАЯ ДЕКОМПЕНСАЦИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ, МИОКАРД, ФРАКЦИЯ ВЫБРОСА ЛЕВОГО ЖЕЛУДОЧКА, ФУНКЦИОНАЛЬНЫЙ КЛАСС СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ, ИНГИБИТОРЫ АПФ, БЕТА-АДРЕНОБЛОКАТОРЫ, АНТАГОНИСТЫ МИНЕРАЛОКОРТИКОИДНЫХ РЕЦЕПТОРОВ, ДИУРЕТИКИ, ФИЗИЧЕСКИЕ ТРЕНИРОВКИ, рекомендации, сердечная недостаточность, хроническая сердечная недостаточность, ОСТРАЯ ДЕКОМПЕНСАЦИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ, МИОКАРД, ФРАКЦИЯ ВЫБРОСА ЛЕВОГО ЖЕЛУДОЧКА, ФУНКЦИОНАЛЬНЫЙ КЛАСС СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ, ИНГИБИТОРЫ АПФ, БЕТА-АДРЕНОБЛОКАТОРЫ, АНТАГОНИСТЫ МИНЕРАЛОКОРТИКОИДНЫХ РЕЦЕПТОРОВ, ДИУРЕТИКИ, ФИЗИЧЕСКИЕ ТРЕНИРОВКИ, guidelines, heart failure, chronic heart failure, acute decompensated heart failure, myocardium, left ventricular ejection fraction, functional class of heart failure, ACE inhibitors, beta-adrenergic blocker agents, mineralocorticoid receptor antagonists, diuretics, physical exercises

1. Swedberg K., Cleland J., Dargie H., Drexler H., Follath F., Komajda M. et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). European Heart Journal. 2005;26 ( 11 ): 1115-40. DOI:10.1093/eurheartj /ehi204

2. Dickstein K., Cohen-Solal A., Filippatos G., McMurray JJV, Ponikowski P., Poole-Wilson PA et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment ofAcute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal. 2008;29 (19):2388-442. DOI:10.1093/eurheartj/ehn309

3. McMurray JJV, Adamopoulos S., Anker SD, Auricchio A., Böhm M., Dickstein K. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaborati. European Journal of Heart Failure. 2012;14 (8):803-69. DOI:10.1093/eur-jhf/hfs105

4. Ponikowski P., Voors AA, Anker SD, Bueno H., ClelandJGF, Coats AJ S., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiol ogy (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European HeartJournal. 2016;37 (27):2129-200.DOI:10.1093 / eurheartj / ehw128

5. Hunt SA, American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J. Am Coll Cardiol. 2005;46 (6):e1-82. DOI:10.1016/j. jacc. 2005.08.022

6. Jessup M., Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG et al. 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation. Circulation. 2009;119 (14):1977-2016. DOI:10.1161/CIRCULA-TIONAHA. 109.192064

7. Yancy CW, Jessup M., Bozkurt B., Butler J., Casey DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62 (16):e147-239. DOI:10.1016/j. jacc. 2013.05.019

8. Yancy CW, Jessup M., Bozkurt B., Butler J., Casey DE, Colvin MM, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update ofthe 2013 ACCF / AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016;134 (13):e282-93. DOI:10.1161/CIR. 0000000000000435

9. Yancy CW, Jessup M., Bozkurt B., Butler J., Casey DE, Colvin MM et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society ofAmerica. Circulation. 2017;136 (6):e137-61. DOI:10.1161/CIR. 0000000000000509

10. Heart Failure Society Of America null. HFSA 2006 Comprehensive Heart Failure Practice Guideline. J. Card Fail. 2006;12 (1):e1-2. DOI:10.1016/j. cardfail. 2005.11.005

11. Heart Failure Society ofAmerica. HFSA 2010 Comprehensive Heart Failure Practice Guideline. Journal of Cardiac Failure. 2010;16 (6):e1-194. DOI:10.1016/j. cardfail. 2010.04.004

12. Фомин И. В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016; (8):7-13. DOI:10.15829/1560-4 071-2016-8-7-13

13. Фомин И. В., Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т., Бадин Ю. В., Галявич А. С. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации - данные ЭПОХА - ХСН (Часть II). Журнал Сердечная Недостаточность. 2006;7 (3):112-5.

14. Фомин И. В. Эпидемиология хронической сердечной недостаточности в Российской Федерации. Хроническая сердечная недостаточность. -М.: ГЭОТАР-Медиа; 2010. с. 7-77. [Fomin I. V. Epidemiologiya hronicheskoj serdechnoj nedostatochnosti v Rossijskoj Federacii. Hronicheskaya serdechnaya nedostatochnost’. -M.: GEOTAR-Media; 2010. p. 7-77.] ISBN: 978-5-9704-1472-9

15. Поляков Д. С., Фомин И. В., Валикулова Ф. Ю., Вайсберг А. Р., Краием Н., Бадин Ю. В. и др. Эпидемиологическая программа ЭПОХА - ХСН: декомпенсация хронической сердечной недостаточности в реальной клинической практике (ЭПОХА -Д - ХСН). Журнал Сердечная Недостаточность. 2016;17 (5):299-305. DOI:10.18087/rhfj. 2016.5.2239

16. Козиолова Н. А., Никонова Ю. Н., Шилова Я. Э., Агафонов А. В., Полянская Е. А. Характеристика хронической сердечной недостаточности на фоне перманентной формы фибрилляции предсердий. Журнал Сердечная Недостаточность. 2013;14 (1):14-21 DOI:10.18087/rhfj. 2013.1.1806

17. Mosterd A., Hoes A.W. Clinical epidemiology of heart failure. Heart. 2007;93 (9):1137-46. DOI:10.1136/hrt. 2003.025270

18. Артемьева Е. Г., Маленкова В. Ю., Фролова Е. В. Распространен ность артериальной гипертензии при хронической сердечной недостаточности в Чувашской Республике. Медицинский альманах. 2011; (16):51-4.

19. Сергеева Е. М., Малишевский М. В., Васина А. А., Мищенко Т. А., Кузьмина Ю. С., Раемгулов Р. А. Лечение хронической сердечной недостаточности в первичном звене муниципального здравоохранения в г. Тюмени. Медицинская наука и образование Урала. 2015;16 (4):32-4.

20. Шакирова Р. М., Галявич А. С., Камалов Г. М. Распространенность сердечно-сосудистых заболеваний и сахарного диабета в Республике Татарстан и их взаимосвязь с симптомами хронической сердечной недостаточности. Журнал Сердечная Недостаточность. 2005;6 (2):72-3.

21. Смирнова Е. А. Изучение распространенности и этиологии хронической сердечной недостаточности в Рязанской области. Российский кардиологический журнал. 2010; (2):78-83.

22. Бабанская Е. Б., Меньшикова Л. В., Дац Л. С. Эпидемиология хронической сердечной недостаточности в городе Иркутске. Бюллетень ВСНЦ СО РАМН. 2012; (5-1):25-8.

23. Gerber Y., Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R. et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Internal Medicine. 2015;175 (6):996. DOI:10.1001/jamainternmed. 2015.0924

24. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield M.M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. New EnglandJournal of Medicine. 2006;355 (3):251-9.DOI:10.1056/NEJMoa052256

25. Фомин И. В., Бадин Ю. В., Поляков Д. С., Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т. и др. Предгипертония: как часто встречается данное состояние сердечно-сосудистой системы у граждан Европейской части России (данные исследования ЭПОХА-АГ, 2002-2007 гг.). Современные технологии в медицине. 2013;5 (2):38-46.

26. Троицкая Е. А., Котовская Ю. В., Кобалава Ж. Д. Прогностическое значение высокой межвизитной вариабельности систолического артериального давления у больных с хронической сердечной недостаточностью со сниженной фракцией выброса. Материалы IV всероссийской конференции «Противоречия современной кардиологии: спорные и нерешенные вопросы». МЮЕ Partner; 2015. с. 138.

27. Капанадзе Л. Г., Герасимова В. В., Мареев Ю. В., Рогоза А. Н., Мареев В. Ю. Факторы, влияющие на 5-летнюю выживаемость больных легкой и умеренной ХСН: роль уровня офисного АД и показателей суточного профиля АД в прогнозе заболевания. Журнал Сердечная Недостаточность. 2013;14 (6):353-61.

28. Глезер М. Г., Чесникова А. И., Гиляревский С. Р., Перепеч Н. Б., Асташкин Е. И., Лопатин Ю. М. и др. Снижение частоты сердечных сокращений у больных ишемической болезнью с хронической сердечной недостаточностью - цель и средства. Кардиология. 2014;54 (4):109-20.

29. Фомин И. В., Поляков Д. С. ß-адреноблокаторы: нереализованность задач или неготовность врачей в Российской Федерации к оптимизации лечения? Системные гипертензии. 2014;11 (1):56- 63.

30. ClelandJ. Ue EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. European Heart Journal. 2003;24 (5):442-63. DOI:10.1016/S0195-668X (02) 00823-0

31. Жиров И. В., Романова Н. В., Терещенко С. Н., Осмоловская Ю. Ф. Эпидемиология и особенности терапии хронической сердечной недостаточности в сочетании с фибрилляцией предсердий. Кардиология. 2015; (3):91-6. DOI:10.18565/cardio. 2015.3.91-96

32. Козиолова Н. А. Закономерности формирования хронической сердечной недостаточности у больных ишемической болезнью сердца и хронической обструктивной болезнью легких на фоне множественной коморбидной патологии. Журнал Сердечная Недостаточность. 2016;17 (3):151-63.

33. Ефремова Е. В., Шутов А. М. Коморбидность и прогноз больных при хронической сердечной недостаточности. Журнал Сердечная Недостаточность. 2014;15 (5):294-300.

34. Мареев Ю. В., Мареев В. Ю. Характеристика и лечение пациентов с ХСН, госпитализированных в стационар. Кардиология. 2017;57 (S4):20-30.

35. Арутюнов А. Г., Рылова А. К., Арутюнов Г. П. Регистр госпитализированных пациентов с декомпенсацией кровообращения (Павловский регистр). Сообщение 1. Соврем енная клиническая характеристика пациента с декомпенсацией кровообращения. Клинические фенотипы пациентов. Журнал Сердечная Недостаточность. 2014;15 (1):23-32.

36. Арутюнов А. Г., Драгунов Д. О., Арутюнов Г. П., Рылова А. К., Пашкевич Д. Д., Витер К. В. и др. Первое открытое исследование синдрома острой декомпенсации сердечной недостаточности и сопутствующих заболеваний в Российской Федерации. Независимый регистр ОРАКУЛ-РФ. Кардиология. 2015;55 (5):12- 21.

37. Мареев В. Ю., Даниелян М. О., Беленков Ю. Н. Сравнительная характеристика больных ХСН в зависимости от величины фрак ции выброса по результатам Российского многоцентрового исследования ЭПОХА-О-ХСН: снова о проблеме ХСН с сохраненной систолической функцией левого желудочка. Журнал Сердечная Недостаточность. 2006;7 (4):164-71.

38. Ощепкова Е. В., Лазарева Н. В., Салтыкова Д. Ф., Терещенко С. Н. Первые результаты Российского регистра хронической сердечной недостаточности. Кардиология. 2015;55 (5):22-8.

39. Арутюнов А. Г., Рылова А. К., Арутюнов Г. П. Регистр госпитализированных пациентов с декомпенсацией кровообращения (регистр Павловской больницы). Сообщение 2. Клиническое значение и прогностическая роль некоторых параметров, определяемых при физикальном и инструментальном обследовании пациентов с декомпенсацией кровообращения. Журнал Сердечная Недостаточность. 2014;15 (2):67-75. DOI:10.18087/rhfj. 2014.2.1934

40. Cleland JG, Swedberg K., Cohen-Solal A., Cosin-AguilarJ, Dietz R., Follath F. et al. The Euro Heart Failure Survey of the EUROHEART survey programme. A survey on the quality of care among patients with heart failure in Europe. The Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The Medicines Evaluation Group Centre for Health Economics University of York. Eur J. Heart Fail. 2000;2 (2):123-32.

41. Агеев Ф. Т., Даниелян М. О., Мареев В. Ю., Беленков Ю. Н. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА-О-ХСН). Журнал Сердечная Недостаточность. 2004;5 (1):4-7.

42. Borlaug BA, Paulus W.J. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. European Heart Journal. 2011;32 (6):670-9. DOI:10.1093/eurheartj/ehq426

43. Paulus WJ, Tschöpe C., Sanderson JE, Rusconi C., Flachskampf FA, Rademakers FE et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. European Heart Journal. 2007;28 (20):2539-50. DOI:10.1093/eur-heartj / ehm037

44. Marwick TH, Raman SV, Carrio I., Bax J.J. Recent Developments in Heart Failure Imaging. JACC: Cardiovascular Imaging. 2010;3 (4):429-39. DOI:10.1016/j. jcmg. 2010.02.002

45. Paterson DI, OMeara E., Chow BJ, Ukkonen H., Beanlands R.S. Recent advances in cardiac imaging for patients with heart failure: Current Opinion in Cardiology. 2011;26 (2):132-43. DOI:10.1097/HCO. 0b013e32834380e7

46. McMurray JJV. Systolic Heart Failure. New England Journal of Medicine. 2010;362 (3):228-38. DOI:10.1056/NEJMcp0909392

47. Chen J., Normand S-LT, Wang Y., Krumholz H.M. National and Regional Trends in Heart Failure Hospitalization and Mortality Rates for Medicare Beneficiaries, 1998-2008. JAMA. 2011;306 (15):1669. DOI:10.1001/jama. 2011.1474

48. Dunlay SM, Redfield MM, Weston SA, Therneau TM, Hall Long K, Shah ND et al. Hospitalizations After Heart Failure Diagnosis. Jour nal of the American College of Cardiology. 2009;54 (18):1695-702. DOI:10.1016/j. jacc. 2009.08.019

49. Khot UN, Jia G., Moliterno DJ, LincoffAM, Khot MB, Harrington R.A. et al. Prognostic Importance of Physical Examination for Heart Failure in Non - ST-Elevation Acute Coronary Syndromes: The Enduring Value of Killip Classification. JAMA. 2003;290 (16):2174. DOI:10.1001/jama. 290.16.2174

50. Davie AP, Francis CM, Caruana L., Sutherland GR, McMurray J.J. Assessing diagnosis in heart failure: which features are any use? QJM. 1997;90 (5):335-9. PMID:9205668

51. Mant J., Doust J., Roalfe A., Barton P., Cowie M., Glasziou P. et al. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technology Assessment [Internet]. 2009 [cited on Febrary 1, 2018];13 (32). DOI:10.3310/hta13320

52. Oudejans I., Mosterd A., Bloemen JA, Valk MJ, van Velzen E., Wielders JP et al. Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests. European Journal of Heart Failure. 2011;13 (5):518-27. DOI:10.1093/eur-jhf/hfr021

53. Fonseca C. Diagnosis ofheart failure in primary care. Heart Failure Reviews. 2006;11 (2):95-107. DOI:10.1007/s10741-006-9481-0

54. Kelder JC, Cramer MJ, van Wijngaarden J., van Tooren R., Mosterd A., Moons KGM et al. The Diagnostic Value of Physical Examination and Additional Testing in Primary Care Patients With Suspected Heart Failure. Circulation. 2011;124 (25):2865-73. DOI:10.1161/CIRCU-LATIONAHA. 111.019216

55. Rutten F.H. Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. BMJ. 2005;331 (7529):1379-0. DOI:10.1136/bmj. 38664.661181.55

56. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurrayJJV. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. European Journal of Heart Failure. 2009; 11 (2):130-9. DOI:10.1093/eurjhf/hfn013

57. Daniels LB, Clopton P., Bhalla V., Krishnaswamy P., Nowak RM, McCord J. et al. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. American Heart Journal. 2006;151 (5):999-1005. DOI:10.1016/j. ahj. 2005.10.011

58. Беленков Ю. Н., Мареев В. Ю. Принципы рационального лечения хронической сердечной недостаточности. -М.: Медиа Медика; 2000. 266 с.

59. Мареев В. Ю., Даниелян М. О. Оптимизация применения БЕталока ЗОК у больных ХСН в повседневной врачебной практикЕ. Дизайн и результаты исследования БЕЗЕ. Журнал Сердечная Недостаточность. 2005;6 (6):251-7.

60. Мареев В. Ю. Организация исследования и характеристика больных в исследовании «ФАСОН». Журнал Сердечная Недостаточность. 2002;3 (2):97-8.

61. Мареев Ю. В., Герасимова В. В., Горюнова Т. В., Петрухина А. А., Даниелян М. О., Капанадзе Л. Г. и др. Факторы, определяющие прогноз при хронической сердечной недостаточности: роль ширины и морфологии комплекса QRS. Журнал Сердечная Недостаточность. 2012;13 (5):255-66.

62. Rudski LG, Lai WW, Afilalo J., Hua L., Handschumacher MD, Chandrasekaran K. et al. Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography. Journal of the American Society of Echocardiography. 2010;23 (7):685-713. DOI:10.1016/j. echo. 2010.05.010

63. Dokainish H., Nguyen JS, Bobek J., Goswami R., Lakkis N.M. Assessment of the American Society of Echocardiography-European Association of Echocardiography guidelines for diastolic function in patients with depressed ejection fraction: an echocardiographic and invasive haemodynamic study. European Journal of Echocardiography. 2011;12 (11):857-64. DOI:10.1093/ejechocard/jer157

64. Kirkpatrick JN, Vannan MA, Narula J, Lang RM. Echocardiography in Heart Failure.Journal of the American College of Cardiology. 2007;50 (5):381-96. DOI:10.1016/j. jacc. 2007.03.048

65. Lancellotti P., Moura L., Pierard LA, Agricola E., Popescu BA, Tribouilloy C. et al. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease). European Journal of Echocardiography. 2010;11 (4):307-32. DOI:10.1093/ejecho-card/jeq031

66. Lancellotti P., Tribouilloy C., Hagendorff A., Moura L., Popescu BA, Agricola E. et al. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 1: aortic and pulmonary regurgitation (native valve disease). European Journal of Echocardiography. 2010;11 (3):223-44. DOI:10.1093/ejecho-card/jeq030

67. Popescu BA, Andrade MJ, Badano LP, Fox KF, Flachskampf FA, Lancellotti P et al. European Association of Echocardiography recommendations for training, competence, and quality improvement in echocardiography. European Journal of Echocardiography. 2009;10 (8):893 905. DOI:10.1093/ejechocard/jep151

68. Nagueh SF, Bhatt R, Vivo RP, Krim SR, Sarvari SI, Russell K et al. Echocardiographic Evaluation of Hemodynamics in Patients With Decompensated Systolic Heart Failure. Circulation: Cardiovascular Imaging. 2011;4 (3):220-7. DOI:10.1161/ CIRCIMAGING. 111.963496

69. Sicari R, Nihoyannopoulos P, Evangelista A, Kasprzak J, Lancellotti P, Poldermans D et al. Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC). European Journal of Echocardiography. 2008;9 (4):415-37. DOI:10.1093/ejechocard/jen175

70. Davie AP, Francis CM, Love MP, Caruana L, Starkey IR, Shaw TRD et al. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ. 1996;312 (7025):222-222. DOI:10.1136/bmj. 312.7025.222

71. Thomas JT, Kelly RF, Thomas SJ, Stamos TD, Albasha K, Parrillo JE et al. Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure. The American Journal of Medicine. 2002;112 (6):437-45. DOI:10.1016/S0002-9343 (02)01048-3

72. Khunti K., Squire I., Abrams KR, Sutton A.J. Accuracy of a 12-lead electrocardiogram in screening patients with suspected heart failure for open access echocardiography: a systematic review and meta-analysis. EuropeanJournal of Heart Failure. 2004;6 (5):571-6. DOI:10.1016/j. ejheart. 2004.03.013

73. Madias J.E. Why Recording of an Electrocardiogram Should be Required in Every Inpatient and Outpatient Encounter of Patients with Heart Failure: ECG IN HEART FAILURE. Pacing and Clinical Electrophysiology. 2011;34 (8):963-7. DOI:10.1111/j. 1540-8159.2011.03131. x

74. Schwitter J. Extending the Frontiers of Cardiac Magnetic Resonance. Circulation. 2008;118 (2):109-12. DOI:10.1161/CIRCU-LATIONAHA. 108.790139

75. Gebker R., Schwitter J., Fleck E., Nagel E. How We Perform Myocardial Perfusion With Cardiovascular Magnetic Resonance. Journal of Cardiovascular Magnetic Resonance. 2007;9 (3):539-47. DOI: 10.1080/10976640600897286

76. Beller GA, Heede R.C. SPECT Imaging for Detecting Coronary Artery Disease and Determining Prognosis by Noninvasive Assessment of Myocardial Perfusion and Myocardial Viability. Journal of Cardiovascular Translational Research. 2011;4 (4):416-24. DOI:10.1007/s12265-011-9290-2

77. Leong DP, De Pasquale CG, Selvanayagam JB. Heart Failure With Normal Ejection Fraction: The Complementary Roles of Echocar diography and CMR Imaging.JACC: Cardiovascular Imaging. 2010;3 (4):409-20. DOI:10.1016/j. jcmg. 2009.12.011

78. Myerson S.G. Valvular and Hemodynamic Assessment with CMR. Heart Failure Clinics. 2009;5 (3):389-400. DOI:10.1016/j. hfc. 2009.02.004

79. Raman SV, Simonetti O.P. RAe CMR Examination in Heart Failure. Heart Failure Clinics. 2009;5 (3):283-300. DOI:10.1016/j. hfc. 2009.02.002

80. Sheikine Y., Di Carli M.F. Integrated PET/CT in the assessment of etiology and viability in ischemic heart failure. Current Heart Failure Reports. 2008;5 (3):136-42. DOI:10.1007/s11897-008-0022-0

81. Miller JM, Rochitte CE, Dewey M, Arbab-Zadeh A, Niinuma H, Gottlieb I et al. Diagnostic Performance of Coronary Angiography by 64-Row CT. New EnglandJournal ofMedicine. 2008;359 (22):2324 36. DOI:10.1056/NEJMoa0806576

82. Beanlands RSB, Nichol G, Huszti E, Humen D, Racine N, Freeman M et al. F-18-Fluorodeoxyglucose Positron Emission Tomography Imaging-Assisted Management of Patients With Severe Left Ventricular Dysfunction and Suspected Coronary Disease. Journal of the American College of Cardiology. 2007;50 (20):2002-12. DOI:10.1016/j. jacc. 2007.09.006

83. Ewald B, Ewald D, RAakkinstian A, Attia J. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. Internal MedicineJournal. 2008;38 (2):101 13. DOI:10.1111/j. 1445-5994.2007.01454. x

84. Doust JA, Glasziou PP, Pietrzak E., Dobson A.J. A Systematic Review of the Diagnostic Accuracy of Natriuretic Peptides for Heart Failure. Archives of Internal Medicine. 2004;164 (18):1978. DOI: 10.1001/archinte. 164.18.1978

85. Zaphiriou A., Robb S., Murray-RAomas T., Mendez G., Fox K., McDonagh T. et al. RAe diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: Results of the UK natriuretic peptide study. EuropeanJournal ofHeart Failure. 2005;7 (4):537-41. DOI:10.1016/j. ejheart. 2005.01.022

86. Maisel A., Mueller C., Adams K., Anker SD, Aspromonte N., Cleland JGF et al. State of the art: Using natriuretic peptide levels in clinical practice. European Journal of Heart Failure. 2008;10 (9):824-39. DOI:10.1016/j. ejheart. 2008.07.014

87. Fuat A., Murphy JJ, Hungin APS, Curry J., Mehrzad AA, Hetherington A. et al. RAe diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. BrJ Gen Pract. 2006;56 (526):327-33. PMID:16638247

88. Yamamoto K, BurnettJC, Bermudez EA,Jougasaki M, Bailey KR, Redfield MM. Clinical criteria and biochemical markers for the detection of systolic dysfunction. Journal of Cardiac Failure. 2000;6 (3):194 200. DOI:10.1054/jcaf. 2000.9676

89. Cowie MR, Struthers AD, Wood DA, Coats AJ, RAompson SG, Poole-Wilson PA et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. RAe Lancet. 1997;350 (9088):1349-53. DOI:10.1016/S0140-6736 (97) 06031-5

90. Krishnaswamy P, Lubien E, Clopton P, KoonJ, Kazanegra R, Wanner E et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med. 2001;111 (4):274-9. PMID:11566457

91. Kelder JC, Cowie MR, McDonagh TA, Hardman SMC, Grobbee DE, Cost B. et al. Quantifying the added value of BNP in suspected heart failure in general practice: an individual patient data meta-analysis. Heart. 2011;97 (12):959-63. DOI:10.1136/hrt. 2010.220426

92. Kelder JC, Cramer MJ, Verweij WM, Grobbee DE, Hoes A.W. Clinical Utility of RAree B-Type Natriuretic Peptide Assays for the Initial Diagnostic Assessment of New Slow-Onset Heart Failure. Journal of Cardiac Failure. 2011;17 (9):729-34. DOI:10.1016/j. cardfail. 2011.04.013

93. Gustafsson F., Steensgaard-Hansen F., Badskjær J., Poulsen AH, Corell P., Hildebrandt P. Diagnostic and Prognostic Performance of N-Terminal ProBNP in Primary Care Patients With Suspected Heart Failure. Journal of Cardiac Failure. 2005;11 (5):S15-20. DOI:10.1016/j. cardfail. 2005.04.022

94. Nielsen OW, Rasmussen V. Christensen NJ, Hansen J.F. Neuroendocrine testing in community patients with heart disease: plasma N-ter-minal proatrial natriuretic peptide predicts morbidity and mortality stronger than catecholamines and heart rate variability. Scandinavian Journal of Clinical and Laboratory Investigation. 2004;64 (7):619-28. DOI:10.1080/00365510410002878

95. Porapakkham P. B-Type Natriuretic Peptide - Guided Heart Failure Therapy: A Meta-analysis. Archives of Internal Medicine. 2010;170 (6):507. DOI:10.1001/archinternmed. 2010.35

96. Lang R, Bierig M, Devereux R, Flachskampf F, Foster E, Pellikka P, et al. Recommendations for chamber quantification^. EuropeanJournal of Echocardiography. 2006;7 (2):79-108. DOI:10.1016/j. euje. 2005.12.014

97. Фомин И. В., Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т., Бадин Ю. В., Галявич А. С. и др. Распространенность ХСН в Европейской части Российской Федерации - данные ЭПОХА-ХСН. Журнал Сердечная Недостаточность. 2006;7 (1):4-7.

98. Lang RM, Badano LP, Mor-Avi V., Afilalo J., Armstrong A., Ernande L. et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography. 2015;28 (1):1-39. e14. DOI:10.1016/j. echo. 2014.10.003

99. Lang RM, Badano LP, Tsang W., Adams DH, Agricola E., Buck T. et al. EAE/ASE Recommendations for Image Acquisition and Display Using Three-Dimensional Echocardiography. European Heart Journal - Cardiovascular Imaging. 2012;13 (1):1-46. DOI:10.1093/ehj-ci/jer316

100. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography. European Journal of Echocardiography. 2008; 10 (2): 165-93. DOI:10.1093/ejechocard/jep007

101. Nagueh SF, Middleton KJ, Kopelen HA, Zoghbi WA, Quinones M.A. Doppler Tissue Imaging: A Noninvasive Technique for Evaluation of Left Ventricular Relaxation and Estimation of Filling Pressures. Journal of the American College of Cardiology. 1997;30 (6):1527-33. DOI:10.1016/S0735-1097 (97) 00344-6

102. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H., Edvardsen T. et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am Soc Echocardiogr. 2016;29 (4):277-314. DOI:10.1016/j. echo. 2016.01.011

103. Schwitter J., Arai A.E. Assessment of cardiac ischaemia and viability: role of cardiovascular magnetic resonance. European Heart Journal. 2011;32 (7):799-809. DOI:10.1093/eurheartj/ehq481

104. Kilner PJ, Geva T, Kaemmerer H, Trindade PT, Schwitter J, Webb GD. Recommendations for cardiovascular magnetic resonance in adults with congenital heart disease from the respective working groups of the European Society of Cardiology. European HeartJournal. 2010;31 (7):794-805. DOI:10.1093/eurheartj/ehp586

105. CMR Update. Schwitter J., редактор. -Zürich: Schwitter; 2008. 239 p. ISBN: 978-3-033-01674-3

106. Bruder O., Schneider S., Nothnagel D., Pilz G., Lombardi M., Sinha A. et al. Acute Adverse Reactions to Gadolinium-Based Contrast Agents in CMR. JACC: Cardiovascular Imaging. 2011;4 ( 11 ) : 1171-6. DOI:10.1016/j. jcmg. 2011.06.019

107. Cooper LT, Baughman KL, Feldman AM, Frustaci A., Jessup M., Kuhl U. et al. The role of endomyocardial biopsy in the management of cardiovascular disease: A Scientific Statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. European Heart Journal. 2007;28 (24):3076-93. DOI:10.1093 / eurheartj / ehm45 6

108. Arena R., Myers J., Guazzi M. Cardiopulmonary Exercise Testing Is a Core Assessment for Patients With Heart Failure. Congestive Heart Failure. 2011;17 (3):115-9. DOI:10.1111/j. 1751-7133.2011.00216. x

109. Charron P., Arad M., Arbustini E., Basso C., Bilinska Z., Elliott P. et al. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal. 2010;31 (22):2715-26.DOI:10.1093/eurheartj/ehq271

110. Wedel H., McMurray JJV Lindberg M., Wikstrand J., Cleland JGF, Cornel JH et al. Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. European Journal of Heart Failure. 2009;11 (3):281-91. DOI:10.1093/eur-jhf/hfn046

111. Allen LA, Felker GM, Pocock S., McMurray JJV Pfeffer MA, Swedberg K. et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. European Journal of Heart Failure. 2009;11 (2): 170-7. DOI:10.1093/eurjhf/hfn031

112. Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S., Olofsson B., Michelson EL et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. The Lancet. 2009;374 (9689):543-50. DOI:10.1016/S0140-6736 (09) 61378-7

113. Felker GM, Allen LA, Pocock SJ, Shaw LK, McMurray JJV Pfeffer MA, et al. Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure. Journal of the American College of Cardiology. 2007;50 (1):40-7. DOI:10.1016/j. jacc. 2007.02.067

114. Pocock SJ, Wang D., Pfeffer MA, Yusuf S., McMurray JJV, Swedberg KB et al. Predictors of mortality and morbidity in patients with chronic heart failure. European Heart Journal. 2006;27 (1):65-75. DOI:10.1093/eurheartj/ehi555

115. Komajda M., Carson PE, Hetzel S., McKelvie R., McMurrayJ, Ptaszynska A. et al. Factors Associated With Outcome in Heart Failure With Preserved Ejection Fraction: Findings From the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-PRESERVE). Circulation: Heart Failure. 2011;4 (1):27-35. DOI:10.1161/CIRCHEART-FAILURE. 109.932996

116. Ketch um ES, Levy W.C. Establishing Prognosis in Heart Failure: A Multimarker Approach. Progress in Cardiovascular Diseases. 2011;54 (2):86-96. DOI:10.1016/j. pcad. 2011.03.003

117. Pfeffer MA, Swedberg K., Granger CB, Held P., McMurray JJV, Michelson EL et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362 (9386):759-66.

118. Zile MR, Gaasch WH, Anand IS, Haass M., Little WC, Miller AB et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation. 2010;121 (12): 1393-405. DOI:10.1161/CIRCULATIONAHA. 109.909614

119. Whitman IR, Agarwal V., Nah G., Dukes JW, Vittinghoff E., Dewland TA et al. Alcohol Abuse and Cardiac Disease. Journal of the American College of Cardiology. 2017;69 (1):13-24. DOI:10.1016/j. jacc. 2016.10.048

120. AlFaleh H., Elasfar AA, Ullah A., AlHabib KF, Hersi A., Mimish L. et al. Worsening heart failure in «real-world» clinical practice: predictors and prognostic impact: WHF in «real-world» clinical practice. European Journal of Heart Failure. 2017;19 (8):987-95. DOI:10.1002/ejhf. 515

121. Voors AA, Ouwerkerk W., Zannad F., van Veldhuisen DJ, Samani NJ, Ponikowski P. et al. Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure: Mortality and hospitalization models in heart failure. European Journal of Heart Failure. 2017;19 (5):627-34. DOI:10.1002/ejhf. 785

122. Rahimi K., Bennett D., Conrad N., Williams TM, Basu J., Dwight J. et al. Risk Prediction in Patients With Heart Failure. JACC: Heart Failure. 2014;2 (5):440-6. DOI:10.1016/j. jchf. 2014.04.008

123. Мареев В. Ю. Фармакоэкономическая оценка использования иАПФ в амбулаторном лечении больных сердечной недостаточностью (ФАСОН). ЖСН. 2002;3 (1):38-9.

124. Ho KK, Anderson KM, Kannel WB, Grossman W., Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88 (1):107-15. DOI:10.1161/01. CIR. 88.1.107

125. Yusuf S., Hawken S., Ôunpuu S., Dans T., Avezum A., Lanas F. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet. 2004;364 (9438):937-52. DOI:10.1016/S0140-6736(04)17018-9

126. Preiss D., Campbell RT, Murray HM, Ford I., Packard CJ, Sattar N., et al. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. European Heart Journal. 2015;36 (24):1536-46. DOI:10.1093/eur-heartj/ehv072

127. Shepherd J., Cobbe SM, Ford I., Isles CG, Lorimer AR, Macfarlane PW et al. Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia. New England Journal of Medicine. 1995;333 (20) : 1301-8. DOI: 10.1056/NEJM199511163332001

128. Yusuf S, Lonn E, Pais P, Bosch J, Lopez-Jaramillo P, Zhu J et al. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. New England Journal of Medicine. 2016;374 (21):2032 43. DOI:10.1056/NEJMoa1600177

129. Ridker PM, Danielson E., Fonseca FAH, Genest J., Gotto AM, Kastelein JJP et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New EnglandJournal of Medicine. 2008;359 (21):2195-207. DOI:10.1056/NEJMoa0807646

130. Blood-Pressure and Cholesterol Lowering in the HOPE-3 Trial. New England Journal of Medicine. 2016;375 (12):1190-4. DOI:10.1056/NEJMc1608916

131. Lonn EM, Bosch J, Lopez-Jaramillo P, Zhu J, Liu L, Pais P et al. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine. 2016;374 (21):2009 20. DOI:10.1056/NEJMoa1600175

132. Wilhelmsen L., Rosengren A., Eriksson H., Lappas G. Heart failure in the general population of men - morbidity, risk factors and prognosis. Journal of Internal Medicine. 2001;249 ( 3):253-61. DOI:10.1046/j. 1365-2796.2001.00801. x

133. Authors/Task Force Members, Fuster V. Ryden LE, Cannom DS, Crijns HJ, Curtis AB et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. European Heart Journal. 2006;27 (16):1979-2030. DOI:10.1093/eurheartj/ehl176

134. Мареев В. Ю., Даниелян М. О., Беленков Ю. Н. Первые результаты национального эпидемиологического исследования. Эпидемиологическое Обследование больных ХСН в реальной практике (по Обращаемости) ЭПОХА-О-ХСН. Журнал Сердечная Недостаточность. 2003;4 (3): 116-20.

135. Kannel W.B. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA: The Journal of the American Medical Association. 1996;275 (20):1571-6. DOI:10.1001/jama. 275.20.1571

136. Effects Morbidity of Treatment on in Hypertension: I.I. Results in Patients With Diastolic Blood Pressure Averaging 90 Through 114 mm Hg. JAMA. 1970;213 (7):1143. DOI:10.1001/jama. 1970.03170330025003

137. Kostis J.B. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA: RAe Journal of the American Medical Association. 1997;278 (3):212-6. DOI:10.1001/jama. 278.3.212

138. RAomopoulos C., Parati G., Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials. Journal of Hypertension. 2016;34 (4):613-22. DOI:10.1097/HJH. 0000000000000881

139. Baker D.W. Prevention of heart failure. Journal of Cardiac Failure. 2002;8 (5):333-46. DOI:10.1054/jcaf. 2002.0805333

140. RAe SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. New England Journal of Medicine. 2015;373 (22):2103-16. DOI:10.1056/NEJMoa1511939

141. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C. et al. 2017 ACC/AHA/AA-PA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American College of Cardiology. 2018;71 (19):e127-248. DOI:10.1016/j. jacc. 2017.11.006

142. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA. 2000;283 (15):1967-75. PMID:10789664

143. Julius S., Kjeldsen SE, Weber M., Brunner HR, Ekman S., Hansson L. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. RAe Lancet. 2004;363 (9426):2022-31. DOI: 10.1016/S0140-6736 (04) 16451-9

144. Yusuf S., Diener H-C, Sacco RL, Cotton D., Ôunpuu S., Lawton WA, et al. Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events. New England Journal of Medicine. 2008;359 (12):1225-37. DOI:10.1056/NEJMoa0804593

145. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. The Lancet. 2001;358 (9287):1033-41. DOI: 10.1016/S0140-6736 (01) 06178-5

146. Beckett NS, Peters R., Fletcher AE, Staessen JA, Liu L., Dumitrascu D. et al. Treatment of Hypertension in Patients 80 Years of Age or Older. New England Journal of Medicine. 2008;358 (18):1887-98. DOI:10.1056/NEJMoa0801369

147. Hansson L., Zanchetti A., Carruthers SG, Dahlöf B., Elmfeldt D., Julius S. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. RAe Lancet. 1998;351 (9118):1755-62. DOI:10.1016/S0140-6736 (98) 04311-6

148. Tight blood pressure control and risk of macrovascular and microvas-cular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BmJ. 1998;317 (7160):703-13. PMID:9732337

149. Arima H., Hart RG, Colman S., Chalmers J., Anderson C., Rodgers A., et al. Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke. 2005;36 (10):2164-9. DOI:10.1161/01. STR. 0000181115.59173.42

150. Izzo JL, Gradman A.H. Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure. Medical Clinics of North America. 2004;88 (5):1257-71. DOI:10.1016/j. mcna. 2004.06.002

151. Чазова И. Е., Ратова Л. Г., Бойцов С. А., Небиеридзе Д. В., Карпов Ю. А., Белоусов Ю.Б. и др. Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные Гипертензии. 2010; (3):5-26

152. Чазова И. Е., Ощепкова Е. В., Жернакова Ю. В., Архипов М. В., Барбараш О. Л., Галявич А.С. и др. Клинические рекомендации Диагностика и лечение артериальной гипертонии. Кардиологический вестник. 2015; X. (1):3-30.

153. Мареев В. Ю., Беленков Ю. Н., Агеев Ф. Т., Фомин И. В., Хохлов Р. А., Галявич А. С. Первые результаты Российского эпидемиологического исследования по ХСН (ЭПОХА-ХСН). Журнал Сердечная Недостаточность. 2003;4 ( 1 ): 17-8.

154. Cleland JGF, Swedberg K., Follath F., Komajda M., Cohen-Solal A., Aguilar JC et al. The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24 (5):442-63. PMID:12633546

155. Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebocontrolled, multicentre trial (the EUROPA study). Lancet. 2003;362 (9386):782-8.

156. Effects of an Angiotensin-Converting - Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. New England Journal of Medicine. 2000;342 (3):145-53. DOI:10.1056/NEJM200001203 420301

157. Angiotensin-Converting - Enzyme Inhibition in Stable Coronary Artery Disease. New EnglandJournal ofMedicine. 2004;351 (20):2058-68. DOI:10.1056/NEJMoa042739

158. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. New England Journal of Medicine. 2008;358 (15):1547-59. DOI:10.1056/NEJMoa0801317

159. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. The Lancet. 2008;372 (9644):1174-83. DOI:10.1016/S0140-6736 (08) 61242-8

160. Massie BM, Carson PE, McMurray JJ, Komajda M., McKelvie R., Zile MR et al. Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. New England Journal of Medicine. 2008;359 (23):2456-67. DOI:10.1056/NEJMoa0805450

161. The Norwegian Multicenter Study Group. Timolol-Induced Reduction in Mortality and Reinfarction in Patients Surviving Acute Myocardial Infarction. New EnglandJournal of Medicine. 1981;304 (14):801-7. DOI: 10.1056/NEJM198104023041401

162. Chadda K., Goldstein S., Byington R., Curb J.D. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation. 1986;73 (3):503-10. DOI:10.1161/01. CIR. 73.3.503

163. Pfeffer MA, Braunwald E., Moyé LA, Basta L., Brown EJ, Cuddy TE, et al. Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction: Results of the Survival and Ventricular Enlargement Trial. New England Journal of Medicine. 1992;327 (10):669-77. DOI:10.1056/NEJM199209033271001

164. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. Lancet. 1994;343 (8906):1115-22. PMID:7910229

165. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. The Lancet. 1995;345 (8951):669-85. DOI:10.1016/S0140-6736 (95) 90865-X

166. Pfeffer MA, McMurrayJJV, Velazquez EJ, Rouleau J-L, Kober L, Maggioni AP et al. Valsartan, Captopril, or Both in Myocardial Infarc tion Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. New England Journal of Medicine. 2003;349 (20):1893-906. DOI:10.1056/NEJMoa032292

167. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. New England Journal of Medicine. 2003;348 (14):1309-21. DOI:10.1056/NEJ-Moa030207

168. Vantrimpont P, Rouleau JL, Wun CC, Ciampi A, Klein M, Sussex B et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. J Am Coll Cardiol. 1997;29 (2):229-36. PMID:9014971

169. Kjekshus J, Pedersen TR, Olsson AG, Færgeman O, Pyörälä K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease.Journal of Cardiac Failure. 1997;3 (4):249-54. DOI: 10.1016/S 1071-9164 (97) 90022-1

170. Lewis SJ. Effect of Pravastatin on Cardiovascular Events in Older Patients with Myocardial Infarction and Cholesterol Levels in the Average Range: Results of the Cholesterol and Recurrent Events (CARE) Trial. Annals of Internal Medicine. 1998;129 (9):681. DOI:10.7326/ 0003-4819-129-9-199811010-00002

171. Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels. New England Journal of Medicine. 1998;339 (19): 1349-57. DOI: 10.1056/NEJM199811053391902

172. Jones CG, ClelandJG. Meeting report - the LIDO, HOPE, MOXCON and WASH studies: heart outcomes prevention evaluation: the Warfarin/Aspirin Study of Heart Failure. European Journal of Heart Failure. 1999;1:425-431.

173. Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JGF, Ezekowitz M et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Wafarin and Antiplatelet Therapy in Chronic Heart failure (WATCH) trial. Circulation. 2009; 119 (12):1616-24. DOI:10.1161/CIRCULATIONAHA. 108.801753

174. Homma S, Thompson JLP, Sanford AR, Mann DL, Sacco RL, Levin B et al. Benefit of Warfarin Compared With Aspirin in Patients With Heart Failure in Sinus Rhythm: A Subgroup Analysis of WARCEF, a Randomized Controlled Trial. Circulation: Heart Failure. 2013;6 (5):988-97. DOI:10.1161/CIRCHEARTFAIL-URE. 113.000372

175. Homma S, Thompson JLP, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. New England Journal of Medicine. 2012;366 (20): 1859-69. DOI:10.1056/NEJMoa1202299

176. Акчурин Р. С., Васюк Ю. А., Карпов Ю. А. Национальные рекомендации по диагностике и лечению стабильной стенокардии. Кардиоваскулярная терапия и профилактика. 2008;7 (6 S-4):1-37.

177. Ежов М. В., Сергиенко И. В., Аронов Д. М., Арабидзе Г. Г., Ахмеджанов Н. М., Бажан С. С. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VI пересмотр. Атеросклероз и дислипидемии. 2017; (3):5-22.

178. Levy D. The Progression From Hypertension to Congestive Heart Failure. JAMA: The Journal of the American Medical Association. 1996;275 (20):1557. DOI:10.1001/jama. 1996.03530440037034

179. Мареев В. Ю., Беленков Ю. Н. Хроническая сердечная недостаточность и инсулиннезависимый сахарный диабет: случайная связь или закономерность. Терапевтический архив. 2003;75 (10):1-10.

180. Ильина А. В., Мареев В. Ю., Герасимова В. В., Джахангиров Т. Ш., Беленков Ю. Н. Эффективность терапии иАПФ фозиноприлом больных с ХСН в сочетании с СД 2 типа (по материалам исследования ФАСОН). Журнал Сердечная Недостаточность. 2005;6 (5): 181-5.

181. Krumholz HM, Chen Y-T, Wang Y., Vaccarino V., Radford MJ, Horwitz R.I. Predictors of readmission among elderly survivors of admission with heart failure. American Heart Journal. 2000;139 (1):72-7. DOI:10.1016/S0002-8703 (00) 90311-9

182. Shindler DM, Kostis JB, Yusuf S., Quinones MA, Pitt B., Stewart D. et al. Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry. The American Journal of Cardiology. 1996;77 (11):1017-20. DOI:10.1016/S0002-9149 (97) 89163-1

183. Lewis EJ, Hunsicker LG, Bain RP, Rohde R.D. The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy. New EnglandJournal ofMedicine. 1993;329 ( 20):1456-62. DOI:10.1056 /NEJM199311113292004

184. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355 (9200):253-9. PMID:10675071

185. Brenner BM, Cooper ME, de Zeeuw D., Keane WF, Mitch WE, Parving H-H et al. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. New England Journal ofMedicine. 2001;345 (12):861-9. DOI:10.1056/NEJMoa011161

186. Berl T., Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau J-L, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med. 2003;138 (7):542-9. PMID:12667024

187. Zinman B., Wanner C., Lachin JM, Fitchett D., Bluhmki E., Hantel S. et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015;373 (22):2117-28. DOI:10.1056/NEJMoa1504720

188. Neal B., Perkovic V. Mahaffey KW, de Zeeuw D., Fulcher G., Erondu N. et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine. 2017;377 (7):644-57. DOI:10.1056/NEJMoa1611925

189. Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW et al. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering DrugsClinical Perspective: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation. 2017;136 (3):249 59. DOI:10.1161/CIRCULATIONAHA. 117.029190

190. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352 (9131):854-65. PMID :9742977

191. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28 (10):2345-51.

192. McAlister FA, Eurich DT, Majumdar SR, Johnson JA. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. European Journal of Heart Failure. 2008;10 (7):703 8. DOI:10.1016/j. ejheart. 2008.05.013

193. Crowley MJ, Diamantidis CJ, McDuffie JR, Cameron CB, Stanifer JW, Mock CK et al. Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. Annals of Internal Medicine. 2017;166 (3): 191. DOI: 10.7326/M16-1901

194. Лапина Ю. В., Нарусов О. Ю., Мареев В. Ю. Рациональная Эффективная Многокомпонентная терапия в БОрьбе с Сахаруглеводного обмена. Журнал Сердечная Недостаточность. 2007;8 (4):164-70.

195. Lipska K.J. Metformin Use in Patients With Historical Contraindications. Annals of Internal Medicine. 2017;166 (3):225. DOI:10.7326/M16-2712

196. Tzoulaki I., Molokhia M., Curcin V., Little MP, Millett CJ, Ng A. et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 2009;339 (dec031):b4731 - b4731. DOI:10.1136/bmj. b4731

197. Udell JA, Cavender MA, Bhatt DL, Chatterjee S., Farkouh ME, Scirica B.M. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. RAe Lancet Diabetes & Endocrinology. 2015;3 (5):356-66. DOI:10.1016/S2213-8587 (15) 00044-3

198. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J. et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2015;373 (3):232-42. DOI:10.1056/NEJMoa1501352

199. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL et al. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. New England Journal of Medicine. 2013;369 (14): 1327-35. DOI: 10.1056/NEJMoa1305889

200. Scirica BM, Bhatt DL, Braunwald E., Steg PG, DavidsonJ, Hirshberg B. et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine. 2013;369 (14): 1317-26. DOI: 10.1056/NEJMoa1307684

201. Marso SP, Daniels GH, Brown-Frandsen K., Kristensen P., Mann JFE, Nauck MA et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2016;375 (4):311-22. DOI:10.1056/NEJMoa1603827

202. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. New England Journal of Medicine. 2015;373 (23):2247-57.DOI:10.1056/NEJMoa1509225

203. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New EnglandJournal of Medicine. 2016;375 (19):1834 44. DOI:10.1056/NEJMoa1607141

204. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Trials. JAMA. 2007;298 (10):1180. DOI: 10.1001/jama. 298.10.1180

205. Komajda M, McMurray JJV, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal. 2010;31 (7):824-31. DOI:10.1093/eurheartj/ehp604

206. Rahman A, Kittikulsuth W, Fujisawa Y, Sufiun A, Rafiq K, Hitomi H, et al. Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome: Journal of Hypertension. 2016;34 (5):893-906. DOI:10.1097/HJH. 0000000000000871

207. Ferrannini E., Ramos SJ, Salsali A., Tang W., List J.F. Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33 (10):2217-24. DOI:10.2337/dc10-0612

208. Rosenstock J., Vico M., Wei L., Salsali A., List J.F. Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy. Diabetes Care. 2012;35 (7):1473-8. DOI:10.2337/dc11-1693

209. Del Prato S., Nauck M., Duran-Garcia S., Maffei L., Rohwedder K., Theuerkauf A. et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes, Obesity and Metabolism. 2015;17 (6):581-90. DOI:10.1111/dom. 12459

210. Sonesson C., Johansson PA, Johnsson E., Gause-Nilsson I. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovascular Diabetology. 2016;15 (1). DOI:10.1186/s12933-016-0356-y

211. Kalra S., Jain A., Ved J., Unnikrishnan A. Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect. Indian Journal of Endocrinology and Metabolism. 2016;20 (5):725. DOI: 10.4103/2230-8210.183826

212. Ogawa W., Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. Journal of Diabetes Investigation. 2016;7 (2):135-8. DOI:10.1111/jdi. 12401

213. Verma S., McMurray JJV, Cherney DZI. The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition: The Search for the Sweet Spot in Heart Failure. JAMA Cardiology. 2017;2 (9):939.DOI:10.1001/jamacardio. 2017.1891

214. Nishimura R.A., Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton R.A. et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am Coll Cardiol. 2014;63 (22):2438-88. DOI:10.1016/j. jacc. 2014.02.537

215. Leon MB, Smith CR, Mack M., Miller DC, Moses JW, Svensson LG, et al. Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. New England Journal of Medicine. 2010;363 (17):1597-607. DOI:10.1056/NEJMoa1008232

216. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG et al. Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients. New England Journal of Medicine. 2011;364 (23):2187-98. DOI:10.1056/NEJMoa1103510

217. Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR et al. Two-Year Outcomes after Transcatheter or Surgical Aor-tic-Valve Replacement. New England Journal of Medicine. 2012;366 (18): 1686-95. DOI:10.1056/NEJMoa1200384

218. Bach DS, Bolling S.F. Improvement Following Correction of Secondary Mitral Regurgitation in End-Stage Cardiomyopathy With Mitral An-nuloplasty. The American Journal of Cardiology. 1996;78 (8):966-9. DOI:10.1016/S0002-9149 (96) 00481-X

219. Greenberg B., Massie B., Bristow JD, Cheitlin M., Siemienczuk D., Topic N. et al. Long-term vasodilator therapy of chronic aortic insufficiency. A randomized double-blinded, placebo-controlled clinical trial. Circulation. 1988;78 (1):92-103. DOI:10.1161/01. CIR. 78.1.92

220. Scognamiglio R., Rahimtoola SH, Fasoli G., Nistri S., Volta S.D. Nifedipine in Asymptomatic Patients with Severe Aortic Regurgitation and Normal Left Ventricular Function. New EnglandJournal of Medicine. 1994; 331 (11):689-94. DOI: 10.1056/NEJM199409153311101

221. Мареев В. Ю., Даниелян М. О. Недостаточность митрального клапана в практике терапевта. РМЖ. 1999; (15):706-10.

222. Feldman T., Foster E., Glower DD, Kar S., Rinaldi MJ, Fail PS et al. Percutaneous Repair or Surgery for Mitral Regurgitation. New England Journal of Medicine. 2011;364 (15):1395-406. DOI:10.1056/NEJ-Moa1009355

223. Kenchaiah S., Evans JC, Levy D., Wilson PWF, Benjamin EJ, Larson MG et al. Obesity and the Risk of Heart Failure. New England Journal ofMedicine. 2002;347 (5):305-13. DOI:10.1056/NEJ-Moa020245

224. Walsh CR, Larson MG, Evans JC, Djousse L., Ellison RC, Vasan RS, et al. Alcohol Consumption and Risk for Congestive Heart Failure in the Framingham Heart Study. Annals of Internal Medicine. 2002;136 (3):181. DOI:10.7326/0003-4819-136-3-200202050-00005

225. Abramson JL, Williams SA, Krumholz HM, Vaccarino V. Moderate alcohol consumption and risk of heart failure among older persons. JAMA. 2001;285 (15):1971-7. PMID:11308433

226. Vinogradova NG, Zhirkova MM, Fomin IV, Polyakov DS, Fomin IV, Federal State Budgetary Educational Institution of Higher Education, «Nizhny Novgorod State Medical Academy» of the Ministry of Health of the Russian Federation et al. Efficacy of therapy for chronic heart failure at the outpatient stage in the conditions of a municipal center for CHF. Russian Heart Failure Journal. 2017;17 (4):270-8. DOI:10.18087/rhfj. 2017.4.2355

227. Cowie MR, Mosterd A., Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC et al. The epidemiology of heart failure. European Heart Journal. 1997;18 (2):208-25. DOI:10.1093/oxfordjournals. eurheartj. a015223

228. Wolfel E.E. Can we predict and prevent the onset of acute decompensated heart failure? Circulation. 2007;116 (14):1526-9. DOI: 10.1161 /CIRCULATIONAHA. 107.729608

229. Setoguchi S., Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. American Heart Journal. 2007;154 (2):260-6. DOI:10.1016/j. ahj. 2007.01.041

230. Solomon SD, DobsonJ, Pocock S., Skali H., McMurrayJJV, Granger CB et al. Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure. Circulation. 2007;116 (13):1482-7. DOI:10.1161/CIRCULATIONAHA. 107.696906

231. van der Wal MHL, van Veldhuisen DJ, Veeger NJGM, Rutten FH, Jaarsma T. Compliance with non-pharmacological recommendations and outcome in heart failure patients. European Heart Journal. 2010;31 (12): 1486-93. DOI:10.1093/eurheartj/ehq091

232. Arutyunov AG, Dragunov DO, Arutyunov GP, Sokolova A.V. Impact of the dosing of basic drugs on the risk of rehospitalization in patients with chronic heart failure. Terapevticheskii arkhiv. 2016;88 (1):29. DOI: 10.17116/terarkh201688129-34

233. Formiga F., Chivite D., Manito N., Casas S., Llopis F., Pujol R. Hospitalization due to acute heart failure. Role of the precipitating factors. International Journal of Cardiology. 2007;120 (2):237-41. DOI:10.1016/j. ijcard. 2006.10.004

234. Мареев В. Ю., Беграмбекова Ю. Л., Даниелян М. О., Агеев Ф. Т., Гиляревский С. Р., Беленков Ю. Н. и др. Какие вопросы задаются и на какие вопросы способны ответить исследования по немедикаментозному лечению пациентов с сердечной недостаточностью. Уроки исследования ШАНС. Журнал Сердечная Недостаточность. 2014;15 (6):383-96.

235. Lainscak M., Blue L., Clark AL, Dahlström U., Dickstein K., Ekman I. et al. Self-care management of heart failure: practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology. EuropeanJournal of Heart Failure. 2011; 13 (2):115-26. DOI:10.1093/eurjhf/hfq219

236. Schou M., Gustafsson F., Videbaek L., Tuxen C., Keller N., Handberg J. et al. Extended heart failure clinic follow-up in low-risk patients: a randomized clinical trial (NorthStar). European Heart Journal. 2013;34 (6):432-42. DOI:10.1093/eurheartj/ehs235

237. Gelbrich G., Störk S., Kreißl-Kemmer S., Faller H., Prettin C., Heuschmann PU et al. Effects of structured heart failure disease management on mortality and morbidity depend on patients’ mood: results from the Interdisciplinary Network for Heart Failure Study: Effects of structured HF management depend on patients’ mood. European Journal of Heart Failure. 2014;16 ( 10): 1133-41. DOI:10.1002/ejhf. 150

238. Anker SD, Ponikowski P., Varney S., Chua TP, Clark AL, Webb-Peploe KM et al. Wasting as independent risk factor for mortality in chronic heart failure. The Lancet. 1997;349 (9058):1050-3. DOI:10.1016/S0140-6736 (96) 07015-8

239. Anker S.D. Inflammatory mediators in chronic heart failure: an overview. Heart. 2004;90 (4):464-70. DOI:10.1136/hrt. 2002.007005

240. von Haehling S, Genth-Zotz S, Anker SD, Volk HD. Cachexia: a therapeutic approach beyond cytokine antagonism. Int J Cardiol. 2002;85 (1):173-83. PMID:12163222

241. Cicoira M, Kalra PR, Anker SD. Growth hormone resistance in chronic heart failure and its therapeutic implications. Journal of Cardiac Failure. 2003;9 (3):219-26. DOI:10.1054/jcaf. 2003.23

242. Alsafwah S, Laguardia SP, Arroyo M, Dockery BK, Bhattacharya SK, Ahokas RA. et al. Congestive heart failure is a systemic illness: a role for minerals and micronutrients. Clin Med Res. 2007;5 (4):238-43. DOI: 10.3121/cmr. 2007.737

243. Арутюнов Г. П., Костюкевич О. И., Былова Н. А. Распространенность, клиническая значимость гипотрофии и эффективность нутритивной поддержки у пациентов, страдающих хронической сердечной недостаточностью. Экспериментальная и клиническая гастроэнтерология. 2009; (2):22-33

244. Witte KKA, Nikitin NP, Parker AC, von Haehling S., Volk H-D, Anker SD et al. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. European Heart Journal. 2005;26 (21):2238-44. DOI:10.1093/eurheartj/ehi442

245. Doukky R., Avery E., Mangla A., Collado FM, Ibrahim Z., Poulin M-F, et al. Impact of Dietary Sodium Restriction on Heart Failure Outcomes. JACC: Heart Failure. 2016;4 (1):24-35. DOI:10.1016/j. jchf. 2015.08.007

246. Paterna S., Gaspare P., Fasullo S., Sarullo FM, Di Pasquale P. Normalsodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend? Clinical Science. 2008;114 (3):221-30. DOI:10.1042/CS20070193

247. Lennie TA, Song EK, Wu J-R, Chung ML, Dunbar SB, Pressler SJ et al. Three gram sodium intake is associated with longer event-free survival only in patients with advanced heart failure. Journal of Cardiac Failure. 2011;17 (4):325-30. DOI:10.1016/j. cardfail. 2010.11.008

248. Damgaard M, Norsk P, Gustafsson F, Kanters JK, Christensen NJ, Bie P et al. Hemodynamic and neuroendocrine responses to changes in sodium intake in compensated heart failure. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2006;290 (5):R1294-301. DOI:10.1152/ajpregu. 00738.2005

249. Nehra A, Jackson G, Miner M, Billups KL, Burnett AL, Buvat J et al. The Princeton III Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular Disease. Mayo Clinic Proceedings. 2012;87 (8):766-78. DOI:10.1016/j. mayocp. 2012.06.015

250. Kostis JB, Jackson G., Rosen R., Barrett-Connor E., Billups K., Burnett AL et al. Sexual Dysfunction and Cardiac Risk (the Second Princeton Consensus Conference). The American Journal of Cardiology. 2005;96 (2):313-21. DOI:10.1016/j. amjcard. 2005.03.065

251. Webster LJ, Michelakis ED, Davis T., Archer S.L. Use of Sildenafil for Safe Improvement of Erectile Function and Quality of Life in Men With New York Heart Association Classes II and III Congestive Heart Failure: A Prospective, Placebo-Controlled, Double-blind Crossover Trial. Archives of Internal Medicine. 2004;164 (5):514. DOI:10.1001/archinte. 164.5.514

252. Freitas D, Athanazio R, Almeida D, Dantas N, Reis F. Sildenafil improves quality of life in men with heart failure and erectile dysfunction. International Journal of Impotence Research. 2006;18 (2):210 2. DOI:10.1038/sj. ijir. 3901385

253. Belardinelli R., Lacalaprice F., Faccenda E., Purcaro A., Perna G. Effects of short-term moderate exercise training on sexual function in male patients with chronic stable heart failure. International Journal of Cardiology. 2005;101 (1):83-90. DOI:10.1016/j. ijcard. 2004.05.020

254. Беграмбекова Ю. Л., Дробижев М. Ю., Мареев В. Ю., Кикта С. В. Можно ли сказать что-то новое о депрессиях у больных хронической сердечной недостаточностью? Журнал Сердечная Недостаточность. 2015;16 (6):360-7.

255. Дробижев М. Ю., Беграмбекова Ю. Л., Мареев В. Ю., Кикта С. В. Влияние депрессии и тревоги на клинические исходы у больных ХСН. Журнал Сердечная Недостаточность. 2016;17 (2):91-8

256. Piepoli MF, Crisafulli A. Pathophysiology of human heart failure: importance of skeletal muscle myopathy and reflexes. Experimental Physiology. 2014;99 (4):609-15. DOI:10.1113 / expphysiol. 2013.074310

257. Poole DC, Hirai DM, Copp SW, Musch TI. Muscle oxygen transport and utilization in heart failure: implications for exercise (in) tolerance. AJP: Heart and Circulatory Physiology. 2012;302 (5):H1050-63. DOI:10.1152/ajpheart. 00943.2011

258. De Sousa E, Veksler V, Bigard X, Mateo P, Ventura-Clapier R. Heart failure affects mitochondrial but not myofibrillar intrinsic properties of skeletal muscle. Circulation. 2000;102 (15):1847-53. PMID:11023942

259. Ribeiro JP, Chiappa GR, Callegaro CC. fbe contribution of inspiratory muscles function to exercise limitation in heart failure: pathophysiological mechanisms. Rev Bras Fisioter. 2012;16 (4):261-7. PMID:22801449

260. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ. 2004;328 (7433):189-0. DOI: 10.1136/bmj. 37938.645220. EE

261. Davies EJ, Moxham T, Rees K, Singh S, Coats AJS, Ebrahim S et al. Exercise training for systolic heart failure: Cochrane systematic review and meta-analysis. European Journal of Heart Failure. 2010;12 (7):706-15. DOI:10.1093/eurjhf/hfq056

262. Smart N., Marwick T.H. Exercise training for patients with heart failure: a systematic review of factors that improve mortality and morbidity. Ue American Journal of Medicine. 2004;116 (10):693-706. DOI:10.1016/j.amjmed. 2003.11.033

263. Pandey A., Parashar A., Kumbhani DJ, Agarwal S., Garg J., Kitzman D., et al. Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials. Circ Heart Fail. 2015;8 (1):33-40. DOI: 10.1161/CIRCHEARTFAILURE. 114.001615

264. Isnard R., Pousset F., Trochu J-N, ChafirovskaiHa O., Carayon A., Golmard J-L et al. Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure. The American Journal of Cardiology. 2000;86 (4):417-21. DOI: 10.1016/S0002-9149 (00) 00957-7

265. Guazzi M., Adams V., Conraads V., Halle M., Mezzani A., Vanhees L. et al. Clinical Recommendations for Cardiopulmonary Exercise Testing Data Assessment in Specific Patient Populations. Circulation. 2012;126 (18):2261-74.DOI:10.1161/CIR.0b013e31826fb946

266. Scardovi AB, Coletta C., De Maria R., Perna S., Aspromonte N., Feola M., et al. fbe cardiopulmonary exercise test is safe and reliable in elderly patients with chronic heart failure: Journal of Cardiovascular Medicine. 2007;8 (8):608-12. DOI:10.2459/01. JCM. 0000281698.53983.4e

267. Corrà U., Agostoni PG, Anker SD, Coats AJS, Crespo Leiro MG, de Boer fb. et al. Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology: Cardiopulmonary exercise testing and prognosis in H.F. European Journal of Heart Failure. 2018;20 (1):3-15. DOI:10.1002/ejhf. 979

268. Bellet RN, Adams L., Morris N.R. fbe 6-minute walk test in outpatient cardiac rehabilitation: validity, reliability and responsiveness - a systematic review. Physiotherapy. 2012;98 (4):277-86. DOI:10.1016/j. physio. 2011.11.003

269. ATS Statement: Guidelines for the Six-Minute Walk Test. American J ournal of Respiratory and Critical Care Medicine. 2002;166 (1):111 7. DOI:10.1164/ajrccm. 166.1. at1102

270. Арутюнов Г. П. Вопросы немедикаментозного лечения пациентов, страдающих сердечной недостаточностью. Журнал Сердечная Недостаточность. 2001;2 (1):35-6.

271. Осипова И. В. «Свободный выбор нагрузки» физических тренировок - эффективный метод лечения хронической сердечной недостаточности. Журнал Сердечная Недостаточность. 2001;2 (4):176-80.

272. Ribeiro JP, Chiappa GR, Neder JA, Frankenstein L. Respiratory muscle function and exercise intolerance in heart failure. Curr Heart Fail Rep. 2009;6 (2):95-101. PMID:19486593

273. Dall’Ago P., Chiappa GRS, Guths H., Stein R., Ribeiro J.P. Inspiratory muscle training in patients with heart failure and inspiratory muscle weakness: a randomized trial. J. Am Coll Cardiol. 2006;47 (4):757-63. DOI:10.1016/j. jacc. 2005.09.052

274. Callegaro CC, Martinez D., Ribeiro PAB, Brod M., Ribeiro J.P. Augmented peripheral chemoreflex in patients with heart failure and inspiratory muscle weakness. Respir Physiol Neurobiol. 2010;171 (1):31-5. DOI:10.1016/j. resp. 2010.01.009

275. Kolesnikova EA, Arutyunov GP, Rylova AK, Lobzeva VI, Rylova NV. Respiratory muscle trainings as a way of physical rehabilitation for old patients with complicated myocardial infarction. European HeartJournal. 2013;34 (suppl 1):P5786 - P5786. DOI:10.1093/eur-heartj/eht310. P5786

276. Арутюнов Г. П., Рылова Н. В., Колесникова Е. А., Рылова А. К. Тренировки дыхательной мускулатуры в программе реабилитации больных с ХСН III-IV ФК и легочной гипертензией. CardioСоматика. 2011; (S1):8.

277. Арутюнов Г. П., Колесникова Е. А., Рылова А. К. Современные подходы к реабилитации больных с хронической сердечной недостаточностью. CardioСоматика. 2010; (1):20-4.

278. Mancini DM, Henson D., La Manca J., Donchez L., Levine S. Benefit of selective respiratory muscle training on exercise capacity in patients with chronic congestive heart failure. Circulation. 1995;91 (2):320-9. PMID:7805234

279. Arutyunov GP, Kolesnikova EA, Begrambekova YL, Orlova IA, Rylova AK, Aronov DM et al. Exercise training in chronic heart failure: practical guidance of the Russian Heart Failure Society. Russian Heart Failure Journal. 2017;18 (1):41-66. DOI:10.18087/rhfj. 2017.1.2339

280. Shah P., Pellicori P., Macnamara A., Urbinati A., Clark A.L. Is Swimming Safe in Heart Failure? A Systematic Review: Cardiology in Review. 2017;25 (6):321-5. DOI:10.1097/CRD. 0000000000000154

281. Vanhees L. Effect of exercise training in patients with an implantable cardioverter defibrillator. European Heart Journal. 2004;25 (13):1120-6. DOI:10.1016/j. ehj. 2004.04.034

282. Belardinelli R., Capestro F., Misiani A., Scipione P., Georgiou D. Moderate exercise training improves functional capacity, quality of life, and endothelium-dependent vasodilation in chronic heart failure patients with implantable cardioverter defibrillators and cardiac resynchronization therapy: European Journal of Cardiovascular Prevention & Rehabilitation. 2006;13 (5):818-25. DOI:10.1097/01. hjr. 0000230104.93771.7d

283. Piccini JP, Hellkamp AS, Whellan DJ, Ellis SJ, Keteyian SJ, Kraus WE et al. Exercise Training and Implantable Cardioverter-Defibrillator Shocks in Patients With Heart Failure. JACC: Heart Failure. 2013;1 (2):142-8. DOI:10.1016/j. jchf. 2013.01.005

284. Feldman AM, Silver MA, Francis GS, de Lame P-A, Parmley WW. Treating Heart Failure With Enhanced External Counterpulsation (EECP): Design of the Prospective Evaluation of EECP in Heart Fail ure (PEECH) Trial. Journal of Cardiac Failure. 2005;11 (3):240-5. DOI:10.1016/j. cardfail. 2004.10.001

285. Габрусенко С. А., Малахов В. В., Сергиенко И. В., Бугрий М. Е., Саидова М. А., Кухарчук В. В. и др. Новые возможности в лечении больных сердечной недостаточностью. Метод наружной контрпульсации. Кардиология. 2008;48 (9): 10-6.

286. Soran O., Fleishman B., Demarco T., Grossman W., Schneider VM, Manzo K. et al. Enhanced External Counterpulsation in Patients With Heart Failure: A Multicenter Feasibility Study. Congestive Heart Failure. 2002;8 (4):204-27. DOI:10.1111/j. 1527-5299.2002.01731. x

287. Ponikowski P., Voors AA, Anker SD, Bueno H., ClelandJGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure. 2016;18 (8):891-975. DOI:10.1002/ejhf. 592

288. Florea VG, Rector TS, Anand IS, Cohn J.N. Heart Failure With Improved Ejection Fraction: Clinical Characteristics, Correlates of Recovery, and SurvivalCLINICAL PERSPECTIVE: Results From the Valsartan Heart Failure Trial. Circulation: Heart Failure. 2016;9 (7):e003123. DOI:10.1161/CIRCHEARTFAILURE. 116.003123

289. Solomon SD, Claggett B., Lewis EF, Desai A., Anand I., Sweitzer NK, et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016;37 (5):455-62. DOI:10.1093/eur-heartj/ehv464

290. Lund LH, Claggett B., Liu J., Lam CS,Jhund PS, Rosano GM et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J. Heart Fail. 2018; DOI:10.1002/ejhf. 1149

291. Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273 (18):1450-6.

292. Мареев В. Ю., Даниелян М. О., Беленков Ю. Н. Влияние терапии на прогноз и выживаемость больных с хронической сердечной недостаточностью. Русский медицинский журнал. 1999;2:9-12.

293. Shekelle PG, Rich MW, Morton SC, Atkinson CSW, Tu W., Maglione M. et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J. Am Coll Cardiol. 2003;41 (9):1529-38. PMID:12742294

294. Keyhan G., Chen S-F, Pilote L. Angiotensin-converting enzyme inhibitors and survival in women and men with heart failure. European Journal of Heart Failure. 2007;9 (6-7):594-601. DOI:10.1016/j. ejheart. 2007.03.004

295. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П., Васюк Ю. А., Глезер М. Г., Кобалава Ж. Д. и др. Применение диклофенака и целебрекса у пациентов с артериальной гипертонией и болями в нижней части спины на фоне гипотензивной терапии аккупро или норваском (исследование ДОЦЕНТ). Журнал Сердечная Недостаточность. 2005;6 (5):204-208.

296. Bank AJ, Kubo SH, Rector TS, Heifetz SM, Williams RE. Local forearm vasodilation with intra-arterial administration of enalaprilat in hu mans. Clinical Pharmacology and Therapeutics. 1991;50 (3):314-21. DOI:10.1038/clpt. 1991.142

297. Bleumink GS, Feenstra J, Sturkenboom MCJM, Stricker BHC. Nonsteroidal anti-inflammatory drugs and heart failure. Drugs. 2003;63 (6):525-34

298. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. Journal of the American College of Cardiology. 1992;20 (7):1549-55. DOI:10.1016/0735-1097 (92) 90449-W

299. Мареев В. Ю. Взаимодействие лекарственных средств при лечении больных с сердечно-сосудистыми заболеваниями. Ингибиторы АПФ и аспирин. Есть ли повод для тревоги? Сердце: журнал для практикующих врачей. 2002;1 (4):161-168.

300. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam M.A. Antiplatelet Agents and Survival: A Cohort Analysis From the Studies of Left Ventricular Dysfunction (SOLVD) Trial. Journal of the American College of Cardiology. 1998;31 (2):419-25. DOI:10.1016/S0735-1097 (97) 00502-0

301. Nguyen KN, Aursnes I., Kjekshus J. Interaction Between Enalapril and Aspirin on Mortality After Acute Myocardial Infarction: Subgroup Analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). The American Journal of Cardiology. 1997;79 (2):115-9. DOI:10.1016/S0002-9149 (96) 00696-0

302. Kindsvater S., Leclerc K., Ward J. Effects of coadministration of aspirin or clopidogrel on exercise testing in patients with heart failure receiving angiotensin-converting enzyme inhibitors**The opinions and research contained herein are exclusively those of the authors and are not to be considered as official or reflecting the views of the Department of the Army, Department of the Air Force, or the Department of Defense. The American Journal of Cardiology. 2003;91 (11):1350-2. DOI:10.1016/S0002-9149 (03) 00328-X

303. Spaulding C., Charbonnier B., Cohen-Solal A., Juilliere Y., Kromer EP, Benhamda K. et al. Acute Hemodynamic Interaction of Aspirin and Ticlopidine With Enalapril: Results of a Double-Blind, Randomized Comparative Trial. Circulation. 1998;98 (8):757-65. DOI:10.1161/01. CIR. 98.8.757

304. Лопатин Ю. М. Совместное применение аспирина и ингибиторов АПФ при ХСН: позиция «За». Журнал Сердечная Недостаточность. 2003;4 (3):149-152.

305. Мареев В. Ю. Аспирин при хронической сердечной недостаточности. Взаимодействие аспирина с основными средствами лечения декомпенсации. Журнал Сердечная Недостаточность. 4 (3):153-

306. Teo KK, Yusuf S., Pfeffer M., Torp-Pedersen C., Kober L., Hall A. et al. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet. 2002;360 (9339):1037-43.

307. Harjai KJ, Solis S., Prasad A., Loupe J. Use of aspirin in conjunction with angiotensin-converting enzyme inhibitors does not worsen long-term survival in heart failure. International Journal of Cardiology. 2003;88 (2-3):207-14. DOI:10.1016/S0167-5273 (02) 00401-1

308. Collaboration A.T. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324 (7329):71-86. DOI: 10.1136/bmj. 324.7329.71

309. Progress. Effects of a Perindopril-Based Blood Pressure-Lowering Regimen on Disability and Dependency in 6105 Patients With Cerebrovascular Disease: A Randomized Controlled Trial. Stroke. 2003;34 (10):2333-8. DOI:10.1161/01. STR. 0000091397.81767.40

310. Gruppoitalianoperlostudiodell. GISSI-3: effects of lisiriopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. The Lancet [Internet]. 1994 [cited on Febrary 12, 2018];343 (8906). DOI: 10.1016/S0140-6736 (94) 90232-1

311. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N EnglJ Med. 1991;325 (5):293-302. DOI: 10.1056/NEJM199108013250501

312. Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection Fractions. New EnglandJournal ofMedicine. 1992;327 (10):685-91. DOI:10.1056/NEJM199209033271003

313. Cohn JN, Johnson G., Ziesche S., Cobb F., Francis G., Tristani F. et al. A Comparison of Enalapril with Hydralazine - Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure. New England Journal of Medicine. 1991;325 (5):303-10. DOI:10.1056/NEJM19 9108013250502

314. Willenheimer R. Effect on Survival and Hospitalization of Initiating Treatment for Chronic Heart Failure With Bisoprolol Followed by Enalapril, as Compared With the Opposite Sequence: Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005;112 (16):2426-35. DOI: 10.1161/CIRCULATIONAHA. 105.582320

315. Packer M., Califf RM, Konstam MA, Krum H., McMurray JJ, Rouleau J-L et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106 (8):920-6.

316. Dickstein K., Kjekshus J., OPTIMAAL Steering Committee of the OP-TIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360 (9335):752-60. PMID:12241832

317. Kleber FX, Doering W. Prognosis of mild chronic heart failure: effects ofthe ACE inhibitor captopril. Herz. 1991;16 Spec No 1:283-93.

318. Kleber FX, Niemöller L. Long-term survival in the Munich Mild Heart Failure Trial (MHFT). "Шє American Journal of Cardiology. 1993;71 (13):1237-9. DOI:10.1016/0002-9149 (93) 90657-X

319. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losar-tan Heart Failure Survival Study ELITE II. RAe Lancet. 2000;355 (9215):1582-7. DOI:10.1016/S0140-6736 (00) 02213-3

320. Скворцов А. А., Насонова С. Н., Сычев А. В. Эффекты длительной терапии ингибитором ангиотензинпревращающего фермента квинаприлом, антагонистом рецепторов к ангиотензину II и комбинацией квинаприла и валсартана у больных с умеренной хронической сердечной недостаточностью. Основные результаты исследования САДКО - ХСН. Кардиология. 2006;46 (7):33-51

321. Borghi C, Marino P, Zardini P, Magnani B, Collatina S, Ambrosio-ni E. Short- and long-term effects of early fosinopril administration in patients with acute anterior myocardial infarction undergoing intravenous thrombolysis: results from the Fosinopril in Acute Myocardial Infarction Study. FAMIS Working Party. Am Heart J. 1998;136 (2):213-25

322. Erhardt L, Maclean A, Ilgenfritz J, Gelperin K, Blumenthal M. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. European Heart Journal. 1995;16 (12):1892-9. DOI:10.1093/oxfordjournals. eurheartj. a060844

323. Brown EJ, Chew PH, MacLean A, Gelperin K, Ilgenfritz JP, Blumenthal M. Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Ue American Journal of Cardiology. 1995;75 (8):596-600. DOI: 10.1016/S0002-9149 (99) 80624-9

324. Zannad F, Chati Z, Guest M, Platc F. Differential effects offosinopril and enalapril in patients with mild to moderate chronic heart failure. American Heart Journal. 1998;136 (4):672-80. DOI:10.1016/S0002-8703(98)70015-8

325. Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal. 2006;27 (19):2338-45. DOI:10.1093 / eurheartj / ehl250

326. Massie BM, Armstrong PW, Cleland JGF, Horowitz JD, Packer M, Poole-Wilson PA et al. Toleration of High Doses of Angiotensin-Converting Enzyme Inhibitors in Patients With Chronic Heart Failure: Results From the ATLAS Trial. Archives of Internal Medicine. 2001;161 (2):165.DOI:10.1001/archinte. 161.2.165

327. Giles TD, Katz R., Sullivan JM, Wolfson P., Haugland M., Kirlin P. et al. Short- and long-acting angiotensin-converting enzyme inhibitors: A randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. Journal of the American College of Cardiology. 1989;13 (6):1240-7. DOI:10.1016/0735-1097 (89) 90294-5

328. Sica DA, Cutler RE, Parmer RJ, Ford N.F. Comparison of the Steady-State Pharmacokinetics of Fosinopril, Lisinopril and Enalapril in Patients with Chronic Renal Insufficiency: Clinical Pharmacokinetics. 1991;20 (5):420-7. DOI:10.2165/00003088-199120050-00006

329. Greenbaum R., Zucchelli P., Caspi A., Nouriel H., Paz R., Sclarovsky S. et al. Comparison of the pharmacokinetics of fosinoprilat with ena-laprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency. Br J. Clin Pharmacol. 2000;49 (1):23-31. PMID:10606834

330. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) - Correction. JAMA. 2004;291 (18):2196. DOI:10.1001/jama. 291.18.2196

331. ClelandJG, Erhardt L., Murray G., Hall AS, Ball S.G. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence ofheart failure. A report from the AIRE Study Investigators. Eur Heart J. 1997;18 (1):41-51. PMID:9049514

332. Kober L., Torp-Pedersen C., Carlsen JE, Bagger H., Eliasen P., Lyngborg K. et al. A Clinical Trial of the Angiotensin-Converting-Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial Infarction. New England Journal of Medicine. 1995;333 (25): 1670-6. DOI: 10.1056/NEJM199512213332503

333. Ambrosioni E., Borghi C., Magnani B. The Effect of the AngiotensinConverting - Enzyme Inhibitor Zofenopril on Mortality and Morbidity after Anterior Myocardial Infarction. New England Journal of Medicine. 1995;332 (2):80-5. DOI:10.1056/NEJM19950112332 0203

334. Effects of Angiotensin-Converting Enzyme Inhibition With Perindopril on Left Ventricular Remodeling and Clinical Outcome: Results of the Randomized Perindopril and Remodeling in Elderly With Acute Myocardial Infarction (PREAMI) Study. Archives of Internal Medicine. 2006;166 (6):659. DOI:10.1001/archinte. 166.6.659

335. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, doubleblind, placebo-controlled, multicentre trial (the EUROPA study). The Lancet. 2003;362 (9386):782-8. DOI:10.1016/S0140-6736 (03)14286-9

336. Мареев В. Ю. Ингибиторы ангиотензинпревращающего фермента в лечении больных с коронарной болезнью сердца. Взгляд 2003 года. Кардиология. 2003;43 (12):4-14.

337. Riegger GAJ. Effects of quinapril on exercise tolerance in patients with mild to moderate heart failure. European Heart Journal. 1991;12 (6):705-11. DOI: 10.1093/eurh ear tj/12.6.705

338. Pflugfelder PW, Baird MG, Tonkon MJ, DiBianco R., Pitt B. Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. The Quinapril Heart Failure Trial Investigators. J. Am Coll Cardiol. 1993;22 (6):1557-63. PMID:8227822

339. Widimsky J., Kremer HJ, Jerie P., Uhlir O. Czech and Slovak spirapril intervention study (CASSIS). A randomized, placebo and active-controlled, double-blind multicentre trial in patients with congestive heart failure. Eur J. Clin Pharmacol. 1995;49 (1-2):95-102.

340. Мареев В. Ю., Ольбинская Л. И., Мартынов А. И. Проспективное, многоцентровое, открытое исследование эффективности и переносимости КВАдроприла у больных с Недостаточностью Кровообращения, обусловленной ишемической болезнью сердца и дилатационной кардиомиопатией (Исследование КВАНК). Журнал Сердечная Недостаточность. 2007;8 (1):42-7.

341. Packer M. Functional Renal Insufficiency During Long-Term Therapy with Captopril and Enalapril in Severe Chronic Heart Failure. Annals of Internal Medicine. 1987;106 (3):346. DOI:10.7326/0003-48 19-106-3-346

342. Packer M., Lee WH, Kessler PD, Medina N., Yushak M., Gottlieb S.S. Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure. Journal of the American College of Cardiology. 1987;10 (4):837-44. DOI:10.1016/S0735-1097 (87) 80278-4

343. David D., Jallad N., Germino FW, Willett MS, de Silva J., Weidner SM, et al. A comparison of the cough profile of fosinopril and enalapril in hypertensive patients with a history of ace inhibitor-associated cough. AmericanJournal of Therapeutics. 1995;2 (10):806-13. DOI:10.109 7/00045391-199510000-00013

344. MacFadyen RJ, Lees KR, Reid J.L. Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study. Heart. 1991;66 (3):206-11. DOI:10.1136/hrt. 66.3.206

345. Navookarasu NT, Rahman AR, Abdullah I. First-dose response to angiotensin-converting enzyme inhibition in congestive cardiac failure: a Malaysian experience. Int J. Clin Pract. 1999;53 (1):25-30. PMID:10344062

346. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. The NETWORK Investigators. Eur Heart J. 1998;19 (3):481-9.

347. Pitt B., Poole-Wilson PA, Segal R., Martinez FA, Dickstein K., Camm AJ et al. Effect oflosartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE I.I. Lancet. 2000;355 (9215):1582-7. PMID:10821361

348. Konstam MA, Neaton JD, Dickstein K., Drexler H., Komajda M., Martinez FA et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. The Lancet. 2009;374 (9704):1840-8. DOI:10.1016/S0140-6736 (09) 61913-9

349. Granger CB, McMurrayJJ, Yusuf S., Held P., Michelson EL, Olofsson B. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. The Lancet. 2003;362 (9386):772-6. DOI:10.1016/S0140-6736 (03) 14284-5

350. McMurray JJ, Östergren J., Swedberg K., Granger CB, Held P., Michelson EL et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensinconverting-enzyme inhibitors: the CHARM-Added trial. The Lancet. 2003;362 (9386):767-71. DOI:10.1016/S0140-6736 (03) 14283-3

351. Yusuf S., Pfeffer MA, Swedberg K., Granger CB, Held P., McMurray JJ et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. The Lancet. 2003;362 (9386):777-81. DOI:10.1016/S0140-6736(03)14285-7

352. Maggioni AP, Anand I., Gottlieb SO, Latini R., Tognoni G., Cohn JN, et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J. Am Coll Cardiol. 2002;40 (8):1414-21. PMID:12392830

353. Hollenberg NK. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. Curr Hypertens Rep. 2002;4 (6):411; discussion 412. PMID:12462208

354. Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, Chiang Y-T et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. Journal of the American College of Cardiology. 2002;40 (5):970-5. DOI:10.1016/S0735-1097 (02) 02063-6

355. McKelvie RS, Rouleau J-L, White M., Afzal R., Young JB, Maggioni AP et al. Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. Eur Heart J. 2003;24 (19):1727-34. PMID :14522567

356. Cohn JN, Tognoni G. A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure. New England Journal of Medicine. 2001;345 (23):1667-75. DOI:10.1056/NEJMoa010713

357. Munar MY, Singh H. Drug dosing adjustments in patients with chronic kidney disease. Am Fam Physician. 2007;75 (10):1487-96. PMID:17555141

358. Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3 (1):1-163.

359. Mareev V. Yu., M. V. Lomonosov Moscow State University, Mareev V.Y. Draft conclusion of the expert Council on chronic heart failure. Russian Heart Failure Journal. 2016;17 (4):291-6. DOI:10.18087/rhfj. 2016.4.2266

360. McMurray JJV, Packer M., Desai AS, Gong J., Lefkowitz MP, Rizkala AR et al. Angiotensin - niprilysin Inhibition versus enalapril in heart failure. New EnglandJournal of Medicine. 2014;371 (11):993-1004. DOI:10.1056/NEJMoa1409077

361. Packer M., McMurray JJV, Desai AS, Gong J., Lefkowitz MP, Rizkala AR et al. Angiotensin receptor niprilysin Inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131 (1):54-61. DOI:10.1161/CIRCULA-TIONAHA. 114.013748

362. Okumura N.,Jhund PS, GongJ, Lefkowitz MP, Rizkala AR, Rouleau JL et al. Effects of Sacubitril/Valsartan in the PARA.DIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background TherapyCLINICAL PERSPECTIVE. Circulation: Heart Failure. 2016;9 (9):e003212. DOI:10.1161/CIRCHEARTFAILURE. 116.003212

363. Lewis EF, Claggett BL, McMurray JJV, Packer M., Lefkowitz MP, Rouleau JL et al. Health-Related Quality of Life Outcomes in PARADIGM-HF. Circulation: Heart Failure. 2017;10 (8):e003430. DOI: 10.1161 / CIRCHEARTFAILURE. 116.003430

364. Solomon SD, Rizkala AR, Gong J., Wang W., Anand IS, Ge J. et al. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure. 2017;5 (7):471-82. DOI:10.1016/j.jchf. 2017.04.013

365. Claggett B., Packer M., McMurrayJJV, Swedberg K., RouleauJ, Zile MR, et al. Estimating the Long-Term Treatment Benefits of Sacubitril - Valsartan. New England Journal of Medicine. 2015;373 (23):2289-90. DOI:10.1056/NEJMc1509753

366. Böhm M., Young R., Jhund PS, Solomon SD, Gong J., Lefkowitz MP, et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARA.-DIGM-HF. Eur Heart J. 2017;38 (15):1132-43. DOI:10.1093/eur-heartj/ehw570

367. Seferovic JP, Claggett B., Seidelmann SB, Seely EW, Packer M., Zile MR et al. Effect of sacubitril/ valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARA.DIGM-HF trial. The Lancet Diabetes & Endocrinology. 2017;5 (5):333-40. DOI:10.1016 /S2213-8587 (17)30087-6

368. Damman K., Testani J.M. "Шє kidney in heart failure: an update. European Heart Journal. 2015;36 (23):1437-44. DOI:10.1093/eur-heartj/ehv010

369. Mogensen UM, Kober L., Jhund PS, Desai AS, Senni M., Kristensen SL et al. Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PA^ADIGM-HF: Sacubitril/valsartan, uric acid, and heart failure. European Journal of Heart Failure [Internet]. 2017 [cited on Febrary 22, 2018]; DOI:10.1002/ejhf. 1056

370. Desai AS, McMurrayJJV Packer M., Swedberg K., Rouleau JL, Chen F., et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. European Heart Journal. 2015;36 (30):1990-7. DOI:10.1093/eur-heartj/ehv186

371. Cohn JN, Levine TB, Olivari MT, Garberg V., Lura D., Francis GS et al. Plasma Norepinephrine as a Guide to Prognosis in Patients with Chronic Congestive Heart Failure. New EnglandJournal of Medicine. 1984;311 (13):819-23.DOI:10.1056/NEJM198409273111303

372. Francis GS, Benedict C.,Johnstone DE, Kirlin PC, Nicklas J., Liang CS et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82 (5):1724-9. DOI:10.1161/01. CIR. 82.5.1724

373. Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т. Хроническая сердечная недостаточность: избранные лекции по кардиологии. -Москва: ГЭОТАР-Медиа; 2006. 432 с. [Belenkov Yu. N., Mareev V. Yu., Ageev F. T. Chronic heart failure: selected lectures on cardiology. -M.: GEOTAR-Media; 2006. - 423p.] ISBN: 978-5-9704-0119-4

374. Communal C., Singh K., Pimentel DR, Colucci W.S. Norepinephrine Stimulates Apoptosis in Adult Rat Ventricular Myocytes by Activation of the -Adrenergic Pathway. Circulation. 1998;98 (13):1329-34. DOI:10.1161/01. CIR. 98.13.1329

375. Беленков Ю. Н., Скворцов А. А., Мареев В. Ю. Клинико-гемодинамические и нейрогормональные эффекты длительной терапии ß-адреноблокатором бисопрололом больных с тяжелой хронической сердечной недостаточностью. Кардиология. 2003;43 (10):10-21.

376. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow M.R. Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomized study. Journal of the American College of Cardiology. 1995;25 (6):1225-31. DOI:10.1016/0735-1097 (95) 00012-S

377. Беленков Ю. Н., Мареев В. Ю., Скворцов А. А. Эналаприл против Карведилола. Сравнительное рандомизированное исследование у больных хронической сердечной недостаточностью (ЭКСТАЗ). Журнал. Сердечная Недостаточность. 2001;2 (2):84-91.

378. McEniery CM, Schmitt M., Qasem A., Webb DJ, Avolio AP, Wilkinson IB et al. Nebivolol Increases Arterial Distensibility In Vivo. Hypertension. 2004;44 (3):305-10. DOI:10.1161/01. HYP. 0000137983.45556.6e

379. Packer M., Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM et al. Ue Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure. New England Journal of Medicine. 1996;334 (21):1349-55. DOI:10.1056/NEJM199605233342101

380. Pasternak B., Svanström H., Melbye M., Hviid A. Association of Treatment With Carvedilol vs Metoprolol Succinate and Mortality in Patients With Heart Failure. JAMA Internal Medicine. 2014;174 (10):1597. DOI:10.1001/jamainternmed. 2014.3258

381. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Austra lia/New Zealand Heart Failure Research Collaborative Group. Lancet. 1997;349 (9049):375-80. PMID:9033462

382. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353 (9146):9-13.

383. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). The Lancet. 1999;353 (9169):2001-7. DOI:10.1016/S0140-6736 (99) 04440-2

384. Packer M., Coats AJS, Fowler MB, Katus HA, Krum H., Mohacsi P. et al. Effect of Carvedilol on Survival in Severe Chronic Heart Failure. New EnglandJournal ofMedicine. 2001;344 (22):1651-8. DOI:10.1056/ NEJM200105313442201

385. Flather MD, Shibata MC, Coats AJS, Van Veldhuisen DJ, Parkhomenko A., Borbola J. et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European HeartJournal. 2005;26 (3):215-25. DOI: 10.1093/eurheartj/ehi115

386. Gaffney TE, Braunwald E. Importance of the adrenergic nervous system in the support of circulatory function in patients with congestive heart failure. The American Journal of Medicine. 1963;34 (3):320-4. DOI:10.1016/0002-9343 (63) 90118-9

387. Cleland J., Pennell D., Ray S., Coats A., Macfarlane P., Murray G. et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. The Lancet. 2003;362 (9377):14-21. DOI:10.1016/S0140-6736 (03) 13801-9

388. Heart Failure Society Of America. Executive Summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. Journal of Cardiac Failure. 2006;12 (1):10-38. DOI:10.1016/j. cardfail. 2005.12.001

389. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П., Коротеев А. В., Ревишвили А. Ш. Национальные рекомендации ВНОК И. ОССН по диагностике и лечению ХСН (второй пересмотр). Журнал Сердечная Недостаточность. 2007;8 (1):4-41.

390. Waagstein F., Hjalmarson A., Swedberg K., Bristow MR, Gilbert EM, Camerini F. et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. The Lancet. 1993;342 (8885):1441-6. DOI:10.1016/0140-6736 (93) 92930-R

391. Hjalmarson Â, Goldstein S., Fagerberg B., Wedel H., Waagstein F., Kjekshus J. et al. Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients With Heart Failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF).JAMA. 2000;283 (10):1295. DOI: 10.1001/jama. 283.10.1295

392. Packer M., Fowler MB, Roecker EB, Coats AJS, Katus HA, Krum H. et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106 (17):2194-9. DOI:10.1161/01. CIR. 0000035653.72855. BF

393. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. The Lancet. 1997;349 (9049):375-80. DOI:10.1016/S0140-6736 (97) 80008-6

394. Poole-Wilson PA, Swedberg K., ClelandJG, Di Lenarda A., Hanrath P., Komajda M. et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. The Lancet. 2003;362 (9377):7-13. DOI:10.1016/S0140-6736 (03) 13800-7

395. Flather MD, Shibata MC, Coats AJS, Van Veldhuisen DJ, Parkhomenko A., Borbola J. et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26 (3):215-25. DOI:10.1093/eurheartj/ehi115

396. Van Veldhuisen DJ, Cohen-Solal A, Böhm M, Anker SD, Babalis D, Roughton M et al. Beta-Blockade With Nebivolol in Elderly Heart Failure Patients With Impaired and Preserved Left Ventricular Ejection Fraction.Journal of the American College of Cardiology. 2009;53 (23):2150-8. DOI:10.1016/j. jacc. 2009.02.046

397. Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J., Coats AJS et al. Beta-blockers for heart failure with reduced, midrange, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. European Heart Journal. 2018;39 (1):26-35. DOI:10.1093/eurheartj/ehx564

398. Willenheimer R. Effect on Survival and Hospitalization of Initiating Treatment for Chronic Heart Failure With Bisoprolol Followed by Enalapril, as Compared With the Opposite Sequence: Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005;112 (16):2426-35. DOI:10.1161/CIRCULA-TIONAHA. 105.582320

399. Kotecha D., Manzano L., Krum H., Rosano G., Holmes J., Altman DG, et al. Effect of age and sex on efficacy and tolerability of ß blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. BMJ. 2016; i1855. DOI:10.1136/bmj. i1855

400. McAlister FA, Wiebe N., Ezekowitz JA, Leung AA, Armstrong P.W. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;150 (11):784-94. PMID:19487713

401. Waagstein F., Caidahl K., Wallentin I., Bergh CH, Hjalmarson A. Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation. 1989;80 (3):551-63. PMID:2548768

402. Gattis WA, O’Connor CM, Leimberger JD, Felker GM, Adams KF, Gheorghiade M. Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. The American Journal of Cardiology. 2003;91 (2):169-74. DOI:10.1016/S0002-9149 (02)03104-1

403. Jondeau G., Neuder Y., Eicher J-C, Jourdain P., Fauveau E., Galinier M., et al. B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. European Heart Journal. 2009;30 (18):2186-92. DOI: 10.1093/eurheartj/ehp323

404. Dorow P., Thalhofer S., Bethge H., Disselhoff G., Wagner G. Long-term treatment of angina pectoris with bisoprolol or atenolol in patients with chronic obstructive bronchitis: a randomized, double-blind crossover study. J. Cardiovasc Pharmacol. 1990;16 Suppl 5: S36-44. PMID:11527135

405. dal Negro RW, Tognella S., Pomari C. Once-Daily Nebivolol 5mg Does Not Reduce Airway Patency in Patients with Chronic Obstructive Pulmonary Disease and Arterial Hypertension: A Placebo-Controlled Crossover Study. Clinical Drug Investigation. 2002;22 (6):361-7. DO I:10.2165/00044011-200222060-00003

406. Bakris GL, Fonseca V., Katholi RE, McGill JB, Messerli F., Phillips et al. Differential Effects of -Blockers on Albuminuria in Patients With Type 2 Diabetes. Hypertension. 2005;46 (6):1309-15. DOI:10.1161/01. HYP. 0000190585.54734.48

407. Poirier L., Cléroux J., Nadeau A., Lacourcière Y. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J. Hypertens. 2001;19 (8):1429-35. PMID:11518851

408. Celik T, Iyisoy A, Kursaklioglu H, Kardesoglu E, Kilic S, Turhan H et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients: Journal of Hypertension. 2006;24 (3):591-6. DOI:10.1097/01. hjh. 0000209993.26057. de

409. Swedberg K., Komajda M., Böhm M., BorerJS, Ford I., Dubost-Brama A., et al. Ivabradine and outcomes in chronic heart failure (SHIFT ): a randomised placebo-controlled study. The Lancet. 2010;376 (9744):875-85. DOI:10.1016/S0140-6736 (10) 61198-1

410. DiFrancesco D., Camm J.A. Heart rate lowering by specific and selective I. (f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs. 2004;64 (16):1757-65. PMID:15301560

411. Bois P., BescondJ, Renaudon B., Lenfant J. Mode of action of bradycardic agent, S. 16257, on ionic currents of rabbit sinoatrial node cells. Brit ish Journal of Pharmacology. 1996;118 (4):1051-7. DOI:10.1111/j. 1476-5381.1996. tb15505. x

412. Виноградов А.В. Мочегонные средства в клинике внутренних болезней. Медицина; 1969. 152 с.

413. Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т. Хроническая сердечная недостаточность. Избранные лекции по кардиологии. 2006. 432 с. ISBN: 5-9704-0119-6

414. Kjekshus J., Swedberg K. Tolerability of enalapril in congestive heart failure. The American Journal of Cardiology. 1988;62 (2):67A-72A. DOI:10.1016/S0002-9149 (88) 80088-2

415. Swedberg K., Eneroth P., Kjekshus J., Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CON SEN SUS Trial Study Group. Circulation. 1990;82 (5):1730-6. DOI:10.1161/01. CIR. 82.5.1730

416. Ljungman S., Kjekshus J., Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). The American Journal of Cardiology. 1992;70 (4):479-87. DOI:10.1016/0002-9149 (92) 91194-9

417. Tsuyuki RT, Yusuf S., Rouleau JL, Maggioni AP, McKelvie RS, Wiecek EM et al. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. CanJ Cardiol. 1997;13 (12):1166-74. PMID:9444298

418. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J et al. Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart Failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study: The RESOLVD Pilot Study Investigators. Circulation. 1999;100 (10):1056 64. DOI:10.1161/01. CIR. 100.10.1056

419. Svensson M, Gustafsson F, Galatius S0, Hildebrandt PR, Atar D. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? Journal of Cardiac Failure. 2004;10 (4):297-303. DOI:10.1016/j. cardfail. 2003.10.012

420. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A et al. Rates ofHyperkalemia after Publication of the Randomized Aldactone Evaluation Study. New England Journal of Medicine. 2004;351 (6):543-51. DOI:10.1056/NEJMoa040135

421. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. New England Journal of Medicine. 1999;341 (10):709-17. DOI:10.1056/NEJM199909023411001

422. Packer M. Identification of risk factors predisposing to the development of functional renal insufficiency during treatment with converting-enzyme inhibitors in chronic heart failure. Cardiology. 1989;76 Suppl 2:50-5. DOI:10.1159/000174559

423. Pitt B., White H., NicolauJ, Martinez F., Gheorghiade M., Aschermann M. et al. Eplerenone Reduces Mortality 30 Days After Randomization Following Acute Myocardial Infarction in Patients With Left Ventricular Systolic Dysfunction and Heart Failure. Journal of the American College ofCardiology. 2005;46 (3):425-31. DOI:10.1016/j. jacc. 2005.04.038

424. Pitt B., Gheorghiade M., Zannad F., Anderson JL, van Veldhuisen DJ, Parkhomenko A. et al. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction №30%. European Journal of Heart Failure. 2006;8 (3):295-301. DOI:10.1016/j. ejheart. 2005.11.008

425. Zannad F., McMurray JJV, Krum H., van Veldhuisen DJ, Swedberg K., Shi H. et al. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine. 2011;364 (1):11-21. DOI: 10.1056/NEJMoa1009492

426. Zannad F., Alla F., Dousset B., Perez A., Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000;102 (22):2700-6. PMID:11094035

427. Udelson JE, Feldman AM, Greenberg B., Pitt B., Mukherjee R., Solomon HA et al. Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Effect of Aldosterone Antagonism With Eplerenone on Ventricular Remodeling in Patients With Mild-to-Moderate Heart Failure and Left Ventricular Systolic Dysfunction. Circulation: Heart Failure. 2010;3 (3):347-53. DOI:10.1161/CIRCHEARTFAILURE. 109.906909

428. Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV Konstam MA, Udelson J.E. Quantitative Evaluation of Drug or Device Effects on Ventricular Remodeling as Predictors of ^erapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection Fraction. J. ournal of the American College of Cardiology. 2010;56 (5):392-406. DOI:10.1016/j. jacc. 2010.05.011

429. Li X., Qi Y., Li Y., Zhang S., Guo S., Chu S. et al. Impact of Mineralocorticoid Receptor Antagonists on Changes in Cardiac Structure and Function of Left Ventricular Dysfunction: A Meta-analysis of Randomized Controlled Trials. Circulation: Heart Failure. 2013;6 (2):156-65. DOI:10.1161/CIRCHEARTFAILURE. 112.000074

430. Phelan D., ^avendiranathan P., Collier P., Marwick T.H. Aldosterone antagonists improve ejection fraction and functional capacity independently offunctional class: a meta-analysis ofrandomised controlled trials. Heart. 2012;98 (23):1693-700. DOI:10.1136/heartjnl-2012-30 2178

431. Swedberg K, Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Shi H et al. Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure. Journal of the American College of Cardiology. 2012;59 (18):1598-603. DOI:10.1016/j. jacc. 2011.11.063

432. Bapoje SR, Bahia A., Hokanson JE, Peterson PN, Heidenreich PA, Lindenfeld J. et al. Effects of Mineralocorticoid Receptor Antagonists on the Risk of Sudden Cardiac Death in Patients With Left Ventricular Systolic Dysfunction: A Meta-analysis of Randomized Controlled Trials. Circulation: Heart Failure. 2013;6 (2):166-73. DOI:10.1161/CIRCHEARTFAILURE. 112.000003

433. Hu L., Chen Y., Deng S., Du J., She Q. Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis: Additional use of aldosterone antagonist in mild-to-moderate CHF patients. British Journal of Clinical Pharmacology. 2013;75 (5):1202-12. DOI:10.1111/bcp. 12012

434. Authors/Task Force Members, McMurrayJJV, Adamopoulos S., Anker SD, Auricchio A., Bohm M. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: "Шє Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2012;33 (14):1787-847. DOI:10.1093/eurheartj/ehs 104

435. Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1):1-163.

436. Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: "Шє ROSE acute heart failure randomized trial. JAMA. 2013;310 (23):2533. DOI:10.1001/ja-ma. 2013.282190

437. Cody R.J. Diuretic treatment for the sodium retention of congestive heart failure. Archives of Internal Medicine. 1994;154 (17):1905-14. DOI: 10.1001/archinte. 154.17.1905

438. PattersonJH, Adams KF, Applefeld MM, Corder CN, Masse B.R. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group. Pharmacotherapy. 1994;14 (5):514-21.

439. Brater D.C. Diuretic ^erapy. Wood AJJ, редактор. New EnglandJournal ofMedicine. 1998;339 (6):387-95. DOI:10.1056/NEJM199808 063390607

440. Мухарлямов Н. М., Мареев В. Ю. Лечение хронический сердечной недостаточности. - М.: Медицина; 1985. 208 с.

441. Vasko M.R. Furosemide Absorption Altered in Decompensated Congestive Heart Failure. Annals of Internal Medicine. 1985;102 (3):314. DOI:10.7326/0003-4819-102-3-314

442. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R. et al. Amiodarone or an implantable cardioverter - defibrillator for congestive heart failure. New England Journal of Medicine. 2005;352 (3):225-37.DOI:10.1056/NEJMoa043399

443. Staessen JA, Wang J-G, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. The Lancet. 2001;358 (9290):1305-15. DOI:10.1016/S0140-6736 (01) 06411-X

444. Kjekshus J., Dunselman P., Blideskog M., Eskilson C., Hjalmarson Å, McMurray JV et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics. European Journal of Heart Failure. 2005;7 (6):1059-69. DOI:10.1016/j. ejheart. 2005.09.005

445. GISSI-HF investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. The Lancet. 2008;372 (9645):1231-9. DOI:10.1016/S0140-6736 (08) 61240-4

446. Horwich TB, Hamilton MA, MacLellan WR, Fonarow G.C. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. Journal of Cardiac Failure. 2002;8 (4):216-24. DOI:10.1054/jcaf. 2002.0804216

447. Brater DC, Chennavasin P., Seiwell R. Furosemide in patients with heart failure: Shift in dose-response curves. Clinical Pharmacology and Therapeutics. 1980;28 (2):182-6. DOI:10.1038/clpt. 1980.148

448. Dormans TPJ, van Meyel JJM, Gerlag PGG, Tan Y., Russel FGM, Smits P. Diuretic efficacy of high dose furosemide in severe heart failure: Bolus injection versus continuous infusion. Journal of the American College of Cardiology. 1996;28 (2):376-82. DOI:10.1016/0735-1097(96) 00161-1

449. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR et al. Diuretic strategies in patients with acute decompensated heart failure. New EnglandJournal ofMedicine. 2011;364 (9):797-805. DOI:10.1056/NEJMoa1005419

450. Sharma K., VaishnavJ, Kalathiya R., Miller J., Shah N., Hill T. et al. Randomized Evaluation of Heart Failure with Preserved Ejection Fraction Patients with Acute Heart Failure and Dopamine (Ropa-Dop) Trial. Journal of Cardiac Failure. 2017;23 (11):831. DOI:10.1016/j. cardfail. 2017.10.006

451. Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure*. Clinical Pharmacology & Therapeutics. 1995;57 (6):601-9. DOI:10.1016/0009-9236(95)90222-8

452. Fortuno A., Muniz P., Ravassa S., Rodriguez JA, Fortuno MA, Zalba G. et al. Torasemide Inhibits Angiotensin II Induced Vasoconstriction and Intracellular Calcium Increase in the Aorta of Spontaneously Hypertensive Rats. Hypertension. 1999;34 (1):138-43. DOI:10.1161/01. HYP. 34.1.138

453. Yamato M., Sasaki T., Honda K., Fukuda M., Akutagawa O., Okamoto M. et al. Effects of Torasemide on Left Ventricular Function and Neurohumoral Factors in Patients With Chronic Heart Failure. Circulation Journal. 2003;67 (5):384-90. DOI:10.1253/circj. 67.384

454. Kasama S. Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure. Heart. 2006;92 (10):1434-40. DOI:10.1136/hrt. 2005.079764

455. Агеев Ф. Т., Жубрина Е. С., Гиляревский С. Р., Мареев В. Ю., Хосева Е. Н., Голшмид М. В. Сравнительная эффективность и безопасность длительного применения торасемида и фуросемида у больных с компенсированной сердечной недостаточностью. Влияние на маркеры фиброза миокарда. Журнал Сердечная Недостаточность. 2013;14:55-62.

456. Müller K., Gamba G., Jaquet F., Hess B. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV-efficacy and quality oflife. EuropeanJournal of Heart Failure. 2003;5 (6):793-801. DOI:10.1016/S1388-9842 (03) 00150-8

457. Stroupe KT, Forthofer MM, Brater DC, Murray M.D. Healthcare Costs of Patients with Heart Failure Treated with Torasemide or Furosemide: PharmacoEconomics. 2000;17 (5):429-40. DOI:10.2165/00 019053-200017050-00002

458. Мареев В. Ю., Выгодин В. А., Беленков Ю. Н. ДиУретическая терапия Эффективными дозами перораЛЬных диуретиков торасемида (Диувер) и фуросемида в лечении больных с обострением Хронической Сердечной Недостаточности (ДУЭЛЬ - ХСН). Журнал Сердечная Недостаточность. 12 (1):3-10.

459. Cosin J., Diez J., on behalf of the TORIC investigators. Torasemide in chronic heart failure: results ofthe TORIC study. EuropeanJournal of Heart Failure. 2002;4 (4):507-13. DOI:10.1016/S1388-9842 (02) 00122-8

460. Verbrugge FH, Grieten L., Mullens W. Management of the Cardiorenal Syndrome in Decompensated Heart Failure. Cardiorenal Medicine. 2014;4 (3-4):176-88. DOI:10.1159/000366168

461. Jones P., Greenstone M. Carbonic anhydrase inhibitors for hypercapnic ventilatory failure in chronic obstructive pulmonary disease. Cochrane Airways Group, редактор. Cochrane Database of Systematic Reviews [Internet]. 2001 [cited on Febrary 1, 2018]; DOI:10.1002/14651858. CD002881

462. Philippi H., Bieber I., Reitter B. Acetazolamide Treatment for Infantile Central Sleep Apnea. Journal of Child Neurology. 2001;16 (8):600-3. DOI:10.1177/088307380101600813

463. Javaheri S. Acetazolamide Improves Central Sleep Apnea in Heart Failure: A Double-Blind, Prospective Study. American Journal of Respiratory and Critical Care Medicine. 2006;173 (2):234-7. DOI:10.1164/rccm. 200507-1035OC

464. Bart BA, Goldsmith SR, Lee KL, Givertz MM, O’Connor CM, Bull DA et al. Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome. New England Journal of Medicine. 2012;367 (24):2296-304. DOI:10.1056/NEJMoa1210357

465. Bastien N., Haddad H., Bergeron S., Ignaszewski A., Searles G. The para-sail study: patient reported outcomes from the Canadian real world experience use of sacubitril/valsartan in patients with heart failure and reduced ejection fraction. Canadian Journal of Cardiology. 2017;33 (10):S162-3. DOI:10.1016/j. cjca. 2017.07.316

466. Vardeny O., Claggett B., Packer M., Zile MR, Rouleau J., Swedberg K., et al. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PAiRA-DIGM-HF trial: Angiotensin receptor neprilysin inhibitor and heart failure. European Journal of Heart Failure. 2016;18 (10):1228-34. DOI:10.1002/ejhf. 580

467. Mullens W., Abrahams Z., Francis GS, Sokos G., Taylor DO, Starling RC, et al. Importance ofVenous Congestion for Worsening of Renal Function in Advanced Decompensated Heart Failure. Journal of the American College of Cardiology. 2009;53 (7):589-96. DOI:10.1016/j. jacc. 2008.05.068

468. Damman K., Voors AA, Hillege HL, Navis G., Lechat P., van Veldhuisen DJ et al. Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. European Journal of Heart Failure. 2010;12 (9):974-82. DOI:10.1093/eurjhf/hfq118

469. Ferguson DW, Berg WJ, Sanders JS, Roach PJ, Kempf JS, Kienzle M.G. Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. Circulation. 1989;80 (1):65-77. DOI:10.1161/01. CIR. 80.1.65

470. Gheorghiade M., Ferguson D. Digoxin. A neurohormonal modulator in heart failure? Circulation. 1991;84 (5):2181-6. DOI:10.1161/01. CIR. 84.5.2181

471. Нарусов О. В., Мареев В. Ю., Скворцов А. А. Клинические, гемодинамические и нейрогуморальные эффекты дигоксина у больных ХСН. ЖСН. 2000;1 (1):26-30.

472. Rathore SS, Curtis JP, Wang Y., Bristow MR, Krumholz H.M. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289 (7):871-8. DOI:10.1001/jama. 289.7.871

473. Adams KF, Patterson JH, Gattis WA, O’Connor CM, Lee CR, Schwartz TA et al. Relationship of Serum Digoxin Concentration to Mortality and Morbidity in Women in the Digitalis Investigation Group Trial. Journal of the American College of Cardiology. 2005;46 (3):497-504. DOI:10.1016/j. jacc. 2005.02.091

474. The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure. New England Journal of Medicine. 1997;336 (8):525-33. DOI:10.1056/NEJM199702203360801

475. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JGF et al. Efficacy of ß blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. The Lancet. 2014;384 (9961):2235-43. DOI:10.1016/S0140-6736 (14)61373-8

476. Gheorghiade M., Fonarow GC, van Veldhuisen DJ, Cleland JGF, Butler J., Epstein AE et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. European Heart Journal. 2013;34 (20):1489-97. DOI:10.1093/eurheartj/eht120

477. Ziff OJ, Lane DA, Samra M., Griffith M., Kirchhof P., Lip GYH et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015; h4451. DOI: 10.1136/bmj. h4451

478. Jorge E., Baptista R., Martins H., Saraiva F., Costa S., Vieira H. et al. Digoxin in advanced heart failure patients: A question of rhythm. Revista Portuguesa de Cardiologia. 2013;32 (4):303-10. DOI:10.1016/j. repc. 2012.11.007

479. Mareev V. Yu., Mareev Yu. V., Mareev YV, Federal State Budgetary Institution, «Russian Cardiology Science and Production Center» of the Ministry of Health of the Russian Federation. Role of heart rate in mechanisms of compensation and decompensation in CHF patients with sinus rhythm and atrial fibrillation and methods for safe and efficient control of heart rhythm. Part 2. Atrial fibrillation. Kardiologiia. 2017;17 (S2):351-66. DOI:10.18087/cardio. 2401

480. Gheorghiade M., Patel K., Filippatos G., Anker SD, van Veldhuisen DJ, Cleland JGF et al. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. European Journal of Heart Failure. 2013;15 (5):551-9. DOI:10.1093/eur-jhf/hft010

481. TardifJ-C, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. European Heart Journal. 2005;26 (23):2529-36. DOI:10.1093/eurheartj/ehi586

482. Tardif J-C, Ponikowski P, Kahan T, for the ASSOCIATE study Investigators. Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. European Heart Journal. 2009;30 (5):540-8. DOI:10.1093/eurheartj/ehn571

483. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. The Lancet. 2008;372 (9641):817-21. DOI:10.1016/S0140-6736 (08) 61171-X

484. Swedberg K, Komajda M, Böhm M, Borer J S, Ford I, Tavazzi L. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I f Inhibitor Ivabradine Trial (SHIFT). European Journal of Heart Failure. 2010;12 (1):75-81. DOI:10.1093/eur-jhf/hfp154

485. Borer JS, Bohm M, Ford I, Komajda M, Tavazzi L, Sendon JL et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal. 2012;33 (22):2813-20. DOI:10.1093/eur-heartj/ehs259

486. Böhm M, Borer J, Ford I, Gonzalez-JuanateyJR, Komajda M, Lopez-Sendon J et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology. 2013;102 (1):11-22. DOI:10.1007/s00392-012-0467-8

487. Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. The Lancet. 2010;376 (9744):886-94. DOI: 10.1016/S0140-6736 (10) 61259-7

488. Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. European Heart Journal. 2007;28 (24):3012-9. DOI:10.1093/eurheartj/ehm489

489. Marchioli R. Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial Infarction: Time-Course Analysis of the Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI) - Prevenzione. Circulation. 2002;105 (16):1897-903. DOI:10.1161/01. CIR. 0000014682.14181. F2

490. Macchia A, Levantesi G, Franzosi MG, Geraci E, Maggioni AP, Marfisi R et al. Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. EuropeanJournal of Heart Failure. 2005;7 (5):904-9. DOI:10.1016/j. ejheart. 2005.04.008

491. Poole CD, Halcox JP, Jenkins-Jones S, Carr ESM, Schifflers MG, Ray KK et al. Omega-3 Fatty Acids and Mortality Outcome in Patients With and Without Type 2 Diabetes After Myocardial Infarction: A Retrospective, Matched-Cohort Study. Clinical RAerapeutics. 2013;35 (1):40-51. DOI:10.1016/j. clinthera. 2012.11.008

492. Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, Cesana BM et al. Effects of n-3 Polyunsaturated Fatty Acids on Left Ventricular Function and Functional Capacity in Patients With Dilated Cardiomyopathy. Journal of the American College of Cardiology. 2011;57 (7):870-9. DOI:10.1016/j. jacc. 2010.11.017

493. Finzi AA, Latini R, Barlera S, Rossi MG, Ruggeri A, Mezzani A et al. Effects of n-3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter-defibrillators: A substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell’ Insufficienza Cardiaca (GISSI-HF) trial. American Heart Journal. 2011;161 (2):338-343. e1. DOI:10.1016/j. ahj. 2010.10.032

494. Ghio S, Scelsi L, Latini R, Masson S, Eleuteri E, Palvarini M et al. Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. European Journal of Heart Failure. 2010;12 (12):1345-53. DOI:10.1093/eurjhf/hfq172

495. Moertl D, Hammer A, Steiner S, Hutuleac R, Vonbank K, Berger R. Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin. American HeartJournal. 2011;161 (5):915. e1-915. e9. DOI:10.1016/j. ahj. 2011.02.011

496. Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN. RAe influence of atrial fibrillation on prognosis in mild to moderate heart failure. RAe V-HeFT Studies. RAe V-HeFT VA Cooperative Studies Group. Circulation. 1993;87 (6 Suppl): VI102-110.

497. Dunkman WB. RAromboembolism and antithrombotic therapy in congestive heart failure: Journal of Cardiovascular Risk. 1995;2 (2):107 17. DOI:10.1097/00043798-199504000-00005

498. Katz SD. Left ventricular thrombus and the incidence of thromboembolism in patients with congestive heart failure: can clinical factors identify patients at increased risk?: Journal of Cardiovascular Risk. 1995;2 (2):97-102. DOI:10.1097/00043798-199504000-00003

499. Cioffi G, Pozzoli M, Forni G, Franchini M, Opasich C, Cobelli F et al. Systemic thromboembolism in chronic heart failure: A prospective study in 406 patients. European Heart Journal. 1996;17 (9):1381-9. DOI:10.1093/oxfordjournals. eurheartj. a015073

500. Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Brandenburg RO, Frye RL. Ue natural history of idiopathic dilated cardiomyopathy. RAe American Journal of Cardiology. 1981;47 (3):525-31. DOI:10.1016/0002-9149(81)90534-8

501. Stratton JR, Nemanich JW, Johannessen ОД., Resnick AD. Fate of left ventricular thrombi in patients with remote myocardial infarction or idiopathic cardiomyopathy. Circulation. 1988;78 (6):1388-93. DOI:10.1161/01. CIR. 78.6.1388

502. Spyropoulos AC. Emerging Strategies in the Prevention of Venous Thromboembolism in Hospitalized Medical Patients. Chest. 2005;128 (2):958-69. DOI:10.1378/chest. 128.2.958

503. Howell M. Congestive heart failure and outpatient risk of venous thromboembolism A retrospective, case-control study. Journal of Clinical Epidemiology. 2001;54 (8):810-6. DOI:10.1016/S0895-4356 (00) 00373-5

504. Samama MM, Cohen AT, Darmon J-Y, Desjardins L, Eldor A, Janbon C et al. A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients. New England Journal of Medicine. 1999;341 (11):793-800. DOI:10.105 6/NEJM199909093411103

505. Turpie AGG. Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in medical patients with enoxaparin (MEDENOX) trial. The American Journal of Cardiology. 2000;86 (12):48-52. DOI:10.1016/S0002-9149 (00) 01481-8

506. Ageno W, Turpie AGG. Clinical trials of deep vein thrombosis prophylaxis in medical patients. Clinical Cornerstone. 2005;7 (4):16-22. DOI: 10.1016/S 1098-3597 (05) 80099-7

507. ESC Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Endorsed by the European Respiratory Society (ERS). European Heart Journal. 2014;35 (43):3033-73. DOI:10.1093/eur-heartj/ehu283

508. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA et al. Comparison of Low-Intensity Warfarin Therapy with Conven-tional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism. New England Journal of Medicine. 2003;349 (7):631-9. DOI:10.1056/NEJMoa035422

509. Nunnelee JD. Review of an Article: Dabigatran versus warfarin in the treatment of acute venous thromboembolism (2009). Schulman S, Kearon C, Kakkar A et al., N Engl J Med 361;2342-2352. Journal of Vascular Nursing. 2010;28 (2):84. DOI:10.1016/j. jvn. 2010.03.002

510. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for Extended Treatment of Venous Thromboembolism. New England Journal of Medicine. 2013;368 (8):699-708. DOI: 10.1056/NEJMoa1207541

511. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. New England Journal of Medicine. 2013;369 (9):799-808. DOI: 10.1056/NEJMoa1302507

512. The EINSTEIN - PE Investigators. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. New England Journal of Medicine. 2012;366 (14):1287-97. DOI:10.1056/NEJMoa1113572

513. Developed with the special contribution of the European Heart Rhythm Association (EHRA), Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), Authors/Task Force Members, Camm AJ, Kirchhof P, Lip GYH et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal. 2010;31 (19):2369-429. DOI:10.1093/eur-heartj/ehq278

514. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic Therapy in Atrial Fibrillation. Chest. 2004;126 (3):429S-456S. DOI:10.1378/chest. 126.3_suppl. 429S

515. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367 (9526):1903-12. DOI:10.1016/S0140-6736 (06) 68845-4

516. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, SelbyJV et al. Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation. New England Journal of Medicine. 2003;349 (11 ):1019-26. DOI:10.1056/NEJMoa022913

517. Baker D.W. Management of Heart Failure: I.V. Anticoagulation for Patients With Heart Failure Due to Left Ventricular Systolic Dysfunction. JAMA. 1994;272 (20):1614. DOI:10.1001/jama. 1994.03520200070038

518. Dries DL, Domanski MJ, Waclawiw MA, Gersh B.J. Effect of Antithrombotic Therapy on Risk of Sudden Coronary Death in Patients With Congestive Heart Failure. The American Journal of Cardiology. 1997;79 (7):909-13. DOI:10.1016/S0002-9149 (97) 00013-1

519. Singer DE, Chang Y., Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N. et al. Should Patient Characteristics Influence Target Anticoagulation Intensity for Stroke Prevention in Nonvalvular Atrial Fibrillation?: The ATRIA Study. Circulation: Cardiovascular Quality and Outcomes. 2009;2 (4):297-304. DOI:10.1161/CIRCOUT-COMES. 108.830232

520. Connolly SJ, Ezekowitz MD, Yusuf S., Eikelboom J., Oldgren J., Parekh A. et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2009;361 (12):1139-51. DOI:10.1056/NEJMoa0905561

521. Patel MR, Mahaffey KW, Garg J., Pan G., Singer DE, Hacke W. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New EnglandJournal ofMedicine. 2011;365 (10):883-91. DOI:10.1056/NEJ-Moa1009638

522. Connolly SJ, Eikelboom J., Joyner C., Diener H-C, Hart R., Golitsyn S. et al. Apixaban in Patients with Atrial Fibrillation. New England Journal of Medicine. 2011;364 (9):806-17. DOI:10.1056/NEJ-Moa1007432

523. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M. et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2011;365 (11):981-92. DOI: 10.1056/NEJMoa1107039

524. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H., Buchbinder M. et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. The Lancet. 2009;374 (9689):534-42. DOI:10.1016/S0140-6736 (09) 61343-X

525. Reddy VY, Holmes D., Doshi SK, Neuzil P., Kar S. Safety of Percutaneous Left Atrial Appendage Closure: Results From the Watchman Left Atrial Appendage System for Embolic Protection in Patients With AF (PROTECT AF) Clinical Trial and the Continued Access Registry. Circulation. 2011;123 (4):417-24. DOI:10.1161/CIRCULA-TIONAHA. 110.976449

526. Grygier M., Wojakowski W., Smolka G., Demkow M., Wqsek W., Sorysz D. et al. Przezcewnikowe zamykanie uszka lewego przedsionka -stanowisko grupy ekspertow powolanej przez Asocjacjç Interwencji Sercowo-Naczyniowych oraz Sekcjç Rytmu Serca Polskiego Towarzystwa Kardiologicznego. Kardiologia Polska [Internet]. 2014 [cited on Febrary 25, 2018]; DOI:10.5603/KP. a2018.0057

527. Dai Y-L, Luk T-H, Yiu K-H, Wang M., Yip PMC, Lee SWL et al. Reversal of mitochondrial dysfunction by coenzyme Q10 supplement improves endothelial function in patients with ischaemic left ventricular systolic dysfunction: A randomized controlled trial. Atherosclerosis. 2011;216 (2):395-401. DOI:10.1016/j. atherosclerosis. 2011.02.013

528. Molyneux SL, Florkowski CM, George PM, Pilbrow AP, Frampton CM, Lever M. et al. Coenzyme Q10. Journal of the American College of Cardiology. 2008;52 (18):1435-41. DOI:10.1016/j. jacc. 2008.07.044

529. Fotino AD, Thompson-Paul AM, Bazzano L.A. Effect of coenzyme Q10 supplementation on heart failure: a meta-analysis. American Journal of Clinical Nutrition. 2013;97 (2):268-75. DOI:10.3945/ajcn. 112.040741

530. Каленикова Е. И., Городецкая Е. А., Медведев О. С. Фармакокинетика коэнзима Q10. РМЖ. 2008; (5):338-40.

531. Мареев В. Ю., Минина Ю. В., Беграмбекова Ю. Л. КУДЕсан® (капли 3% для приема внутрь) в лечении больных Сердечной Недостаточностью: эффективность И безопасность в Комбинации со стандартной терапией (КУДЕСНИК). Дизайн и результаты проспективного рандомизированного двойного слепого исследования КУДЕСНИК. Журнал Сердечная Недостаточность. 2016;17 (4):236-49

532. Токарева ОГ, Харитонова ЕВ, Мареев ВЮ. Влияние коэнзима 0,0 в составе стандартной терапии больных хронической сердечной недостаточностью на плазменные уровни мозгового натрийуретического пептида. Журнал Сердечная Недостаточность. 2014;15 (4):232-7

533. Alehagen U, Johansson P, Björnstedt M, Rosén A, Dahlström U. Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: A 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. InternationalJournal of Cardiology. 2013;167 (5):1860-6. DOI:10.1016/j. ijcard. 2012.04.156

534. Mortensen SA, Rosenfeldt F, Kumar A, Dolliner P, Filipiak KJ, Pella D et al. The Effect of Coenzyme Q10 on Morbidity and Mortality in Chronic Heart Failure. JACC: Heart Failure. 2014;2 (6):641-9. DOI:10.1016/j.jchf. 2014.06.008

535. Kannel WB, PlehnJF, Cupples LA. Cardiac failure and sudden death in the Framingham Study. American Heart Journal. 1988;115 (4):869 75. DOI:10.1016/0002-8703 (88) 90891-5

536. Luu M., Stevenson WG, Stevenson LW, Baron K., Walden J. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation. 1989;80 (6):1675-80. DOI:10.1161/01. CIR. 80.6.1675

537. Poole-Wilson P.A. Mode of death in heart failure: findings from the ATLAS trial. Heart. 2003;89 (1):42-8. DOI:10.1136/heart. 89.1.42

538. Chen Z-M. CAST: randomised placebo-controlled trial of early aspirin use in 20000 patients with acute ischaemic stroke. The Lancet. 1997;349 (9066):1641-9. DOI:10.1016/S0140-6736 (97) 04010-5

539. PicciniJP, BergerJS, O’Connor C.M. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. European Heart Journal. 2009;30 (10):1245-53. DOI:10.1093/eur-heartj/ehp100

540. Boutitie F., Boissel J-P, Connolly SJ, Camm AJ, Cairns JA, Julian DG et al. Amiodarone Interaction With -Blockers: Analysis of the Merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) Databases. Circulation. 1999;99 (17):2268-75. DOI:10.1161/01. CIR. 99.17.2268

541. Свириденко Н. Ю., Платонова Н. М., Молашенко Н. В., Голицин С. П., Бакалов С. А., Сердюк С. Е. Эндокринные аспекты применения амиодарона в клинической практике. (Алгоритм наблюдения и лечения функциональных расстройств щитовидной железы). Российский Кардиологический Журнал. 2012;2:63-71.

542. Kovoor P. Comparison of sotalol with amiodarone for long-term treatment of spontaneous sustained ventricular tachyarrhythmia based on coronary artery disease. European Heart Journal. 1999;20 (5):364 74. DOI:10.1053/euhj. 1998.1279

543. MacNeil DJ, Davies RO, Deitchman D. Clinical safety profile of sotalol in the treatment of arrhythmias. Am J Cardiol. 1993;72 (4):44A-50A. PMID:8346726

544. Stevenson WG, Stevenson LW. Atrial Fibrillation in Heart Failure. New EnglandJournal ofMedicine. 1999;341 (12):910-1. DOI:10.10 56/NEJM199909163411209

545. Pardaens K, Van Cleemput J, Vanhaecke J, Fagard RH. Atrial fibrillation is associated with a lower exercise capacity in male chronic heart failure patients. Heart. 1997;78 (6):564-8. DOI:10.1136/hrt. 78.6.564

546. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107 (23):2920-5. DOI:10.1161/01. CIR. 0000072767.89944.6E

547. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37(38):2893-962. DOI:10.1093/eurheartj/ehw210

548. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347 (23):1825 33. DOI: 10.1056/NEJMoa021328

549. Van Gelder IC, Groenveld HF, Crijns HJGM, Tuininga YS, Ti-jssen JGP, Alings AM et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362 (15):1363-73. DOI:10.1056/NEJMoa1001337

550. Hagens VE, Crijns HJGM, Van Veldhuisen DJ, Van Den Berg MP, Rienstra M, Ranchor AV et al. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: Results from the RA.te Control versus Electrical cardioversion (RA.CE) study. American Heart Journal. 2005;149 (6):1106-11. DOI:10.1016/j. ahj. 2004.11.030

551. Lundström T, Rydén L. Chronic atrial fibrillation. Long-term results of direct current conversion. Acta Med Scand. 1988;223 (1):53-9. PMID:3348103

552. AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol. 2003;42 (1):20-9. PMID:12849654

553. Letelier LM, Udol K, Ena J, Weaver B, Guyatt GH. Effectiveness ofAmiodarone for Conversion of Atrial Fibrillation to Sinus Rhythm: A Meta-analysis. Archives of Internal Medicine. 2003;163 (7):777. DOI: 10.1001/archinte. 163.7.777

554. Singh SN, Poole J, Anderson J, Hellkamp AS, Karasik P, Mark DB et al. Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure. American Heart Journal. 2006;152 (5):974. e7-974. e11. DOI:10.1016/j. ahj. 2006.08.012

555. Roy D., Talajic M., Dorian P., Connolly S., Eisenberg MJ, Green M. et al. Amiodarone to Prevent Recurrence of Atrial Fibrillation. New England Journal of Medicine. 2000;342 (13):913-20. DOI:10.1056/NE JM200003303421302

556. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O., Kingma T. et al. A Comparison of Rate Control and Rhythm Control in Patients with Recurrent Persistent Atrial Fibrillation. New England Journal of Medicine. 2002;347 (23):1834-40. DOI:10.1056/NEJ-Moa021375

557. Hylek EM, Skates SJ, Sheehan MA, Singer D.E. An Analysis of the Lowest Effective Intensity of Prophylactic Anticoagulation for Patients with Nonrheumatic Atrial Fibrillation. New England Journal of Medicine. 1996;335 (8):540-6. DOI:10.1056/NEJM19960822 3350802

558. Hart RG, Benavente O., McBride R., Pearce L.A. Antithrombotic RAerapy To Prevent Stroke in Patients with Atrial Fibrillation: A Meta-Analysis. Annals of Internal Medicine. 1999;131 (7):492. DOI:10.7326/ 0003-4819-131-7-199910050-00003

559. Healey JS, Baranchuk A., Crystal E., Morillo CA, Garfinkle M., Yusuf S. et al. Prevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. Journal of the American College of Cardiology. 2005;45 (11):1832-9. DOI:10.1016/j. jacc. 2004.11.070

560. Fang W., Li H., Zhang H., Jiang S. RAe role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials: Statin therapy in prevention of atrial fibrillation. British Jour nal of Clinical Pharmacology. 2012;74 (5):744-56. DOI:10.1111/j. 1365-2125.2012.04258. x

561. GISSI-AF Investigators, Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360 (16):1606-17. DOI:10.1056/NEJ-Moa0805710

562. Yamashita T., Inoue H., Okumura K., Kodama I., Aizawa Y., Atarashi H., et al. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II Study). Europace. 2011; 13 (4):473-9. DOI:10.1093/europace/euq439

563. Irbesartan in Patients with Atrial Fibrillation. New England Journal of Medicine. 2011;364 (10):928-38. DOI:10.1056/NEJMoa1008816

564. Goette A., Schon N., Kirchhof P., Breithardt G., Fetsch T., Hausler KG et al. Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) Trial. Circulation: Arrhythmia and Electrophysiology. 2012;5 (1):43-51.DOI:10.1161/CIRCEP. 111.965178

565. Matsuda M., Matsuda Y., Yamagishi T., Takahashi T., Haraguchi M., Tada T. et al. Effects of digoxin, propranolol, and verapamil on exercise in patients with chronic isolated atrial fibrillation. Cardiovascular Research. 1991;25 ( 6):453-7. DOI:10.1093/cvr/25.6.453

566. David D., Di Segni E., Klein HO, Kaplinsky E. Inefficacy of digitalis in the control ofheart rate in patients with chronic atrial fibrillation: Beneficial effect of an added beta adrenergic blocking agent. The American Journal of Cardiology. 1979;44 (7):1378-82. DOI:10.1016/0002-9149 (79)90456-9

567. Farshi R., Kistner D., Sarma J.S., Longmate JA, Singh B.N. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. Journal of the American College of Cardiology. 1999;33 (2):304-10. DOI:10.1016/S0735-1097 (98) 00561-0

568. Khand AU, Rankin AC, Martin W., Taylor J., Gemmell I., Cleland J.G. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? Journal of the American College of Cardiology. 2003;42 (11):1944-51. DOI:10.1016/j. jacc. 2003.07.020

569. Mareev Y., Cleland JGF. Should ß-blockers be used in patients with heart failure and atrial fibrillation? Clin Ther. 2015;37 (10):2215-24. DOI:10.1016/j. clinthera. 2015.08.017

570. Cohn JN, Ziesche S., Smith R., Anand I., Dunkman WB, Loeb H. et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation. 1997;96 (3):856-63. PMID:9264493

571. Thackray S., Witte K., Clark AL, ClelandJGF. Clinical trials update: OP-TIME-CHF, PRA.ISE-2, ALL-HAT. European Journal of Heart Failure. 2000;2 (2):209-12. DOI:10.1016/S1388-9842 (00) 00080-5

572. Packer M., O’Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN et al. Effect of Amlodipine on Morbidity and Mortality in Severe Chronic Heart Failure. New England Journal of Medicine. 1996;335 (15):1107-14. DOI:10.1056 / NEJM19961010 3351504

573. O’Connor CM, Carson PE, Miller AB, Pressler ML, Belkin RN, Neuberg GW et al. Effect of amlodipine on mode of death among patients with advanced heart failure in the praise trial. The American Journal of Cardiology. 1998;82 (7):881-7. DOI:10.1016/S0002-9149 (98) 00496-2

574. Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т. Медикаментозные пути улучшения прогноза больных хронической сердечной недостаточностью. - М.: Инсайт; 1997. 77 с.

575. Horwich TB, MacLellan WR, Fonarow G.C. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. Journal of the American College of Cardiology. 2004;43 (4):642-8. DOI:10.1016/j. jacc. 2003.07.049

576. O’Meara E. Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients With Heart Failure: Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation. 2006;113 (7):986-94. DOI: 10.1161/CIRCULATIONAHA. 105.582577

577. Nanas JN, Matsouka C., Karageorgopoulos D., Leonti A., Tsolakis E., Drakos SG et al. Etiology of anemia in patients with advanced heart failure. Journal of the American College of Cardiology. 2006;48 (12):2485-9. DOI:10.1016/j. jacc. 2006.08.034

578. Node K. Short-Term Statin Therapy Improves Cardiac Function and Symptoms in Patients With Idiopathic Dilated Cardiomyopathy. Circulation. 2003;108 (7):839-43. DOI:10.1161/01. CIR. 0000084539.58092. DE

579. Liao J.K. Statin Therapy for Cardiac Hypertrophy and Heart Failure: Journal of Investigative Medicine. 2004;52 (4):248-53. DOI:10.109 7/00042871-200405000-00033

580. Rauchhaus M., Clark AL, Doehner W., Davos C., Bolger A., Sharma R. et al. The relationship between cholesterol and survival in patients with chronic heart failure. Journal of the American College of Cardiology. 2003;42 (11):1933-40. DOI:10.1016/j. jacc. 2003.07.016

581. Leeper NJ, Ardehali R., deGoma EM, Heidenreich P.A. Statin Use in Patients With Extremely Low Low-Density Lipoprotein Levels Is Associated With Improved Survival. Circulation. 2007;116 (6):613-8. DOI: 10.1161 / CIRCULATIONAHA. 107.694117

582. Davie A. Even low-dose aspirin inhibits arachidonic acid - induced vasodilation in heart failure. Clinical Pharmacology & Therapeutics. 2000;67 (5):530-7. DOI:10.1067/mcp. 2000.106290

583. LindenfeldJ, Robertson AD, Lowes BD, Bristow M.R. Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers. Journal of the American College of Cardiology. 2001;38 (7):1950-6. DOI:10.1016/S0735-1097 (01) 01641-2

584. Latini R., Tognoni G., Maggioni AP, Franzosi M., Santoro E., Baigent C. et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin. Journal of the American College of Cardiology. 2000;35 (7):1801-7. DOI:10.1016/S0735-1097 (00) 00638-0

585. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324 (7329):71-86. PMID:11786451

586. Jones CG, Cleland JGF. The LIDO, HOPE, MOXCON and WASH studies. European Journal of Heart Failure. 1999;1 (4):425-31. DOI: 10.1016/S. 1388-9842 (99) 00059-8

587. Grines CL, Bonow RO, Casey DE, Gardner TJ, Lockhart PB, Moliterno DJ et al. Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery Stents: A Science Advisory From the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, With Representation From the American College of Physicians. Circulation. 2007;115 (6):813-8. DOI:10.1161/CIRCULA-TIONAHA. 106.180944

588. Flather MD, Yusuf S., Kober L., Pfeffer M., Hall A., Murray G. et al. Longterm ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. The Lancet. 2000;355 (9215):1575-81. DOI:10.1016/S0140-6736(00)02212-1

589. Takkouche B., Etminan M., Caama?? o F., Rochon P.A. Interaction Between Aspirin and ACE Inhibitors: Resolving Discrepancies Using a Meta-Analysis. Drug Safety. 2002;25 (5):373-8. DOI:10.2165/0000 2018-200225050-00005

590. Authors/Task Force Members, Hamm CW, Bassand J-P, Agewall S., Bax J., Boersma E. et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2011;32 (23):2999-3054. DOI:10.1093/eurheartj/ehr236

591. Lopatin YM, Rosano GMC, Fragasso G., Lopaschuk GD, Seferovic PM, Gowdak LHW et al. Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. International Journal of Cardiology. 2016;203:909-15. DOI:10.1016/j. ijcard. 2015.11.060

592. McCarthy CP, Mullins KV, Kerins D.M. The role of trimetazidine in cardiovascular disease: beyond an anti-anginal agent. European Heart Journal - Cardiovascular Pharmacotherapy. 2016;2 (4):266-72. DOI:10.1093/ehjcvp/pvv051

593. Ciapponi A., Pizarro R., Harrison J. Trimetazidine for stable angina. The Cochrane Collaboration, редактор. Cochrane Database of Systematic Reviews [Internet]. 2005 [cited on Febrary 1, 2018]; DOI: 10.1002/14651858. CD003614. pub2

594. Danchin N., Marzilli M., Parkhomenko A., Ribeiro J.P. Efficacy Comparison of Trimetazidine with Therapeutic Alternatives in Stable Angina Pectoris: A Network Meta-Analysis. Cardiology. 2011;120 (2):59-72. DOI: 10.1159/000332369

595. Iyengar SS, Rosano GMC. Effect of Antianginal Drugs in Stable Angina on Predicted Mortality Risk after Surviving a Myocardial Infarction: A Preliminary Study (METRO). American Journal Cardiovascular Drugs. 2009;9 (5):293-7. DOI:10.2165/11316840-000000000-00000

596. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W et al. Myocardial Phosphocreatine-to-ATP Ratio Is a Predictor of Mortality in Patients With Dilated Cardiomyopathy. Circulation. 1997;96 (7):2190-6. DOI:10.1161/01. CIR. 96.7.2190

597. Fragasso G. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. European Heart Journal. 2005;27 (8):942-8. DOI:10.1093/eurheartj/ehi816

598. Napoli PD, Giovanni PD, Gaeta MA, Taccardi AA, Barsotti A. Trimetazidine and Reduction in Mortality and Hospitalization in Patients With Ischemic Dilated Cardiomyopathy: A Post Hoc Analysis of the Villa Pini D'Abruzzo Trimetazidine Trial: Journal of Cardiovascular Pharmacology. 2007;50 (5):585-9. DOI:10.1097/FJC. 0b013e31814fa9cb

599. Hu B, Li W, Xu T, Chen T, Guo J. Evaluation of Trimetazidine in Angina Pectoris by Echocardiography and Radionuclide Angiography: A Meta-Analysis of Randomized, Controlled Trials. Clinical Cardiology. 2011;34 (6):395-400. DOI:10.1002/clc. 20888

600. Gao D, Ning N, Niu X, Hao G, Meng Z. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart. 2011;97 (4):278-86. DOI:10.1136/hrt. 2010.208751

601. Васюк Ю. А., Шальнова С. А., Школьник Е. Л., Куликов К. Г. Исследование ПРИМА. Сравнение клинического эффекта триметазидина МВумужчин и женщин. Кардиология. 2011;51 (6):11 5

602. Glezer GMG, on on behalf of the C- study par, Sechenov First Moscow State Medical University, Moscow, Russia. Treatment of Patients With Stable Ischemic Heart Disease in Real Clinical Practice in Russia. The CHOICE-2 Program. Kardiologiia. 2016;5_2016:5-11. DOI: 10.18565/cardio. 2016.5.5-11

603. Zhang L, Lu Y, Jiang H, Zhang L, Sun A, Zou Y et al. Additional Use of Trimetazidine in Patients With Chronic Heart Failure. Journal of the American College of Cardiology. 2012;59 (10):913-22. DOI:10.1016/j. jacc. 2011.11.027

604. Fragasso G, Rosano G, Baek SH, Sisakian H, Di Napoli P, Alberti L et al. Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: Results from an international multicentre retrospective cohort study. International Journal of Cardiology. 2013;163 (3):320-5. DOI:10.1016/j. ijcard. 2012.09.123

605. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE et al. Effect ofVasodilator Therapy on Mortality in Chronic Congestive Heart Failure. New EnglandJournal ofMedicine. 1986;314 (24): 1547-5 2. DOI: 10.1056/NEJM198606123142404

606. Taylor AL, Ziesche S, Yancy C, Carson P, D’Agostino R, Ferdinand K et al. Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure. New England Journal of Medicine. 2004;351 (20):2049-57. DOI:10.1056/NEJMoa042934

607. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: Analysis of the vasodilator-heart failure trials. Journal of Cardiac Failure. 1999;5 (3):178-87. DOI: 10.1016/S 1071-9164 (99) 90001-5

608. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM et al. Effect of oral milrinone on mortality in severe chronic heart failure. "Шє PROMISE Study Research Group. N Engl J Med. 1991;325 (21):1468-75. DOI:10.1056/NEJM199111213252103

609. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ et al. Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure: RAe SURVIVE Randomized Trial. JAMA. 2007;297 (17):1883. DOI:10.1001/jama. 297.17.1883

610. Metra M, Eichhorn E, Abraham WT, LinsemanJ, Bohm M, Corbalan R et al. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. European Heart Journal. 2009;30 (24):3015-26. DOI:10.1093/eurheartj/ehp338

611. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM et al. Effects of Vesnarinone on Morbidity and Mortality in Patients with Heart Failure. New EnglandJournal ofMedicine. 1993;329 (3): 149-55. DOI:10.1056/NEJM199307153290301

612. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical Presentation, Management, and In-Hospital Outcomes of Patients Admitted With Acute Decompensated Heart Failure With Preserved Systolic Function. Journal of the American College of Cardiology. 2006;47 (1):76-84. DOI:10.1016/j. jacc. 2005.09.022

613. Senni M, Paulus WJ, Gavazzi A, Fraser AG, Diez J, Solomon SD et al. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. European Heart Journal. 2014;35 (40):2797-815. DOI:10.1093/eur-heartj/ehu204

614. Ferrari R, Böhm M, Cleland JGF, Paulus WJS, Pieske B, Rapezzi C et al. Heart failure with preserved ejection fraction: uncertainties and dilemmas: Uncertainties and dilemmas of HFpEF. European Journal of Heart Failure. 2015;17 (7):665-71. DOI:10.1002/ejhf. 304

615. Nanayakkara S, Patel HC, Kaye DM. Hospitalisation in Patients With Heart Failure With Preserved Ejection Fraction. Clinical Medicine Insights: Cardiology. 2018;12:117954681775160. DOI:10.1177/1179546817751609

616. Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59 (11):998-1005. DOI:10.1016/j. jacc. 2011.11.040

617. Henkel DM, Redfield MM, Weston SA, Gerber Y, Roger VL. Death in heart failure: a community perspective. Circ Heart Fail. 2008;1 (2):91-7. DOI: 10.1161 / CIRCHEARTFAILURE. 107.743146

618. Fukuta H, Goto T, Wakami K, Ohte N. Effects of drug and exercise intervention on functional capacity and quality of life in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials. European Journal of Preventive Cardiology. 2016;23 (1):78-85. DOI: 10.1177/20474873145 64729

619. Lewis EF, Lamas GA, O’Meara E, Granger CB, Dunlap ME, McKelvie RS et al. Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail. 2007;9 (1):83-91. DOI:10.1016/j. ejheart. 2006.10.012

620. Philbin EF, Rocco TA. Use of angiotensin-converting enzyme inhibitors in heart failure with preserved left ventricular systolic function. American HeartJournal. 1997;134 (2):188-95. DOI:10.1016/S0002-8703 (97)70123-6

621. Fu M, Zhou J, Sun A, Zhang S, Zhang C, Zou Y et al. Efficacy of ACE inhibitors in chronic heart failure with preserved ejection fraction? A meta analysis of 7 prospective clinical studies. International Journal of Cardiology. 2012;155 (1):33-8. DOI:10.1016/ j. ijcard. 2011.01.081

622. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. "Шє American Journal of Medicine. 2003;115 (1):41-6. DOI:10.1016/S0002-9343 (03) 00158-X

623. Bergström A, Andersson B, Edner M, Nylander E, Persson H, Dahlström U. Effect of carvedilol on diastolic function in patients with dia stolic heart failure and preserved systolic function. Results ofthe Swedish Doppler-echocardiographic study (SWEDIC). European Journal of Heart Failure. 2004;6 (4):453-61. DOI:10.1016/j. ejheart. 2004.02.003

624. Lund LH, Benson L, Dahlström U, Edner M, Friberg L. Association Between Use of ß-Blockers and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JAMA. 2014;312 (19):2008. DOI: 10.1001/jama. 2014.15241

625. Kristensen SL, Kober L, Jhund PS, Solomon SD, Kjekshus J, McKelvie RS et al. International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction. Circulation. 2015;131 (1):43-53. DOI:10.1161/ CIRCULATIONAHA. 114.012284

626. Свирида О. Н., Овчинников А. Г., Агеев Ф. Т. Влияние кандесартана и его комбинации со спиронолактоном на диастолическую функцию левого желудочка и содержание биохимических маркеров баланса коллагена у пациентов с хронической сердечной недостаточностью и сохраненной систолической функцией левого желудочка. Журнал Сердечная Недостаточность. 2010;11 (5):263-75

627. Pitt B., Pfeffer MA, Assmann SF, Boineau R., Anand IS, Claggett B. et al. Spironolactone for Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine. 2014;370 (15):1383-92. DOI: 10.1056/NEJMoa1313731

628. Pfeffer MA, Claggett B., Assmann SF, Boineau R., Anand IS, Clausell N. et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131 (1):34-42. DOI:10.1161/ CIRCULATIONAHA. 114.013255

629. Lopez B., Querejeta R., Gonzalez A., Sanchez E., Larman M., Diez J. Effects of loop diuretics on myocardial fibrosis and collagen type I. turnover in chronic heart failure. Journal of the American College of Cardiology. 2004;43 (11):2028-35. DOI:10.1016 /j. jacc. 2003.12.052

630. Овчинников А. Г., Агеев Ф. Т., Азизова А. Г. Сравнительное влияние торасемида и фуросемида на клинический статус и диастолическую функцию левого желудочка у больных с компенсированной сердечной недостаточностью и высоким давлением наполнения левого желудочка. Журнал Сердечная Недостаточность. 2011;12 (6):326-32.

631. Secondary prevention with verapamil after myocardial infarction. The Danish Study Group on Verapamil in Myocardial Infarction. Am J Cardiol. 1990;66 (21):33I-40I. PMID:2147813

632. Komajda M, Isnard R, Cohen-Solal A, Metra M, Pieske B, Ponikowski P et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial: Ivabradine in HFpEF. European Journal of Heart Failure. 2017;19 ( 11 ) : 1495-503. DOI: 10.1002/ejhf. 876

633. Belenkov Yu. N., At’kov O. Yu., Tsibekmakher T. D. Effect of rapid digitalization on the left-ventricular myocardial function according to the echocardiographic data. Kardiologiia. 1977;17 (9):46-50. PMID:926600

634. Holland DJ, Kumbhani DJ, Ahmed SH, Marwick TH. Effects of Treatment on Exercise Tolerance, Cardiac Function, and Mortality in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology. 2011;57 (16):1676-86. DOI:10.1016/j. jacc. 2010.10.057

635. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind ran domised controlled trial. The Lancet. 2012;380 (9851):1387-95. DOI:10.1016/S0140-6736 (12) 61227-6

636. Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J. Cardiothorac Surg. 2016;50 (5):e1-88.DOI:10.1093/ejcts/ezw313 63 8. Authors / Task Force Members, Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal. 2013;34(28):2159-219.DOI:10.1093/eurheartj/eht151

637. Sakata Y., Shiba N., Takahashi J., Miyata S., Nochioka K., Miura M. et al. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. European Heart Journal. 2015;36 ( 15 ):915-23. DOI: 10.1093/eurheartj/ehu504

638. Fitchett D., Inzucchi SE, Lachin JM, Wanner C., van de Borne P., Mattheus M. et al. Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease. Journal of the American College of Cardiology. 2018;71 (3):364-7. DOI:10.1016/j. jacc. 2017.11.022

639. ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal. 2014;35 (37):2541-619. DOI: 10.1093/eurheartj/ehu278

640. Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH et al. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. New EnglandJournal ofMedicine. 2015;373 (24) :2314-24. DOI: 10.1056/NEJMoa1510774

641. Taylor RS, Davies EJ, Dalal HM, Davis R., Doherty P., Cooper C., et al. Effects of exercise training for heart failure with preserved ejection fraction: A systematic review and meta-analysis of comparative studies. International Journal of Cardiology. 2012;162 ( 1 ) :6-13. DOI:10.1016/j. ijcard. 2012.05.070

642. Edelmann F., Gelbrich G., Düngen H-D, Fröhling S., Wachter R., Stahrenberg R. et al. Exercise Training Improves Exercise Capacity and Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction.Journal of the American College of Cardiology. 2011;58 (17):1780-91. DOI:10.1016/j. jacc. 2011.06.054

643. Maggioni AP, Dahlström U., Filippatos G., Chioncel O., Crespo Leiro M., Drozdz J. et al. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J. Heart Fail. 2013;15 (7):808-17. DOI:10.1093/eurjhf/hft050

644. Мареев В. Ю., Арутюнов Г. П., Асташкин Е. И., Вёрткин А. Л., Глезер М. Г., Лопатин Ю. М. и др. Острая декомпенсированная сердечная недостаточность. Согласованная позиция российских экспертов - 2014. Журнал Сердечная Недостаточность. 2014;15 (5):321-36. DOI:10.18087/rhfj. 2014.5.2024

645. Chakko S., Woska D., Martinez H., de Marchena E., Futterman L., Kessler KM et al. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. Am J. Med. 1991;90 (3):353-9.

646. Wang C.S. Does This Dyspneic Patient in the Emergency Department Have Congestive Heart Failure? JAMA. 2005;294 (15):1944. DOI: 10.1001/jama. 294.15.1944

647. Sarasin F.P. Acute dyspnea: what is the diagnostic role of B-type natriuretic peptide? Rev Med Suisse. 2005;1 (29):1888-91.

648. Martindale JL, Wakai A, Collins SP, Levy PD, Diercks D, Hiestand BC et al. Diagnosing Acute Heart Failure in the Emergency Department: A Systematic Review and Meta-analysis. Carpenter C, редактор. Academic Emergency Medicine. 2016;23 (3):223-42. DOI:10.1111/acem. 12878

649. Newby LK, Jesse RL, Babb JD, Christenson RH, De Fer TM, Diamond GA et al. ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2012;60 (23):2427-63. DOI:10.1016/j. jacc. 2012.08.969

650. Januzzi JL, Filippatos G, Nieminen M, Gheorghiade M. Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section. European Heart Journal. 2012;33 (18):2265-71. DOI: 10.1093/eurheartj/ehs191

651. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD et al. RAird universal definition of myocardial infarction. European Heart Journal. 2012;33 (20):2551-67. DOI:10.1093/eur-heartj/ehs184

652. Felker GM, Hasselblad V, Tang WHW, Hernandez AF, Armstrong PW, Fonarow GC et al. Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. EuropeanJournal of Heart Failure. 2012; 14 ( 11 ) : 1257-64. DOI: 10.1093/eurjhf/hfs 110

653. Felker GM, Mentz RJ, Teerlink JR, Voors AA, Pang PS, Ponikowski P et al. Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study: Troponin in Acute Heart Failure. EuropeanJournal of Heart Failure. 2015;17 (12):1262 70. DOI:10.1002/ejhf. 341

654. Adams KF, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). American Heart Journal. 2005;149 (2):209-16. DOI:10.1016/j. ahj. 2004.08.005

655. Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37 (3):267 315.DOI:10.1093 / eurheartj / ehv320

656. Forrester JS, Diamond GA, Swan HJ. Correlative classification of clinical and hemodynamic function after acute myocardial infarction. Am J Cardiol. 1977;39 ( 2):137-45. DOI:10.1016/S0002-9149 (77) 80182-3

657. Nohria A, Mielniczuk LM, Warner Stevenson L. Evaluation and Monitoring of Patients with Acute Heart Failure Syndromes. fje American Journal of Cardiology. 2005;96 (6):32-40. DOI:10.1016/j. amjcard. 2005.07.019

658. Park JH, Balmain S, Berry C, Morton JJ, McMurray JJV. Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction. Heart. 2010;96 (7):533-8. DOI:10.1136/hrt. 2009.175257

659. Rawles JM, Kenmure AC. Controlled trial of oxygen in uncomplicated myocardial infarction. Br MedJ. 1976;1 (6018):1121-3.

660. Vital FMR, Ladeira MT, Atallah AN. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema. Cochrane Database Syst Rev. 2013; (5):CD005351. DOI:10.1002/14651858. CD005351. pub3

661. Park M, Sangean MC, Volpe M de S, Feltrim MIZ, Nozawa E, Leite PF et al. Randomized, prospective trial of oxygen, continuous positive airway pressure, and bilevel positive airway pressure by face mask in acute cardiogenic pulmonary edema. Crit Care Med. 2004;32 (12):2407-15

662. Eapen ZJ, Reed SD, Li Y, Kociol RD, Armstrong PW, Starling RC et al. Do countries or hospitals with longer hospital stays for acute heart failure have lower readmission rates?: Findings from ASCEND-HF. Circ Heart Fail. 2013;6 (4):727-32. DOI:10.1161/ CIRCHEARTFAIL -URE. 112.000265

663. Hernandez AF. Relationship Between Early Physician Follow-up and 30-Day Readmission Among Medicare Beneficiaries Hospitalized for Heart Failure. JAMA. 2010;303 (17):1716. DOI:10.1001/jama. 2010.533

664. Butler J, Anstrom KJ, Felker GM, Givertz MM, Kalogeropoulos AP, Konstam MA et al. Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. JAMA Cardiology. 2017;2 (9):950. DOI:10.1001/jamacardio. 2017.2198

665. Мареев В. Ю., Выгодин В. А., Беленков Ю. Н. ДиУретическая терапия Эффективными дозами перораЛЬных диуретиков торасемида (Диувер®) и фуросемида в лечении больных с обострением Хронической Сердечной Недостаточности (ДУЭЛЬ-ХСН). Журнал Сердечная Недостаточность. 2011;12 (1):3-10

666. DiNicolantonio JJ. Should torsemide be the loop diuretic of choice in systolic heart failure? Future Cardiology. 2012;8 (5):707-28. DOI:10.2217/fca. 12.54

667. Murray MD, Deer MM, Ferguson JA, Dexter PR, Bennett SJ, Perkins SM et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001;111 (7):513-20.

668. Martens P, Nijst P, Mullens W. Current Approach to Decongestive Therapy in Acute Heart Failure. Current Heart Failure Reports. 2015; 12 (6):367-78. DOI: 10.1007/s11897-015-0273-5

669. van Vliet A, Donker AJM, Nauta JJP, Verheugt FWA. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. The American Journal of Cardiology. 1993;71 (3):A21-8. DOI:10.1016/0002-9149 (93)90241-4

670. ButlerJ, Hernandez AF, Anstrom KJ, Kalogeropoulos A, Redfield MM, Konstam MA et al. Rationale and Design of the ATHENA-HF Trial. JACC: Heart Failure. 2016;4 (9):726-35. DOI:10.1016/j. jchf. 2016.06.003

671. Knauf H, Mutschler E. Sequential nephron blockade breaks resistance to diuretics in edematous states. J Cardiovasc Pharmacol. 1997;29 (3):367-72

672. Farag M, Shoaib A, Gorog DA. Nitrates for the Management of Acute Heart Failure Syndromes, A Systematic Review. Journal of Cardiovascular Pharmacology and Therapeutics. 2017;22 (1):20-7. DOI:10.1177/1074248416644345

673. Wakai A, McCabe A, Kidney R, Brooks SC, Seupaul RA, Diercks DB et al. Nitrates for acute heart failure syndromes. Cochrane Database of Systematic Reviews. 2013;6 (8):CD005151. DOI:10.1002/14651858. CD005151.pub2

674. Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Simovitz A et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosor-bide dinitrate in severe pulmonary oedema. The Lancet. 1998;351 (9100):389-93. DOI:10.1016/S0140-6736 (97) 08417-1

675. Belletti A, Castro ML, Silvetti S, Greco T, Biondi-Zoccai G, Pasin L et al. The Effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials. Myles PS, редактор. British Journal of Anaesthesia. 2015;115 (5):656-75. DOI:10.1093/bja/aev284

676. Mebazaa A, Parissis J, Porcher R, Gayat E, Nikolaou M, Boas FV et al. Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods. Intensive Care Medicine. 2011;37 (2):290-301. DOI:10.1007/s00134-010-2073-4

677. Elkayam U, Tasissa G, Binanay C, Stevenson LW, Gheorghiade M, Warnica JW et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. American Heart Journal. 2007;153 (1):98-104. DOI:10.1016 /j. ahj. 2006.09.005

678. Kivikko M, Pollesello P, Tarvasmäki T, Sarapohja T, Nieminen MS, Harjola V-P. Effect of baseline characteristics on mortality in the SURVIVE trial on the effect of levosimendan vs dobutamine in acute heart failure: Sub-analysis of the Finnish patients. Internation al. Journal of Cardiology. 2016;215:26-31. DOI:10.1016/j. ijcard. 2016.04.064

679. Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE et al. A Dose-Dependent Increase in Mortality with Vesnarinone among Patients with Severe Heart Failure. New England Journal of Medicine. 1998;339 (25):1810-6. DOI:10.1056/NEJM199812173 392503

680. De Backer D., Biston P., Devriendt J., Madl C., Chochrad D., Aldecoa C., et al. Comparison of Dopamine and Norepinephrine in the Treatment of Shock. New England Journal of Medicine. 2010;362 (9):779-89. DOI:10.1056/NEJMoa0907118

681. Giamouzis G., Butler J., Starling RC, Karayannis G., Nastas J., Parisis C. et al. Impact of Dopamine Infusion on Renal Function in Hospitalized Heart Failure Patients: Results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. Journal of Cardiac Failure. 2010;16 (12):922-30. DOI:10.1016/j. cardfail. 2010.07.246

682. Triposkiadis FK, Butler J., Karayannis G., Starling RC, Filippatos G., Wolski K. et al. Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: The Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) Trial. International Journal of Cardiology. 2014;172 (1):115-21. DOI:10.1016/j. ijcard. 2013.12.276

683. Packer M., Colucci W., Fisher L., Massie BM, Teerlink JR, Young J. et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC: Heart Failure. 2013;1 (2):103-11. DOI:10.1016/j. jchf. 2012.12.004

684. The Consensus Trial Study Group*. Effects of Enalapril on Mortality in Severe Congestive Heart Failure. New England Journal of Medicine. 1987;316 (23):1429-35. DOI:10.1056/NEJM198706043162301

685. Jondeau G., Neuder Y., Eicher J-C, Jourdain P., Fauveau E., Galinier M. et al. B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. European Heart Journal. 2009;30 (18):2186-92. DOI: 10.1093/eurheartj/ehp323

686. Dentali F., Douketis JD, Gianni M., Lim W., Crowther M.A. Metaanalysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med. 2007;146 (4):278-88.

687. Агеев Ф. Т., Мареев В. Ю., Середенина Е. М., Беленков Ю. Н. Перспективы внедрения специализированных форм активного амбулаторного ведения больных с сердечной недостаточностью: структура, методика и предварительные результаты Российской программы «ШАНС». Журнал Сердечная Недостаточность. 2004;5 (6):268-71.

688. Ревишвили А. Ш., Ардашев А. В., Бойцов С. А., Бокерия Л. А., Голухова Е. З., Давтян К. В. и др. Клинические рекомендации по проведению электрофизиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств. ГОЭТАР-медиа. - Москва; 2013. 597 с. [Revishvili A. SH. i dr., «Klinicheskie rekomendacii po provedeniyu ehlektrofiziologicheskih issledovanij, kateternoj ablyacii i primeneniyu implantiruemyh antiaritmicheskih ustrojstv», 2013.] ISBN: 5-7887-0106-6

689. Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H. et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA. 2002;288 (24):3115-23. PMID:12495391

690. Yu C-M, Chan JY-S, Zhang Q., Omar R., Yip GW-K, Hussin A. et al. Biventricular pacing in patients with bradycardia and normal ejection fraction. New EnglandJournal of Medicine. 2009;361 (22):2123-34. DOI: 10.1056/NEJMoa0907555

691. Curtis AB, Worley SJ, Adamson PB, Chung ES, Niazi I., Sherfesee L. et al. Biventricular pacing for atrioventricular block and systolic dysfunction. New EnglandJournal ofMedicine. 2013;368 (17):1585-93. DOI:10.1056/NEJMoa1210356

692. Doshi RN, Daoud EG, Fellows C., Turk K., Duran A., Hamdan MH et al. Left ventricular-based cardiac stimulation Post AV nodal ablation Evaluation (The PAVE Study). Journal of Cardiovascular Electrophysiology. 2005;16 (11):1160-5. DOI:10.1111/j. 1540-8167.2005.50062. x

693. Brignole M., Botto G., Mont L., Iacopino S., De Marchi G., Oddone D. et al. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. European Heart Journal. 2011;32 (19):2420-9. DOI:10.1093/eurheartj/ehr162

694. Saba MM, Donahue TP, Panotopoulos PTH, Ibrahim SS, Abi-Samra F.M. Long-term mortality in patients with pauses in ventricular electrical activity. Pacing and Clinical Electrophysiology. 2005;28 (11):1203-7. DOI:10.1111/j. 1540-8159.2005.50189. x

695. Hilgard J., Ezri MD, Denes P. Significance of ventricular pauses of three seconds or more detected on twenty-four-hour holter recordings. The American Journal of Cardiology. 1985;55 (8):1005-8. DOI:10.1016/0002-9149 (85) 90735-0

696. ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA.). European HeartJournal. 2013;34 (29):2281-329. DOI:10.1093/eur-heartj/eht150

697. Epstein AE, DiMarco JP, Ellenbogen О.Д., Estes NAM, Freedman R.A., Gettes LS et al. ACC/AHA/HRS 2008 Guidelines for devicebased therapy of cardiac rhythm abnormalities. Journal of the American College of Cardiology. 2008;51 (21):e1-62. DOI:10.1016/j. jacc. 2008.02.032

698. Мареев Ю. В., Шитов В. Н., Саидова М. А. Сердечная ресинхронизирующая терапия. Отбор пациентов и их ведение после имплантации бивентрикулярного электрокардиостимулятора. Кардиология. 2013;53 (3):81-7.

699. Stavrakis S., Lazzara R., Thadani U. The benefit of cardiac resynchronization therapy and QRS duration: a meta-analysis. Journal of Cardiovascular Electrophysiology. 2012;23 (2):163-8. DOI:10.1111/j. 1540-8167.2011.02144. x

700. Sipahi I., Chou JC, Hyden M., Rowland DY, Simon DI, Fang J.C. Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. American Heart Journal. 2012;163 (2):260-267. e3. DOI:10.1016/j. ahj. 2011.11.014

701. Cleland JG, Abraham WT, Linde C., Gold MR, Young JB, Claude Daubert J. et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. European Heart Journal. 2013;34 (46):3547-56. DOI:10.1093/eur-heartj/eht290

702. Ruschitzka F., Abraham WT, Singh JP, BaxJJ, Borer J. S., BrugadaJ et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. New England Journal of Medicine. 2013;369 (15):1395-405. DOI:10.1056/NEJMoa1306687

703. Beshai JF, Grimm R.A., Nagueh SF, Baker JH, Beau SL, Greenberg SM et al. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. New England Journal of Medicine. 2007;357 (24):2461-71.DOI:10.1056/NEJMoa0706695

704. on behalf of the ESTEEM-CRT Investigators, Donahue T., Niazi I., Leon A., Stucky M., Herrmann K. Acute and chronic response to CRT in narrow QRS patients. Journal of Cardiovascular Translational Research. 2012;5 (2):232-41. DOI:10.1007/s12265-011-9338-3

705. Thibault B., Harel F., Ducharme A., White M., Ellenbogen K.A., Frasure-Smith N. et al. Cardiac resynchronization therapy in patients with heart failure and a QRS complex №120 milliseconds: the evaluation of resynchronization therapy for heart failure (LESSER-EARTH) trial. Circulation. 2013;127 (8):873-81. DOI:10.1161/CIRCULATIONAHA. 112.001239

706. Zareba W., Klein H., Cygankiewicz I., Hall WJ, McNitt S., Brown M. et al. Effectiveness of cardiac resynchronization therapy by QRS morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization fjerapy (MADIT-CRT). Circulation. 2011;123 (10):1061-72. DOI:10.1161/CIRCULATIONAHA. 110.960898

707. Birnie DH, Ha A., Higginson L., Sidhu K., Green M., Philippon F. et al. Impact of QRS morphology and duration on outcomes after cardiac resynchronization therapy: results from the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (fj.FT). Circulation: Heart Failure. 2013;6 (6):1190-8. DOI:10.1161/CIRCHEARTFAILURE. 113.000380

708. Moss AJ, Hall WJ, Cannom DS, Klein H., Brown MW, Daubert JP et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. New England Journal of Medicine. 2009;361 (14):1329-38. DOI:10.1056/NEJMoa0906431

709. Tang ASL, Wells GA, Talajic M., Arnold MO, Sheldon R., Connolly S., et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. New England Journal of Medicine. 2010;363 (25):2385-95. DOI: 10.1056/NEJMoa1009540

710. Linde C., Abraham WT, Gold MR, Daubert C. Cardiac resynchronization therapy in asymptomatic or mildly symptomatic heart failure patients in relation to etiology. Journal of the American College of Cardiology. 2010;56 (22):1826-31. DOI:10.1016/j. jacc. 2010.05.055

711. Cleland JGF, Daubert J-C, Erdmann E., Freemantle N., Gras D., Kappenberger L. et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. European Heart Journal. 2006;27 (16):1928-32. DOI:10.1093/eurheartj/ehl099

712. Bristow MR, Saxon LA, Boehmer J., Krueger S., Kass DA, De Marco T. et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. New England Journal of Medicine. 2004;350 (2l):2140-50. DOI:10.1056/NEJM2a032423

713. Healey JS, Hohnloser SH, Exner DV Birnie DH, Parkash R, Connolly SJ et al. Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the Resynchronization for Ambulatory Heart Failure Trial (fj.FT). Circulation: Heart Failure. 2012;5 (5):566-70. DOI:10.1161/CIRCHEARTFAILURE. 112.968867

714. Koplan BA, Kaplan AJ, Weiner S, Jones PW, Seth M, Christman SA. Heart failure decompensation and all-cause mortality in relation to percent biventricular pacing in patients with heart failure. Journal of the American College of Cardiology. 2009;53 (4):355-60. DOI:10.1016/j. jacc. 2008.09.043

715. Cheng A, Landman SR, Stadler RW. Reasons for loss of cardiac resynchronization therapy pacing: insights from 32844 patients. Circulation: Arrhythmia and Electrophysiology. 2012;5 (5):884-8. DOI:10.1161/CIRCEP. 112.973776

716. Gasparini M, Auricchio A, Metra M, Regoli F, Fantoni C, Lamp B et al. Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. European Heart Journal. 2008;29 (13):1644-52. DOI:10.1093/eurheartj/ehn133

717. Gasparini M, Leclercq C, Lunati M, Landolina M, Auricchio A, Santini M et al. Cardiac resynchronization therapy in patients with atrial fibrillation. JACC: Heart Failure. 2013;1 (6):500-7. DOI:10.1016/j. jchf. 2013.06.003

718. Delnoy PPHM, OttervangerJP, Luttikhuis HO, Elvan A, Misier ARR, Beukema WP et al. Comparison of usefulness of cardiac resynchronization therapy in patients with atrial fibrillation and heart failure versus patients with sinus rhythm and heart failure. RAe American Journal of Cardiology. 2007;99 (9):1252-7. DOI:10.1016/j. amjcard. 2006.12.040

719. Tolosana JM, Arnau AM, Madrid AH, Macias A, Lozano IF, Osca J et al. Cardiac resynchronization therapy in patients with permanent atrial fibrillation. Is it mandatory to ablate the atrioventricular junction to obtain a good response? EuropeanJ ournal of Heart Failure. 2012;14 (6):635-41. DOI:10.1093/eurjhf/hfs024

720. Kamath GS, Cotiga D, Koneru JN, Arshad A, Pierce W, Aziz EF et al. fje utility of 12-lead holter monitoring in patients with permanent atrial fibrillation for the identification of nonresponders after cardiac resynchronization therapy. Journal of the American College of Cardiology. 2009;53 (12):1050-5. DOI:10.1016/j. jacc. 2008.12.022

721. Мареев Ю. В., Шитов В. Н., Киктев В. Г., Сапельников О. В., Латыпов Р. С., Гришин И. Р. и др. Сердечная ресинхронизирующая терапия при постоянной форме мерцательной аритмии. Кардиология. 2013;53 (5):43-9.

722. Linde C., Leclercq C., Rex S., Garrigue S., Lavergne T., Cazeau S. et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J. Am Coll Cardiol. 2002;40 (1):111-8. PMID:12103264

723. Kang S-H, Oh I-Y, Kang D-Y, Cha M-J, Cho Y., Choi E-K et al. Cardiac resynchronization therapy and QRS uration: systematic review, meta-analysis, and meta-regression. Journal of Korean Medical Science. 2015;30 (1):24-33. DOI:10.3346/jkms. 2015.30.1.24

724. Steffel J., Robertson M., Singh JP, Abraham WT, Bax JJ, Borer JS et al. The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. European Heart Journal. 2015;36 (30):1983-9. DOI:10.1093/eurheartj/ehv242

725. Barsheshet A., Moss AJ, McNitt S., Jons C., Glikson M., Klein HU et al. Long-term implications of cumulative right ventricular pacing among patients with an implantable cardioverter-defibrillator. Heart Rhythm. 2011;8 (2):212-8. DOI:10.1016/j. hrthm. 2010.10.035

726. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П., Коротеев А. В., Мареев Ю. В., Овчинников А. Г. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Утверждены на Конгрессе ОССН 7 декабря 2012 года, на Правлении ОССН 31 марта 2013 и Конгрессе РКО 25 сентября 2013 года. Журнал Сердечная Недостаточность. 2013;14 (7):379-472. DOI:10.18087/rhfj. 2013.7.1860

727. K0ber L., ^une JJ, Nielsen JC, Haarbo J., Videbæk L., Korup E. et al. Defibrillator implantation in patients with nonischemic systolic heart failure. New England Journal of Medicine. 2016;375 (13):1221-30. DOI:10.1056/NEJMoa1608029

728. Al-Khatib SM, Fonarow GC, Joglar JA, Inoue LYT, Mark DB, Lee KL et al. Primary prevention implantable cardioverter defibrillators in patients with nonischemic cardiomyopathy: a meta-analysis.JAMA Cardiology. 2017;2 (6):685. DOI:10.1001/jamacardio. 2017.0630

729. Beggs SAS, Jhund PS, Jackson CE, McMurray JJV, Gardner R.S. Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis. Heart. 2018;104 (2):144-50. DOI:1 0.1136/heartjnl-2016-310850

730. Shen L.,Jhund PS, Petrie MC, Claggett BL, Barlera S., Cleland JGF et al. Declining risk of sudden death in heart failure. New England Journal ofMedicine. 2017;377 (1):41-51. DOI:10.1056/NEJMoa1609758

731. Connolly S. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. European Heart Journal. 2000;21 (24):2071-8. DOI:10.1053/euhj. 2000.2476

732. Moss AJ, Zareba W., Hall WJ, Klein H., Wilber DJ, Cannom DS et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. New England Journal of Medicine. 2002;346 (12):877-83. DOI:10.1056/NEJMoa013474

733. Desai AS, FangJC, Maisel WH, Baughman K.L. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292 (23):2874-9. DOI:10.1001/jama. 292.23.2874

734. Gasparini M., Proclemer A., Klersy C., Kloppe A., Lunati M., Ferrer JBM et al. Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA. 2013;309 (18):1903. DOI:10.1001/jama. 2013.4598

735. Moss AJ, Schuger C., Beck CA, Brown MW, Cannom DS, Daubert JP et al. Reduction in inappropriate therapy and mortality through ICD programming. New England Journal of Medicine. 2012;367 (24):2275-83.DOI:10.1056/NEJMoa1211107

736. Scott PA, Silberbauer J., McDonagh TA, Murgatroyd F.D. Impact of prolonged implantable cardioverter-defibrillator arrhythmia detection times on outcomes: A meta-analysis. Heart Rhythm. 2014;11 (5):828-35. DOI:10.1016/j. hrthm. 2014.02.009

737. Velazquez EJ, Lee KL, Deja MA, Jain A., Sopko G., Marchenko A. et al. Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction. New EnglandJournal ofMedicine. 2011;364 (17):1607-16. DOI: 10.1056/NEJMoa1100356

738. Bangalore S., Pursnani S., Kumar S., Bagos P.G. Percutaneous Coronary Intervention Versus Optimal Medical Therapy for Prevention of Spontaneous Myocardial Infarction in Subjects With Stable Ischemic Heart Disease. Circulation. 2013;127 (7):769-81. DOI:10.1161/CIRCU-LATIONAHA. 112.131961

739. Trikalinos TA, Alsheikh-Ali AA, Tatsioni A., Nallamothu BK, Kent D.M. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. The Lancet. 2009;373 (9667):911-8. DOI:10.1016/S0140-6736 (09)60319-6

740. Velazquez EJ, Lee KL,Jones RH, Al-Khalidi HR, HillJA, PanzaJA et al. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. New England Journal of Medicine. 2016;374 (16):1511-20. DOI: 10.1056/NEJMoa1602001

741. Nishimura R.A., Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton R.A. et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease. Journal of the American College of Cardiology. 2014;63 (22):e57-185. DOI:10.1016/j. jacc. 2014.02.536

742. Latib А., Giannini А. Cardiac Interventions Today - The Next Frontier of Percutaneous Tricuspid Valve Repair. Cardiac Interventions Today. 2016;10 (4):54-9.

743. Готье С. В., Иткин Г. П., Шемакин С. Ю., Саитгареев Р. Ш., Попцов В. Н., Захаревич В. М. и др. Первый опыт клинического применения отечественного аппарата вспомогательного кровообращения на базе имплантируемого осевого насоса для двухэтапной трансплантации сердца. Вестник трансплантологии и искусственных органов. 2014;15 (3):92-101. DOI:10.15825/1995-1191-20 13-3-92-101

744. Готье С. В., Попцов В. Н., Захаревич В. М., Шевченко А. О., Спирина Е. А., Ухренков С. Г. и др. Пятилетний опыт применения периферической вено-артериальной экстракорпоральной мембранной оксигенации как метода механической поддержки кровообращения у потенциальных реципиентов сердца. Вестник трансплантологии и искусственных органов. 2016;18 (4):16-25. DOI:10.1582 5/ 1995-1191-2016-4-16-32

745. Feldman D., Pamboukian SV, TeutebergJJ, Birks E., Lietz K., Moore SA et al. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: Executive summary. The Journal of Heart and Lung Transplantation. 2013;32 (2):157-87. DOI:10.1016/j. healun. 2012.09.013

746. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W et al. Long-Term Use of a Left Ventricular Assist Device for End-Stage Heart Failure. New England Journal of Medicine. 2001;345 (20): 1435-43. DOI:10.1056/NEJMoa012175

747. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV Feldman D. et al. Advanced Heart Failure Treated with Continuous-Flow Left Ventricular Assist Device. New England Journal of Medicine. 2009; 361 (23):2241-51. DOI:10.1056/NEJMoa0909938

748. Estep JD, Starling RC, Horstmanshof DA, Milano CA, Selzman CH, Shah KB et al. Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients. Journal of the American College of Cardiology. 2015;66 (16):1747-61. DOI:10.1016/j. jacc. 2015.07.075

749. Готье С. В., Иткин Г. П., Шевченко А. О., Халилулин Т. А., Козлов В. А. Длительная механическая поддержка кровообращения как альтернатива трансплантации сердца. Вестник трансплантологии и искусственных органов. 2016; 18 (3):128-36. DOI:10.15825/1995-1191-201 6-3-128-136

750. Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. The Journal of Heart and Lung Transplantation. 2016;35 (1):1-23. DOI:10.1016/j. healun. 2015.10.023

751. Попцов В. Н., Спирина Е. А., Ухренков С. Г., Устин С. Ю., Алиев Э. З., Масютин С. А. и др. Периоперационный период при трансплантации сердца у реципиентов 60 лет и старше. Вестник трансплантологии и искусственных органов. 2016; 18 (4):56-65

752. Goldstein DJ, Bello R., Shin JJ, Stevens G., Zolty R., Maybaum S. et al. Outcomes of cardiac transplantation in septuagenarians. The Journal of Heart and Lung Transplantation. 2012;31 (7):679-85. DOI:10.1016/j. healun. 2012.03.019

753. Weiss ES, Allen JG, Russell SD, Shah AS, Conte J.V. Impact of Recipient Body Mass Index on Organ Allocation and Mortality in Orthotopic Heart Transplantation. The Journal of Heart and Lung Transplantation. 2009;28 (11):1150-7. DOI:10.1016/j. healun. 2009.06.009

754. Готье С. В., Шевченко А. О., Попцов В. Н. Пациент с трансплантированным сердцем. Руководство для врачей по ведению пациентов, перенесших трансплантацию сердца. ООО «Издательство «Триада». - М. - Тверь; 2014. 144 с. [Gautier S. V., Shevchenko A. O., Poptsov V. N. Patient with a transplanted heart. A guide for physicians in the management of patients undergoing heart transplantation. - M. - Tver.:«Triada», 2014. - 144p.] ISBN: 978-5-94789-648-0

755. Шевченко А. О., Туняева И. Ю., Насырова А. А., Миронков Б. Л., Ильинский И. М., Можейко Н. П. и др. Отторжение сердечного трансплантата и неинвазивные показатели функционального состояния стенки общей сонной артерии. Вестник трансплантологии и искусственных органов. 2015;17 (1):5-11. DOI: 10.15825/1995-1191-2015-1-5-11

756. Готье С. В., Шевченко А. О., Кормер А. Я., Попцов В. Н., Шевченко О. П. Перспективы улучшения отдаленных результатов трансплантации сердца. Вестник трансплантологии и искусственных органов. 2014;16 (3):23-30

757. Шевченко А. О. Гиполипидемическая терапия у реципиентов сердца: статины. Вестник трансплантологии и искусственных органов. 2016;18 (2):171-6. DOI: 10.15825/1995-1191-2016-2-171-176

758. Kannel WB, Hjortland M., Castelli W.P. Role of diabetes in congestive heart failure: fje Framingham study. fje American Journal of Cardiology. 1974;34 (1):29-34. DOI:10.1016/0002-9149 (74) 90089-7

759. Hubert HB, Feinleib M., McNamara PM, Castelli W.P. Obesity as an independent risk factor for cardiovascular disease: a 26- year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67 (5):968-77. DOI:10.1161/01. CIR. 67.5.968

760. Hogg K., Swedberg K., McMurray J. Heart failure with preserved left ventricular systolic function.Journal of the American College of Cardiology. 2004;43 (3):317-27. DOI:10.1016/j. jacc. 2003.07.046

761. Sakata Y., Miyata S., Nochioka K., Miura M., Takada T., Tadaki S. et al. Gender differences in clinical characteristics, treatment and long-term outcome in patients with stage C/D. heart failure in Japan. Report from the CHART-2 study. Circ J. 2014;78 (2):428-35. PMID:24317114

762. Lenzen MJ, Rosengren A, Scholte op Reimer WJM, Follath F, Boersma E, Simoons ML et al. Management of patients with heart failure in clinical practice: differences between men and women. Heart. 2008;94 (3):e10. DOI:10.1136/hrt. 2006.099523

763. Kannel WB. Incidence and Epidemiology of Heart Failure. Heart Failure Reviews. 2000;5 (2):167-73. DOI:10.1023/A:1009884820941

764. Rusinaru D, Mahjoub H, Goissen T, Massy Z, Peltier M, Tribouilloy C. Clinical features and prognosis of heart failure in women. A 5-year prospective study. InternationalJournal of Cardiology. 2009;133 (3):327-35. DOI:10.1016/j. ijcard. 2007.12.113

765. Adams KF, Sueta CA, Gheorghiade M, O’Connor CM, Schwartz TA, Koch GG et al. Gender Differences in Survival in Advanced Heart Failure: Insights From the FIRST Study. Circulation. 1999;99 (14):1816 21. DOI:10.1161/01. CIR. 99.14.1816

766. Mullens W, Abrahams Z, Sokos G, Francis GS, Starling RC, Young JB et al. Gender Differences in Patients Admitted With Advanced Decompensated Heart Failure. The American Journal of Cardiology. 2008;102 (4):454-8. DOI:10.1016/j. amjcard. 2008.04.009

767. Roger VL. Trends in Heart Failure Incidence and Survival in a Community-Based Population. JAMA. 2004;292 (3):344. DOI:10.1001/jama. 292.3.344

768. Barker WH. Changing Incidence and Survival for Heart Failure in a Well-Defined Older Population, 1970-1974 and 1990-1994. Circulation. 2006;113 (6):799-805. DOI:10.1161/ CIRCULATIONAHA. 104.492033

769. Vaccarino V, Chen YT, Wang Y, Radford MJ, Krumholz HM. Sex differences in the clinical care and outcomes of congestive heart failure in the elderly. Am Heart J. 1999;138 (5 Pt 1):835-42. PMID:10539813

770. Ohlsson A, Lindahl B, Hanning M, Westerling R. Inequity of access to ACE inhibitors in Swedish heart failure patients: a register-based study. Journal of Epidemiology and Community Health. 2016;70 (1):97 103. DOI: 10.1136/jech-2015-205738

771. Lupon J, Urrutia A, Gonzalez B, Diez C, Altimir S, Albaladejo C et al. Does Heart Failure fjerapy Differ According to Patient Sex? Clinical Cardiology. 2007;30 (6):301-5. DOI:10.1002/clc. 20098

772. ReckelhoffJF. Gender differences in the regulation of blood pressure. Hypertension. 2001;37 (5):1199-208. PMID:11358929

773. Shekelle PG, Rich MW, Morton SC, Atkinson CSW, Tu W, Maglione M et al. Efficacy of angiotensin-converting enzyme inhibitors and betablockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. Journal of the American College of Cardiology. 2003;41 (9):1529-38. DOI:10.1016/S0735-1097 (03) 00262-6

774. Oparil S, Miller AP. Gender and Blood Pressure. RAe Journal of Clinical Hypertension. 2005;7 (5):300-9. DOI:10.1111/j.1524-6175.2005.04087. x

775. Rathore SS, Wang Y, Krumholz HM. Sex-Based Differences in the Effect of Digoxin for the Treatment of Heart Failure. New England Journal of Medicine. 2002;347 (18):1403-11. DOI:10.1056/NEJ-Moa021266

776. Bushnell C, McCullough LD, Awad IA, Chireau MV, Fedder WN, Furie KL et al. Guidelines for the Prevention of Stroke in Women: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2014;45 (5):1545-88. DOI:10.1161/01. str. 0000442009.06663.48

777. Levitan EB, Wolk A, Mittleman MA. Consistency With the DASH Diet and Incidence of Heart Failure. Archives of Internal Medicine. 2009;169 (9):851. DOI:10.1001/archinternmed. 2009.56

778. Rautiainen S, Levitan EB, Mittleman MA, Wolk A. Fruit and vegetable intake and rate of heart failure: a population-based prospective cohort of women: Fruit and vegetables and rate of heart failure. EuropeanJournal of Heart Failure. 2015;17 (1):20-6. DOI:10.1002/ejhf. 191

779. Bleeker GB, Schalij MJ, Boersma E, Steendijk P, Van Der Wall EE, Bax JJ. Does a Gender Difference in Response to Cardiac Resynchronization Therapy Exist? Pacing and Clinical Electrophysiology. 2005;28 (12):1271-5. DOI:10.1111/j. 1540-8159.2005.00267. x

780. Zabarovskaja S, Gadler F, Braunschweig F, Stahlberg M, Hörnsten J, Linde C et al. Women have better long-term prognosis than men after cardiac resynchronization therapy. Europace. 2012;14 (8):1148-55. DOI:10.1093/europace/eus039

781. Kelarijani RB, Saleh DK, Chalian M, Kabir A, Ahmadzad Asl M, Dadjoo Y. Gender- and age-related outcomes of cardiac resynchronization therapy: A pilot observational study. Gender Medicine. 2008;5 (4):415-22. DOI:10.1016/j. genm. 2008.10.005

782. Xu Y-Z, Friedman PA, Webster T, Brooke K, Hodge DO, Wiste HJ et al. Cardiac Resynchronization Therapy: Do Women Benefit More ^an Men? Journal of Cardiovascular Electrophysiology. 2012;23 (2):172-8. DOI:10.1111/j. 1540-8167.2011.02168. x

783. Ghani A., Maas AHEM, Delnoy PPHM, Ramdat Misier AR, Ottervanger JP, Elvan A. Sex-Based Differences in Cardiac Arrhythmias, ICD Utilisation and Cardiac Resynchronisation Therapy. Netherlands HeartJournal. 2011;19 (1):35-40. DOI:10.1007/s12471-010-0050-8

784. Solomon SD, Foster E., Bourgoun M., Shah A., Viloria E., Brown MW, et al. Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: multicenter automatic defibrillator implantation trial: cardiac resynchronization therapy. Circulation. 2010;122 ( 10) :985-92. DOI: 10.1161 /CIRCULATIONAHA. 110.955039

785. Russo AM, PooleJE, Mark DB, Anderson J., Hellkamp AS, Lee KL et al. Primary Prevention with Defibrillator ^erapy in Women: Results from the Sudden Cardiac Death in Heart Failure Trial. Journal of Cardiovascular Electrophysiology. 2008;19 (7):720-4. DOI:10.1111/j. 1540-8167.2008.01129. x

786. Zeitler EP, Hellkamp AS, Schulte PJ, Fonarow GC, Hernandez AF, Peterson ED et al. Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in WomenCLINICAL PERSPECTIVE. Circulation: Heart Failure. 2016;9 (1):e002630. DOI:10.1161/CIRCHEARTFAILURE. 115.002630

787. Fornaro A., Castelli G., Ciaccheri M., Tomberli B., Olivotto I., Gensini GF. Improving survival of chemotherapy-induced cardiomyopathy in the modern heart failure therapy era. European HeartJournal. 2013;34 (suppl_1):P2968 - P2968. DOI:10.1093/eurheartj/eht309. P2968

788. Kalam K., Marwick T.H. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis. European Journal of Cancer. 2013;49 (13):2900-9. DOI:10.1016/j. ejca. 2013.04.030

789. Васюк ЮА, Школьник ЕВ, Несветов ВВ, Школьник ЛД, Варлан ГВ, Пильщиков А.В. Нарушения метаболизма миокарда на фоне химиотерапевтического лечения, а также возможности их коррекции. CardioСоматика. 2013; (4):20-4.

790. Amann K. Cross-Talk between the Kidney and the Cardiovascular System. Journal of the American Society of Nephrology. 2006;17 (8):2112-9. DOI:10.1681/ASN. 2006030204

791. Zoccali C, Goldsmith D, Agarwal R, Blankestijn PJ, Fliser D, Wiecek A et al. Ue complexity of the cardio - renal link: taxonomy, syndromes, and diseases. Kidney International Supplements. 2011;1 (1):2-5. DOI: 10.1038/kisup. 2011.4

792. Zhang Q-L, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: Systematic review. BMC Public Health [Internet]. 2008 [cited on March 21, 2018];8 (1). DOI:10.1186/1471-2458-8-117

793. Zoccali C., Kramer A., Jager K.J. Epidemiology of CKD in Europe: an uncertain scenario. Nephrology Dialysis Transplantation. 2010;25 (6): 1731-3. DOI:10.1093/ndt/gfq250

794. Ronco C., McCullough P., Anker SD, Anand I., Aspromonte N., Bagshaw SM et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J. 2010;31 (6):703-11. DOI:10.1093/eurheartj/ehp507

795. Hatamizadeh P., Fonarow GC, Budoff MJ, Darabian S., Kovesdy CP, Kalantar-Zadeh K. Cardiorenal syndrome: pathophysiology and potential targets for clinical management. Nature Reviews Nephrology. 2013;9 (2):99-111. DOI:10.1038/nrneph. 2012.279

796. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J. High Prevalence of Renal Dysfunction and Its Impact on Outcome in 118,465 Patients Hospitalized With Acute Decompensated Heart Failure: A Report From the ADHERE Database. Journal of Cardiac Failure. 2007;13 (6):422-30. DOI:10.1016/j. cardfail. 2007.03.011

797. Campbell RC, Sui X., Filippatos G., Love TE, Wahle C., Sanders PW, et al. Association of chronic kidney disease with outcomes in chronic heart failure: a propensity-matched study. Nephrology Dialysis Transplantation. 2008;24 (1):186-93. DOI:10.1093/ndt/gfn445

798. Hillege H.L. Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure. Circulation. 2006;113 (5):671-8. DOI:10.1161/CIRCULATIONAHA. 105.580506

799. Gigante A., Liberatori M., Gasperini ML, Sardo L., Di Mario F., Dorelli B. et al. Prevalence and Clinical Features of Patients with the Cardiorenal Syndrome Admitted to an Internal Medicine Ward. Cardiorenal Medicine. 2014;4 (2):88-94. DOI:10.1159/000362566

800. Clementi A., Virzi GM, Goh CY, Cruz DN, Granata A., Vescovo G. et al. Cardiorenal Syndrome Type 4: A Review. Cardiorenal Medicine. 2013;3 (1):63-70. DOI:10.1159/000350397

801. Damman K., Valente MAE, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege H.L. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. European Heart Journal. 2014;35 (7):455-69. DOI:10.1093/eur-heartj/eht386

802. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009; (113):S1-130. DOI:10.1038/ki. 2009.188

803. Levey AS, Bosch JP, Lewis JB, Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130 (6):461-70. PMID:10075613

804. Chronic Kidney Disease Prognosis Consortium, Matsushita K., van der Velde M., Astor BC, Woodward M., Levey AS et al. Association of estimated glomerular filtration rate and albuminuria with allcause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375 (9731):2073-81. DOI:10.1016/S0140-6736 (10) 60674-5

805. O’Seaghdha CM, Hwang S-J, Upadhyay A., Meigs JB, Fox C.S. Predictors of Incident Albuminuria in the Framingham Offspring Cohort. American Journal of Kidney Diseases. 2010;56 (5):852-60. DOI:10.1053/j. ajkd. 2010.04.013

806. Ishani A. Association of Single Measurements of Dipstick Proteinuria, Estimated Glomerular Filtration Rate, and Hematocrit with 25-Year Incidence of End-Stage Renal Disease in the Multiple Risk Factor Intervention Trial. Journal of the American Society of Nephrology. 2006;17 (5):1444-52. DOI:10.1681/ASN. 2005091012

807. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH et al. Characteristics, Treatments, and Outcomes of Patients With Preserved Systolic Function Hospitalized for Heart Failure. Journal of the American College of Cardiology. 2007;50 (8):768-77. DOI:10.1016/j. jacc. 2007.04.064

808. Clark H., Krum H., Hopper I. Worsening renal function during renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction. EurJ Heart Fail. 2014;16 (1):41-8. DOI:10.1002/ejhf. 13

809. Hawkins NM, Huang Z., Pieper KS, Solomon SD, Kober L., Velazquez EJ et al. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European Journal of Heart Failure. 2009; 11 (3):292-8. DOI:10.1093/eurjhf/hfp001

810. Apostolovic S., Jankovic-Tomasevic R., Salinger-Martinovic S., Djordjevic-Radojkovic D., Stanojevic D., Pavlovic M. et al. Frequency and significance of unrecognized chronic obstructive pulmonary disease in elderly patients with stable heart failure. Aging Clinical and Experimental Research. 2011;23 (5-6):337-42. DOI:10.1007/BF03337759

811. Mentz RJ, Schulte PJ, FlegJL, Fiuzat M., Kraus WE, Pina IL et al. Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: Findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION). American HeartJournal. 2013;165 (2):193-9. DOI:10.1016/j. ahj. 2012.10.029

812. Macchia A., Monte S., Romero M., D’Ettorre A., Tognoni G. The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure. European Journal of Heart Failure. 2007;9 (9):942-8. DOI:10.1016/j. ejheart. 2007.06.004

813. Parissis JT, Andreoli C., Kadoglou N., Ikonomidis I., Farmakis D., Dimopoulou I. et al. Differences in clinical characteristics, management and short-term outcome between acute heart failure patients chronic obstructive pulmonary disease and those without this comorbidity. Clinical Research in Cardiology. 2014;103 (9):733-41. DOI:10.1007/s00392-014-0708-0

814. Mentz RJ, Fiuzat M., Wojdyla DM, Chiswell K., Gheorghiade M., Fonarow GC et al. Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF. European Journal of Heart Failure. 2012;14 (4):395-403. DOI:10.1093/eurjhf/hfs009

815. Mentz RJ, Schmidt PH, Kwasny MJ, Ambrosy AP, O’Connor CM, Konstam MA et al. The Impact of Chronic Obstructive Pulmonary Disease in Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction: An Analysis of the EVEREST Trial. Journal of Cardiac Failure. 2012;18 (7):515-23. DOI:10.1016/j. cardfail. 2012.04.010

816. Rutten FH. Diagnosis and management of heart failure in COPD. Rabe KF, Wedzicha JA, Wouters EFM, editor. COPD and Comorbidity [Internet]. European Respiratory Society; 2013 [cited on Febrary 1, 2018]. p. 50-63. ISBN: 978-1-84984-032-3

817. Naeije R., Boerrigter B.G. Pulmonary hypertension at exercise in COPD: does it matter? European Respiratory Journal. 2013;41 (5):1002-4. DOI:10.1183/09031936.00173512

818. Iversen KK, Kjaergaard J., Akkan D., Kober L., Torp-Pedersen C., Hassager C. et al. Chronic obstructive pulmonary disease in patients admitted with heart failure. Journal ofInternal Medicine. 2008;264 (4):361-9. DOI:10.1111/j. 1365-2796.2008.01975. x

819. Le Jemtel TH, Padeletti M., Jelic S. Diagnostic and Therapeutic Challenges in Patients With Coexistent Chronic Obstructive Pulmonary Disease and Chronic Heart Failure. Journal of the American College of Cardiology. 2007;49 (2):171-80. DOI:10.1016/j. jacc. 2006.08.046

820. Zeng Q., Jiang S. Update in diagnosis and therapy of coexistent chronic obstructive pulmonary disease and chronic heart failure. J. Thorac Dis. 2012;4 (3):310-5. DOI:10.3978/j. issn. 2072-1439.2012.01.09

821. Чучалин А. Г. Хроническая обструктивная болезнь легких и сопутствующие заболевания. Терапевтический архив. 2013;85 (8):43-8.

822. Mancini GBJ, Etminan M., Zhang B., Levesque LE, FitzGerald JM, Brophy J.M. Reduction of Morbidity and Mortality by Statins, Angioten sin-Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers in Patients With Chronic Obstructive Pulmonary Disease. Journal of the American College of Cardiology. 2006;47 (12):2554-60. DOI:10.1016/j. jacc. 2006.04.039

823. Mortensen EM, Copeland LA, Pugh MJV, Restrepo MI, de Molina RM, Nakashima B. et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respiratory Research [Internet]. 2009 [cited on Febrary 1, 2018];10 (1). DOI:10.1186/1465-9921-10-45

824. Finnerty JP, Keeping I., Bullough I., Jones J. fje Effectiveness of Outpatient Pulmonary Rehabilitation in Chronic Lung Disease. Chest. 2001;119 (6):1705-10. DOI:10.1378/chest. 119.6.1705

825. Федотов П. А., Ситникова М. Ю., Сафьянова Н. В., Шапорова Н. Л. Хроническая сердечная недостаточность ишемического генеза и хроническая обструктивная болезнь легких: возможности комбинированной терапии, включающей небиволол. Клиницист. 2013; (3-4):40-7.

826. Stefan MS, Rothberg MB, Priya A., Pekow PS, Au DH, Lindenauer P.K. Association between ß-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. fjorax. 2012;67 (11):977-84. DOI:10.1136/thoraxjnl-2012-201945

827. Etminan M., Jafari S., Carleton B., FitzGerald J.M. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulmonary Medicine [Internet]. 2012 [cited on Febrary 1, 2018];12 (1). DOI:10.1186/1471-2466-12-48

828. Rutten F.H. ß-Blockers May Reduce Mortality and Risk of Exacerbations in Patients With Chronic Obstructive Pulmonary Disease. Archives ofInternal Medicine. 2010;170 (10):880. DOI:10.1001/archin-ternmed. 2010.112

829. Du Q., Sun Y., Ding N., Lu L., Chen Y. Beta-Blockers Reduced the Risk of Mortality and Exacerbation in Patients with COPD: A Meta-Analysis of Observational Studies. Chalmers JD, редактор. PLoS ONE. 2014;9 (11):e113048. DOI:10.1371 /journal. pone. 0113048

830. Farland MZ, Peters CJ, Williams JD, Bielak KM, Heidel RE, Ray S.M. ß-Blocker Use and Incidence of Chronic Obstructive Pulmonary Disease Exacerbations. Annals of Pharmacotherapy. 2013;47 (5):651-6. DOI:10.1345/aph. 1R600

831. Ekström MP, Hermansson AB, Ström K.E. Effects of Cardiovascular Drugs on Mortality in Severe Chronic Obstructive Pulmonary Disease: A Time-Dependent Analysis. American Journal of Respiratory and Critical Care Medicine. 2013;187 (7):715-20. DOI:10.1164/rc-cm. 201208-1565OC

832. Tavazzi L., Swedberg K., Komajda M., Böhm M., Borer JS, Lainscak M. et al. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: An efficacy and safety analysis of SHIFT study. International Journal of Cardiology. 2013;170 (2):182-8. DOI:10.1016/j. ijcard. 2013.10.068

833. Au DH, Udris EM, Fan VS, Curtis JR, McDonell MB, Fihn S.D. Risk of Mortality and Heart Failure Exacerbations Associated With Inhaled ß-Adrenoceptor Agonists Among Patients With Known Left Ventricular Systolic Dysfunctiona. Chest. 2003;123 (6):1964-9. DOI:10.1378/chest. 123.6.1964

834. Levy D. fje progression from hypertension to congestive heart failure. JAMA: fje Journal of the American Medical Association. 1996;275 (20):1557-62. DOI: 10.1001/jama. 275.20.1557

835. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet. 1998;352 (9131):854-65. DOI:10.1016/S0140-6736 (98) 07037-8

836. Masoudi FA. Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study. Circulation. 2005;111 (5):583-90. DOI:10.1161/01. CIR. 0000154542.13412. B1

837. Hernandez AV Usmani A, Rajamanickam A, Moheet A. Thiazolidin-ediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis and Meta-Regression Analysis of Placebo-Controlled Randomized Clinical Trials. American Journal Cardiovascular Drugs. 2011;11 (2):115-28. DOI:10.216 5/11587580-000000000-00000

838. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y., Buse JB et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2017;377 (13):1228-39. DOI:10.1056/NEJMoa1612917

839. Barzilay J. Risk and impact of incident glucose disorders in hypertensive older adults treated with an ace inhibitor, a diuretic, or a calcium channel blocker: a report from the allhat trial. American Journal of Hypertension. 2004;17 (5):S1. DOI:10.1016/j. amjhyper. 2004.03.002

840. Gottlieb SS, McCarter RJ, Vogel R.A. Effect of Beta-Blockade on Mortality among High-Risk and Low-Risk Patients after Myocardial Infarction. New England Journal of Medicine. 1998;339 (8):489-97. DOI: 10.1056/NEJM199808203390801

841. Heinemann L., Heise T., Ampudia J., Sawicki P., Sindelka G., Brunner G. et al. Four week administration of an ACE inhibitor and a cardioselective beta-blocker in healthy volunteers: no influence on insulin sensitivity. Eur J. Clin Invest. 1995;25 (8):595-600. PMID:7589016

842. Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ra-gone R et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med. 1997;126 (12):955 9. PMID:9182472

843. Мареев В. Ю., Даниелян М. О., Осмаловская Ю. Ф., Агеев Ф. Т., Серединина Е. М., Жубрина Е. С. и др. НЕбиволол против МЕтопролола: сравнительное рандомиЗированное ИсслеДовАние у больных Хронической Сердечной Недостаточностью (НЕМЕЗИДА - ХСН). ЖСН. 2013;14 (2):63-74.

844. Torp-Pedersen C., Metra M., Charlesworth A., Spark P., Lukas MA, Poole-Wilson PA et al. Effects of metoprolol and carvedilol on preexisting and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart. 2007;93 (8):968-73. DOI:10.1136/hrt. 2006.092379

845. Bakris GL, Fonseca V. Katholi RE, McGill JB, Messerli FH, Phillips R.A. et al. Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension: A Randomized Controlled Trial. JAMA. 2004;292 (18):2227. DOI:10.1001/jama. 292.18.2227

846. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in Heart Failure. Journal of the American College of Cardiology. 2006;48 (8):1527-37. DOI:10.1016/j. jacc. 2006.06.055

847. Оганов Р. Г., Ольбинская Л. И., Смулевич А. Б., Вейн А. М., Дробижев М. Ю., Шальнова С. А. и др. Депрессии и расстройства депрессивного спектра в общемедицинской практике. Результаты программы КОМПАС. Кардиология. 2004;44 (1):48.

848. Jiménez JA, Redwine LL, Rutledge TR, Dimsdale JE, Pung MA, Ziegler MG et al. Depression Ratings and Antidepressant Use among Outpatient Heart Failure Patients: Implications for the Screening and Treatment of Depression. "Шє International Journal of Psychiatry in Medicine. 2012;44 (4):315-34. DOI:10.2190/PM. 44.4. c

849. DeWolfe A., Gogichaishvili I., Nozadze N., Tamariz L., Quevedo HC, Julian E. et al. Depression and Quality of Life Among Heart Failure Patients in Georgia, Eastern Europe: depression and quality of life among heart failure patients. Congestive Heart Failure. 2012;18 (2):107-11. DOI:10.1111/j. 1751-7133.2011.00226. x

850. Feola M., Garnero S., Vallauri P., Salvatico L., Vado A., Leto L. et al. Relationship between Cognitive Function, Depression/Anxiety and Functional Parameters in Patients Admitted for Congestive Heart Failure. Open Cardiovasc MedJ. 2013;7:54-60. DOI:10.2174/1874192401307010054

851. Jiang W., Kuchibhatla M., Cuffe MS, Christopher EJ, Alexander JD, Clary GL et al. Prognostic value of anxiety and depression in patients with chronic heart failure. Circulation. 2004;110 ( 22):3452-6. DOI:10.1161/01. CIR. 0000148138.25157. F9

852. BraunsteinJB, Anderson GF, Gerstenblith G., Weller W., Niefeld M., Herbert R. et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J. Am Coll Cardiol. 2003;42 (7):1226-33. PMID:14522486

853. Newhouse A., Jiang W. Heart Failure and Depression. Heart Failure Clinics. 2014;10 (2):295-304. DOI:10.1016/j. hfc. 2013.10.004

854. Katon W., Lin EHB, Kroenke K. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. General Hospital Psychiatry. 2007;29 (2):147-55. DOI:10.1016/j. genhosppsych. 2006.11.005

855. Egede L.E. Major depression in individuals with chronic medical disorders: prevalence, correlates and association with health resource utilization, lost productivity and functional disability. General Hospital Psychiatry. 2007;29 (5):409-16. DOI:10.1016/j. genhosppsych. 2007.06.002

856. Lichtman JH, Bigger JT, Blumenthal JA, Frasure-Smith N., Kaufmann PG, Lesperance F. et al. Depression and Coronary Heart Disease: Recommendations for Screening, Referral, and Treatment: A Science Advisory From the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Psychiatric Association. Circulation. 2008;118 (17):1768-75. DOI:10.1161/CIRCULATIONAHA. 108.190769

857. U. S. Preventive Services Task Force*. Screening for Depression: Recommendations and Rationale. Annals of Internal Medicine. 2002;136 (10):760. DOI:10.7326/0003-4819-136-10-200205210-00012

858. Thombs BD, Ziegelstein RC, Roseman M., Kloda LA, Ioannidis J.P. There are no randomized controlled trials that support the United States Preventive Services Task Force guideline on screening for depression in primary care: a systematic review. BMC Medicine [Internet]. 2014 [cited on Febrary 1, 2018];12 (1). DOI:10.1186/1741-7015-12-13

859. Whooley M.A. To Screen or Not to Screen? Journal of the American College of Cardiology. 2009;54 (10):891-3. DOI:10.1016/j. jacc. 2009.05.034

860. Оганов Р. Г., Погосова Г. В., Шальнова С. А., Деев А. Д. Депрессивные расстройства в общемедицинской практике по данным исследования КОМПАС: взгляд кардиолога. Кардиология. 2005;45 (8):37-43.

861. Васюк Ю. А., Довженко Т. В. Хроническая сердечная недостаточность и расстройства депрессивного спектра. Журнал Сердечная Недостаточность. 2009;10 (6):342-8.

862. Васюк Ю. А., Довженко Т. В., Школьник Е. Л. Депрессии при хронической сердечной недостаточности ишемического гене-за. Журнал Сердечная Недостаточность. 2004;5 (3): 140-6.

863. Faller H., Störk S., Gelbrich G., Schowalter M., Ertl G., Angermann C.E. Depressive symptoms in heart failure: Independent prognostic factor or marker of functional status? Journal of Psychosomatic Research. 2015;78 (6):569-72. DOI:10.1016/j. jpsychores. 2015.02.015

864. Lahlou-Laforêt K., Ledru F., Niarra R., Consoli SM. Validity of Beck Depression Inventory for the assessment of depressive mood in chronic heart failure patients. Journal of Affective Disorders. 2015;184:256-60. DOI:10.1016/j. jad. 2015.05.056

865. DiMatteo MR, Lepper HS, Croghan T.W. Depression Is a Risk Factor for Noncompliance With Medical Treatment: Meta-analysis of the Effects of Anxiety and Depression on Patient Adherence. Archives of Internal Medicine. 2000;160 (14):2101. DOI:10.1001/archinte. 160.14.2101

866. Ski CF, Thompson DR, Hare DL, Stewart AG, Watson R. Cardiac Depression Scale: Mokken scaling in heart failure patients. Health and Quality of Life Outcomes. 2012;10 ( 1 ) : 141. DOI:10.1186/1477-7525-10-141

867. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review.J Psychosom Res. 2002;52 (2):69-77. PMID:11832252

868. Zigmond AS, Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67 (6):361-70. PMID:6880820

869. Savard LA, Thompson DR, Clark A.M. A meta-review of evidence on heart failure disease management programs: the challenges of describing and synthesizing evidence on complex interventions. Trials [Internet]. 2011 [cited on Febrary 1, 2018];12 (1). DOI:10.1186/1745-6215-12-194

870. de la Porte PWFB-A, Lok DJA, van Veldhuisen DJ, van Wijngaarden J., Cornel JH, Zuithoff NPA et al. Added value of a physician-and-nurse-directed heart failure clinic: results from the Deventer - Alkmaar heart failure study. Heart. 2007;93 (7):819-25. DOI:10.1136/hrt. 2006.095810

871. Clark AM, Thompson D.R. The future of management programmes for heart failure. The Lancet. 2008;372 (9641):784-6. DOI:10.1016/S0140-6736 (08) 61317-3

872. Андрющенко А. В., Дробижев М. Ю., Добровольский А. В. Сравнительная оценка шкал CES-D, BDI и HADS (d) в диагностике депрессий в общемедицинской практике. Журнал неврологии и психиатрии им СС Корсакова. 2003;103 (5):11-8.

873. Беленков Ю. Н., Агеев Ф. Т., Банщиков Г. Т., Волкова Е. Г., Гиляревский С. Р., Донова И. Г. и др. Влияние специализированных форм активного амбулаторного ведения на функциональный статус, качество жизни и показатели гемодинамики больных с выраженной сердечной недостаточностью. Результаты Российской программы «ШАНС». Журнал Сердечная Недостаточность. 2007;8 (3):112-6.

874. Беграмбекова Ю. Л., Мареев В. Ю., Дробижев М. Ю. Школы для пациентов с сердечной недостаточностью. Есть ли ШАНС повлиять на депрессию и тревогу? Вторичный (Post-hoc) анализ исследования ШАНС (Школа и Амбулаторное Наблюдение больных Сердечной недостаточностью). Журнал Сердечная Недостаточность. 2016;17 (6):433-42. DOI:10.18087/rhfj. 2016.6.2281

875. Dekker R.L. Cognitive Therapy for Depression in Patients with Heart Failure: A Critical Review. Heart Failure Clinics. 2011;7 (1):127-41. DOI:10.1016/j. hfc. 2010.10.001

876. Gary R.A., Dunbar SB, Higgins MK, Musselman DL, Smith A.L. Combined exercise and cognitive behavioral therapy improves outcomes in patients with heart failure. Journal of Psychosomatic Research. 2010;69 (2):119-31. DOI:10.1016/j. jpsychores. 2010.01.013

877. Tu R-H, Zeng Z-Y, Zhong G-Q, Wu W-F, Lu Y-J, Bo Z-D et al. Effects of exercise training on depression in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials: Effects of exercise training on depression in HF: a systematic review. European Journal of Heart Failure. 2014;16 (7):749-57. DOI: 10.1002/ejhf. 101

878. O’Connor CM, Jiang W., Kuchibhatla M., Silva SG, Cuffe MS, Callwood DD et al. Safety and Efficacy of Sertraline for Depression in Pa tients With Heart Failure. Journal of the American College of Cardiology. 2010;56 (9):692-9. DOI:10.1016/j. jacc. 2010.03.068

879. Angermann CE, Gelbrich G., Störk S., Gunold H., Edelmann F., Wachter R. et al. Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: RAe MOOD -HF Randomized Clinical Trial. JAMA. 2016;315 (24):2683. DOI: 10.1001/jama. 2016.7635

880. Glassman A.H. Cardiovascular Effects of Tricyclic Antidepressants. Annual Review ofMedicine. 1984;35 (1):503-11. DOI:10.1146/annurev. me. 35.020184.002443

881. Goldberg RJ, Capone RJ, Hunt J.D. Cardiac complications following tricyclic antidepressant overdose. Issues for monitoring policy. JAMA. 1985;254 (13):1772-5. PMID:4032678

882. Pacher P., Ungvari Z., Nanasi PP, Furst S., Kecskemeti V. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? Curr Med Chem. 1999;6 (6):469-80. PMID:10213794

883. Burris KD, Molski TF, Xu C., Ryan E., Tottori K., Kikuchi T. et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol Exp fjer. 2002;302 (1):381-9. PMID:12065741

884. Jordan S., Koprivica V., Chen R., Tottori K., Kikuchi T., Altar C.A. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J. Pharmacol. 2002;441 (3):137-40. PMID:12063084

885. Muscaritoli M., Anker SD, Argilés J., Aversa Z., Bauer JM, Biolo G. et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: Joint document elaborated by Special Interest Groups (SIG) «cachexia-anorexia in chronic wasting diseases» and «nutrition in geriatrics». Clinical Nutrition. 2010;29 (2):154-9. DOI:10.1016/j. clnu. 2009.12.004

886. Beaudart C, Reginster J-Y, Slomian J, Buckinx F, Locquet M, Bruyère O. Prevalence of sarcopenia: the impact of different diagnostic cut-off limits. J Musculoskelet Neuronal Interact. 2014;14 (4):425 31. PMID:25524968

887. Collamati A, Marzetti E, Calvani R, Tosato M, DAngelo E, Sisto AN et al. Sarcopenia in heart failure: mechanisms and therapeutic strategies. J Geriatr Cardiol. 2016;13 (7):615-24. DOI:10.11909/j. issn. 1671-5411.2016.07.004

888. Hajahmadi M, Shemshadi S, Khalilipur E, Amin A, Taghavi S, Maleki M et al. Muscle wasting in young patients with dilated cardiomyopathy: Muscle wasting in young patients with dilated cardiomyopathy. Journal of Cachexia, Sarcopenia and Muscle. 2017;8 (4):542-8. DOI:10.1002/jcsm. 12193

889. Massy-Westropp NM, Gill TK, Taylor AW, Bohannon RW, Hill CL. Hand Grip Strength: age and gender stratified normative data in a population-based study. BMC Research Notes. 2011;4 (1):127. DOI:10.1186/1756-0500-4-127

890. Landi F, Marzetti E, Martone AM, Bernabei R, Onder G. Exercise as a remedy for sarcopenia: Current Opinion in Clinical Nutrition and Metabolic Care. 2013;1. DOI:10.1097/MCO. 0000000000000018

891. Lenk K, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. Journal of Cachexia, Sarcopenia and Muscle. 2010;1 (1):9-21. DOI:10.1007/s13539-010-0007-1

892. Binder EF, Yarasheski KE, Steger-May K, Sinacore DR, Brown M, Schechtman KB et al. Effects of Progressive Resistance Training on Body Composition in Frail Older Adults: Results of a Randomized, Controlled Trial. fje Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2005;60 (11): 1425-31. DOI: 10.1093/gerona/60.11.1425

893. Smart NA, Steele M. RAe Effect of Physical Training on Systemic Proinflammatory Cytokine Expression in Heart Failure Patients: A Systematic Review: physical training and cytokine levels. Congestive Heart Failure. 2011;17 (3):110-4. DOI:10.1111 /j. 1751 7133.2011.00217. x

894. Daly RM. Exercise and nutritional approaches to prevent frail bones, falls and fractures: an update. Climacteric. 2017;20 (2):119-24. DOI :10.1080/13697137.2017.1286890

895. Pinto CL, Botelho PB, CarneiroJA, MotaJF. Impact of creatine supplementation in combination with resistance training on lean mass in the elderly: Creatine and resistance training in the elderly. Journal of Cachexia, Sarcopenia and Muscle. 2016;7 (4):413-21. DOI:10.1002/jc-sm. 12094

896. Арутюнов Г. П., Чернявская Т. К., Костюкевич О. И., Волгина О. Н. Сердечная кахексия. Фарматека. 2008; (11):68-71.

897. Арутюнов Г. П., Костюкевич О. И. Питание больных с хронической сердечной недостаточностью, проблемы нутритивной поддержки, решенные и нерешенные аспекты. ЖСН. 2002;3 (5):245-8.

898. Арутюнов АГ, Костюкевич ОИ, Звонова ЕВ, Топильская Н.В. Исследование распространенности и клинической значимости гипотрофии у терапевтических больных (САТУРН). ЖСН. 2007;8 (3):144-9.

899. Арутюнов Г. П., Костюкевич О. И., Звонова Е. В., Топильская Н. В. Клиническая эффективноСть питАтельной смеси ПепТамен У. пациентов с хронической сеРдечной недостаточностью III-IV ФК по NYHA и призНаками гипотрофии (САТУРН-II), предварительные результаты. Журнал Сердечная Недостаточность. 2007;8 (5):239-43.

900. Zamboni M., Rossi AP, Corzato F., Bambace C., Mazzali G., Fantin F. Sarcopenia, cachexia and congestive heart failure in the elderly. Endocr Metab Immune Disord Drug Targets. 2013;13 (1):58-67. PMID:23369138

901. Von Haehling S. The wasting continuum in heart failure: from sarcopenia to cachexia. Proceedings of the Nutrition Society. 2015;74 (04):367-77. DOI: 10.1017/S0029665115002438

902. Rossignol P., Masson S., Barlera S., Girerd N., Castelnovo A., Zannad F. et al. Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials: Weight loss in the GISSI-HF and Val-HeFT trials. European Journal of Heart Failure. 2015;17 (4):424-33. DOI:10.1002/ejhf. 240

903. Арутюнов Г. П. Кахексия у больных с хронической сердечной недостаточностью. Каков масштаб проблемы? Что мы знаем и что нам делать? ЖСН. 2001;2 (3):101.

904. Clark AL, Coats AJS, Krum H., Katus HA, Mohacsi P., Salekin D. et al. Effect of beta-adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial: Cachexia and beta blockers in chronic heart failure. Journal of Cachexia, Sarcopenia and Muscle. 2017;8 (4):549-56. DOI:10.1002/jcsm. 12191

905. Hoes MF, Grote Beverborg N., Kijlstra JD, Kuipers J., Swinkels DW, Giepmans BNG et al. Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function: Impaired contractility in iron-deficient cardiomyocytes. European Journal of Heart Failure. 2018;20 (5):910-9. DOI:10.1002/ejhf. 1154

906. Nunez J., Comin-Colet J., Minana G., Nunez E., Santas E., Mollar A. et al. Iron deficiency and risk of early readmission following a hospitalization for acute heart failure: Iron deficiency and rehospitalization. European Journal of Heart Failure. 2016;18 (7):798-802. DOI:10.1002/ejhf. 513

907. Pozzo J., Fournier P., Delmas C., Vervueren P-L, Roncalli J., Elbaz M. et al. Absolute iron deficiency without anaemia in patients with chronic systolic heart failure is associated with poorer functional capacity. Archives of Cardiovascular Diseases. 2017;110 (2):99-105. DOI:10.1016/j. acvd. 2016.06.003

908. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ et al. Anemia and Mortality in Heart Failure Patients. Journal of the American College of Cardiology. 2008;52 (10):818-27. DOI:10.1016/j. jacc. 2008.04.061

909. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R et al. Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure. New England Journal of Medicine. 2013;368 (13):1210-9. DOI: 10.1056/NEJMoa1214865

910. Jankowska EA, Kasztura M, Sokolski M, Bronisz M, Nawrocka S, Ole kowska-Florek W et al. Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. European Heart Journal. 2014;35 (36):2468-76. DOI:10.1093/eur-heartj/ehu235

911. Von Haehling S., Gremmler U., Krumm M., Mibach F., Schön N., Taggeselle J. et al. Prevalence and clinical impact of iron deficiency and anaemia among outpatients with chronic heart failure: The PrEP Registry. Clinical Research in Cardiology. 2017;106 (6):436-43. DOI:10.1007/s00392-016-1073-y

912. Yeo TJ, Yeo PSD, Ching-Chiew Wong R., Ong HY, Leong KTG, Jaufeerally F. et al. Iron deficiency in a multi-ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis: Iron deficiency in Asian heart failure. European Journal of Heart Failure. 2014;16 (10):1125-32. DOI:10.1002/ejhf. 161

913. Weiss G., Goodnough L.T. Anemia of chronic disease. New England Journal of Medicine. 2005;352 (10):1011-23. DOI:10.1056/NEJM-ra041809

914. Ezekowitz JA, McAlister FA, Armstrong P.W. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12065 patients with new-onset heart failure. Circulation. 2003;107 (2):223-5. DOI:10.1161/01. CIR. 0000052622.51963. FC

915. Mozaffarian D., Nye R., Levy W.C. Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRA.ISE). J. Am Coll Cardiol. 2003;41 (11):1933-9. PMID:12798560

916. Felker GM, Gattis WA, Leimberger JD, Adams KF, Cuffe MS, Gheo-rghiade M. et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. AmJ Cardiol. 2003;92 (5):625-8. PMID:12943893

917. Solomakhina NI, Nakhodnova ES, Gitel EP, Belenkov YN. Hepcidin and its relationship with inflammation in old and older patients with anemia of chronic disease associated with CHF. Kardiologiia. 2018;17 (S2):4-11. DOI:10.18087/cardio. 2457

918. Lewis GD, Malhotra R., Hernandez AF, McNulty SE, Smith A., Felker GM et al. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. JAMA. 2017;317 (19):1958. DOI:10.1001/jama. 2017.5427

919. Ponikowski P., van Veldhuisen DJ, Comin-Colet J., Ertl G., Komajda M., Mareev V. et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. European Heart Journal. 2015;36 (11):657-68. DOI:10.1093/eurheartj/ehu385

920. Filippatos G., Farmakis D., Colet JC, Dickstein K., Lüscher TF, Wil-lenheimer R. et al. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. European Journal of Heart Failure. 2013;15 (11):1267-76.DOI:10.1093/eurjhf/hft099

921. Bolger AP, Bartlett FR, Penston HS, O’Leary J., Pollock N., Kaprielian R. et al. Intravenous Iron Alone for the Treatment of Anemia in Patients With Chronic Heart Failure. Journal of the American College of Cardiology. 2006;48 (6):1225-7. DOI:10.1016/j. jacc. 2006.07.015

922. Toblli JE, Lombrana A., Duarte P., Di Gennaro F. Intravenous Iron Reduces NT-Pro-Brain Natriuretic Peptide in Anemic Patients With Chronic Heart Failure and Renal Insufficiency. Journal of the American College of Cardiology. 2007;50 (17):1657-65. DOI:10.1016/j. jacc. 2007.07.029

923. Usmanov RI, Zueva EB, Silverberg DS, Shaked M. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol. 2008;21 (2):236-42.

924. Anker SD, Comin Colet J., Filippatos G., Willenheimer R., Dickstein K., Drexler H. et al. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. New EnglandJournal ofMedicine. 2009;361 (25):2436-48.DOI:10.1056/NEJMoa0908355

925. Beshara S., Sorensen J., Lubberink M., Tolmachev V., Langstrom B., Antoni G. et al. Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. British Journal of Haematology. 2003;120 (5):853-9. DOI:10.1046/j. 1365-2141.2003.03590. x

926. Bovelli D., Plataniotis G., Roila F., ESMO Guidelines Working Group. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol. 2010;21 Suppl 5: v277-282. DOI:10.1093/annonc/mdq200

927. Hochhaus A., Kantarjian H. The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients. Journal of Cancer Research and Clinical Oncology. 2013;139 (12):1971-84. DOI:10.1007/s00432-013-1488-z

928. Под ред. Н. И. Переводчиковой. Руководство по химиотерапии опухолевых заболеваний. -М.: Практическая медицина; 2011. 512 с. [Guide for chemotherapy of neoplastic diseases. ed. by Perevodchikova N. I. - M.: Practical medicine, 2011. - 512p. (p. 435-436)] ISBN: 978-5-98811-180-1

929. Gendlin GE, Emelina EI, Nikitin IG, Vasyuk Y.A. Modern view on cardiotoxicity of chemotherapeutics in oncology including anthracy-clines. Russian Journal of Cardiology. 2017; (3):145-54. DOI:10.158 29/1560-4071-2017-3-145-154

930. Vejpongsa P., Yeh ETH. Prevention of Anthracycline-Induced Cardiotoxicity. Journal of the American College of Cardiology. 2014;64 (9):938-45. DOI:10.1016/j. jacc. 2014.06.1167

931. Raj S., Franco VI, Lipshultz S.E. Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment. Curr Treat Options Cardiovasc Med. 2014;16 (6):315. DOI: 10.1007/s11936-014-0315-4

932. Матяш М. Г., Кравчук Т. Л., Высоцкая В. В., Чернов В. И., Гольдберг В. Е. Индуцированная антрациклинами кардиотоксичность: механизмы развития и клинические проявления. Сибирский Онкологический Журнал. 2008; (6):66-75.

933. Shakir D. Chemotherapy Induced Cardiomyopathy: Pathogenesis, Monitoring and Management. Journal of Clinical Medicine Research [Internet]. 2009 [cited on June 1, 2018]; DOI:10.4021/joc-mr2009.02.1225

934. Shuykova KV, Emelina EI, Gendlin GE, Storojakov G.I. Grange of the left ventricle functioning in lymphoma treated with anthracycline antibiotics. Russian Journal of Cardiology. 2016; (1):41-6. DOI:10.158 29/1560-4071-2016-1-41-46

935. Tebbi CK, London WB, Friedman D., Villaluna D., De Alarcon PA, Constine LS et al. Dexrazoxane-Associated Risk for Acute Myeloid Leukemia/Myelodysplastic Syndrome and Other Secondary Malignancies in Pediatric Hodgkin’s Disease. Journal of Clinical Oncology. 2007;25 (5):493-500. DOI:10.1200/JCO. 2005.02.3879

936. Vrooman LM, Neuberg DS, Stevenson KE, Asselin BL, Athale UH, Clavell L et al. fje low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium. European Journal of Cancer. 2011;47 (9):1373-9. DOI:10.1016/j. ejca. 2011.03.022

937. Salzer WL, Devidas M, Carroll WL, Winick N, Pullen J, Hunger SP et al. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children’s oncology group. Leukemia. 2010;24 (2):355-70. DOI:10.1038/leu. 2009.261

938. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A et al. Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy. Journal of the American College of Cardiology. 2006;48 (11):2258-62. DOI:10.1016/j. jacc. 2006.07.052

939. Правдивцева Е. В., Потешкина Н. Г., Сванадзе А. М., Рыльский Д. С. Профилактика кардиотоксического действия антрациклинового антибиотика доксорубицина: роль ингибитора ангиотензинпревращающего фермента периндоприла. Клиницист. 2011; (3):55-61

940. Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, de Caralt TM et al. Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant Hemopathies. Journal of the American College of Cardiology. 2013;61 (23):2355-62. DOI:10.1016/j. jacc. 2013.02.072

941. Felker GM, fjompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342 (15):1077-84. DOI: 10.1056/NEJM200004133421502

942. Стенина М. Б., Фролова М. А. Рак молочной железы: наиболее важные научные события и выводы последних лет. Практическая Онкология. 2011; 12 (1 (45)): 6-11

943. Abi Aad S, Pierce M, Barmaimon G, Farhat FS, Benjo A, Mouhayar E. Hypertension induced by chemotherapeutic and immunosuppresive agents: A new challenge. Critical Reviews in Oncology/Hematology. 2015;93 (1):28-35. DOI:10.1016/j. critrevonc. 2014.08.004

944. Cutter DJ, Schaapveld M, Darby SC, Hauptmann M, van Nimwegen FA, Krol ADG et al. Risk for Valvular Heart Disease After Treatment for Hodgkin Lymphoma. JNCI: Journal of the National Cancer Institute [Internet]. 2015 [cited on June 1, 2018];107 (4). DOI:10.1093/jn-ci/djv008

945. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA., Goto S et al. ß-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13):1340-9. DOI:10.1001/jama.2012.12559